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ABSTRACT 
BACKGROUND 
Following the Institute of Medicine’s 1999 report “To Err is Human”, patient safety has received 
increased attention with regulatory agencies and health care facilities. While a wide variety of 
initiatives have been started, today, more than 10 years after this landmark report, patient safety 
outcomes remain unchanged. Consequently, it is critical to develop new, effective approaches to 
improve medication safety in health care facilities. Major medication safety organizations 
recommend the use of multidisciplinary teams toward the identification and resolution of 
medication errors. 
The role of Swiss hospital pharmacists has changed substantially over the last decade. In the past, 
the pharmacist’s responsibility centered upon the timely dispensing and delivery of medication.  
However, at the present time, the hospital pharmacist is involved as a critical partner in the entire 
medication use process, focusing on the safe and effective use of drugs. 
The aims of this work are to 1) Describe Swiss hospital pharmacists’ perceptions of their current 
and future role in medication safety and 2) Identify efficient tools  to allow hospital pharmacists to 
proactively address medication safety. 
 
PROJECTS 
Chapter 1: Survey of medication safety activities in Swiss hospitals:  
The role of the hospital pharmacist 
A structured online survey was sent to all 41 Swiss hospital pharmacy directors to assess current 
medication safety activities and planned projects, specifically evaluating the role of the pharmacist. 
The 26 respondents (response rate 62%) employed an average of 0.76 pharmacist full-time 
employees per 100 beds (European average: 1 full-time employee per 100 beds). Swiss hospital 
pharmacists are participating in pharmacy & therapeutics committee meetings (23/26 hospitals, 
88%) and providing pharmacovigilance (12/26, 46%). Clinical pharmacy services are offered in 
25/26 institutions (96%) Other activities identified among 22 participants included the 
implementation of eHealth tools (11/22 hospitals, 50%) and the increase of clinical pharmacy 
services (4/22, 18%). 
Tools most likely used in medication safety activities among 24 respondants were direct 
observation (23/24, 96%), critical incident reporting system (20/24, 83%), and chart review (16/23, 
67%). Surveys (7/24, 29%) and analysis of MedWatch data (8/26, 33%) were less often utilized. Of 
the respondents, 38% (9/24) were not familiar with the trigger tool technology.  
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Chapter 2: Evidence-based reviews for the comparative evaluation of drug products 
The American Society of Health-System Pharmacists (ASHP) considers an institutional 
multidisciplinary pharmacy & therapeutics committee and the appropriate management of the drug 
formulary as key steps toward safe medication therapy in the inpatient setting. An objective 
evaluation and formulary selection process is key for safe medication management. Potential 
templates for an evidence- based, efficient approach to drug evaluation are suggested. 
Chapter 3: Medication safety assessment methods:  
How can institutions efficiently address drug-related problems? 
Organizations, including the Institute for Safe Medication Practice, recommend different methods 
for the assessment of medication safety, including incident reporting (IR), direct observation (OB), 
chart review (CH) and trigger tool analysis (TR). However, the optimal method for identifying drug-
related problems (DRPs) is unknown.  
Pubmed, Embase and Scopus databases were systematically searched for any comparative study 
in which IR, OB, CH and TR were compared to one another. Twenty-eight studies were included in 
this review. 
All four assessment techniques have different strengths and weaknesses. Overlap between 
different methods in identifying DRPs is minimal. While TR appears to be the most effective and 
labor-efficient method, IR best identifies high severity DRPs. Considering the lack of overlap and 
the ability of each method to identify different medication errors, the use of a combination of 
methodologies is strongly recommended. 
Chapter 4: Medication use evaluation via manual trigger tool methodology  
in the inpatient setting 
Once a product is added to the formulary, regular medication use evaluations are warranted. The 
trigger tool is an efficient and labor-efficient method for the assessment of medication safety.  
Consequently, a manual trigger tool form for the evaluation of intravenous heparin use was 
developed and piloted.  
A systematic literature review (Pubmed, Embase, Scopus) identified 79 heparin-related safety 
indicators of which 19 were included into the manual trigger tool form.  
The inclusion of only 20 randomly selected patients in a once-yearly assessment allowed the 
efficient identification of critical steps in the medication use process and subsequent continuous 
quality improvement projects.  
Chapter 5: The FDA extended warning for intravenous haloperidol and torsades de  
pointes: How should institutions respond? 
In September 2007 the Food and Drug Administration (FDA) strengthened label warnings for 
intravenous haloperidol regarding cardiac adverse events, including QT prolongation (QTP) and 
torsades de pointes (TdP), based on incident reporting. 
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Case reports were identified by searching the current literature (Pubmed, Embase, Scopus) as well 
as by analyzing the FDA’s adverse event database. 
Seventy cases of IV haloperidol-associated cardiac adverse events were identified; supporting that 
IV haloperidol can be associated with QTP and TdP. However, this complication most often took 
place in the setting of concomitant risk factors. Importantly, our results suggest that a total 
cumulative dose of IV haloperidol of < 2mg can safely be administered without 
electrocardiographic monitoring in patients without concomitant risk factors. 
Chapter 6: The case of IV haloperidol – Does the WHO pharmacovigilance database  
offer evaluable comparative safety data? 
In addition to the analysis of the FDA database, WHO adverse drug reaction (ADR) reports of 
QTP, TdP and/or cardiac arrest involving haloperidol, olanzapine and quetiapine, including  
different routes of administration, were analyzed and compared. 
WHO and FDA pharmacovigilance data is based upon health care provider reported adverse drug 
events. However, considering that the total number of patients receiving the medication usage is 
unavailable, it is not possible for agencies to determine a true rate of incidence of an adverse drug 
event. Nonetheless, regulatory agencies, including the WHO and FDA, rely upon these reports to 
make recommendations regarding the safe, effective use of medications.  
The case of IV haloperidol exemplifies the difficulties associated with reliance upon this database 
for regulatory decisions.The comparative trending analysis showed an overall higher number of 
cardiac ADR reports for oral haloperidol than for the IV administration. In addition, the number of 
overall cardiac ADRs involving QTP and/or TdP was greater for quetiapine or olanzapine 
compared to haloperidol. The reporting odds ratio, although of very limited use for comparative 
evaluation, revealed no significant difference in reporting for haloperidol and quetiapine. Due to the 
limited options for the treatment of acute psychotic events, a thorough risk/benefit evaluation for 




Although staff resources are limited, our survey showed that Swiss hospital pharmacists are 
proactively participating in medication safety activities.  
Several available methods allow for an effective, labor-efficient approach to medication safety 
assessment. With Swiss physicians increasingly dispensing drugs and the discipline of 
pharmacology also in the hands of physicians, comprehensive medication safety assessment 
potentially creates important professional opportunities for hospital pharmacists in Switzerland. 
Carla Meyer-Massetti PhD Thesis, March 2011  7









TABLE OF CONTENTS 
 
7










Medication safety activities in Swiss hospitals: 








Medication safety assessment methods:  








The FDA extended warning for intravenous haloperidol and torsades de pointes:  




The case of IV haloperidol –  
Does the WHO pharmacovigilance database offer evaluable comparative safety data? 
 
124










Carla Meyer-Massetti PhD Thesis, March 2011  8
GLOSSARY & DEFINITIONS 
 
In the German speaking area of Europe, no standardized glossary for medication safety has been 
stipulated so far. In order to standardize the vocabulary and definitions of this work, a short 











Ein unerwünschtes Ereignis, verursacht durch das 
Medikament selber oder durch dessen fehlerhafte 
Verwendung.2 
Der Begriff „unerwünschte Arzneimittelwirkung“ umfasst 
sowohl Medikationsfehler wie auch unerwünschte 
Arzneimittelreaktionen.5 
Das unerwünschte Arzneimittelereignis ist das Ergebnis 
einer medikamentösen Behandlung, das zu einer 
verlängerten Behandlungsdauer führen kann und nicht 
dem zugrundeliegenden Gesundheitszustand des 
Patienten zuzuschreiben ist. Das Ereignis ist direkt auf die 








Eine durch das Arzneimittel selbst verursachte 
unerwünschte Wirkung.2 
Jede gesundheitsschädliche und unbeabsichtigte Wirkung 
eines Medikaments, die in Dosierungen auftritt, welche 






Ein nicht beabsichtigtes Vorkommnis im Zusammenhang 
mit einer medizinischen Behandlung, das zur 
Beeinträchtigung des Zustandes eines Patienten beiträgt 
oder beitragen könnte.2;6  
Eine Schädigung, die auf das medizinische Management 
und nicht auf die Erkrankung eines Patienten 
zurückzuführen ist. Ein unerwünschtes Ereignis kann das 
Ergebnis eines Fehlers sein. 
Ein unerwünschtes Ereignis hat eine Schädigung zur 
Folge, die das Ergebnis einer medizinischen Behandlung 
ist, zu einer verlängerten Behandlungsdauer führen kann 
und nicht dem zugrundeliegenden Gesundheitszustand 
des Patienten zuzuschreiben ist.3;7 
Vorkommnisse bzw. Ereignisse, die möglicherweise, aber 
nicht zwangsläufig zu einem konsekutiven Schaden für 
den Patienten führen.1 
Adverse reaction Unerwünschte 
Wirkung 
Möglicher „Nebeneffekt“ einer medizinischen Intervention, 
oft auch billigend in Kauf genommen oder unvermeidbar.1 
Causality Kausalität Der Arzt ist für einen durch einen vorwerfbaren 
Behandlungsfehler verursachten Schaden rechtlich 
verantwortlich. Notwendig für die Annahme einer 
haftungsbegründenden Kausalität ist, dass der (Primär-) 
Schaden mit praktischer Gewissheit auf dem Fehler 
beruht. Diese liegt vor, wenn eine überzeugende 
Wahrscheinlichkeit im Sinne persönlicher Gewissheit 
gegeben ist, welche Zweifeln Schweigen gebietet, ohne 
sie völlig auszuschließen.1 
Compliance Compliance Konformität mit Instruktionen, insbesondere bezogen auf 
die Medikamenteneinnahme entsprechend den 
Anweisungen des Verschreibers.2 
Modernere Begriffe  für „Compliance“ sind „Adhärenz“ 
(adherence) und Konkordanz (concordance).2 







Complication Komplikation Nicht geplanter und / oder unerwarteter Verlauf, der die 
Heilung erschwert, beeinträchtigt oder vereitelt; s. auch 
unerwünschtes Ereignis.  
Eine Komplikation kann auch auftreten als schicksalhafter 
Krankheitsverlauf, etwa bei Verschlimmerung einer 
Erkrankung oder als Folge einer diagnostischen oder 
therapeutischen Maßnahme.1 
Concordance Konkordanz Zustimmung eines mündigen Patienten zu einer Therapie, 
basierend auf seinem Verständnis der therapeutischen 
Ziele, Verhandlungen, Akzeptanz und Commitment zur 
Therapie („informed consent“).2 
Critical incident 
Sentinel event 
Kritisches Ereignis Ein schwerwiegendes Ereignis, das zu einem 
unerwünschten Ereignis führen könnte oder dessen 
Wahrscheinlichkeit deutlich erhöht.6 
Ein Outcome oder ein anderes wichtiges unerwünschtes 
Ereignis, das in der Gegenwart adäquater Behandlung 
nicht auftritt.2 
Ein Ereignis, das mit einem Schädigungspotential 
einhergeht. Erfolgt keine Einleitung einer 




CIRS Zwischenfallerfassung ist die Meldung von kritischen 
Ereignissen oder Beinahe-Ereignissen.  
Je mehr Zwischenfälle erfasst werden, desto größer ist die 
Chance, Schwachstellen im System zu erkennen und 
durch geeignete Maßnahmen zu eliminieren. Werden 
Beinahefehler reduziert, entstehen weniger echte Fehler.1 
Database Datenbank Eine strukturierte Sammlung von Daten, zur raschen 
Wiederfindung gedacht.2 
Delphi process Delphi Verfahren Schriftliches, objektiviertes Evaluationsverfahren zur 
Erreichung eines fachlichen Konsens in einer Gruppe von 
Experten auf einem bestimmten Gebiet.2 
Disease 
 




Eine Abnormalität oder Störung der körperlichen Struktur 
oder Physiologie; die professionelle Interpretation einer 
Erkrankung, basierend auf den Schilderungen einer 
Person (eines Patienten) in Kombination mit zusätzlichen 










Jegliche Umstände, die eine kompetente Fachperson als 
inkonsistent mit der Erreichung des therapeutischen Ziels 
beurteilen würde. 
Ein potentielles / theoretisches Medikations-assoziiertes 
Problem besteht in einer Diskrepanz zwischen dem 
tatsächlichen Behandlungsplan und den vorgegebenen 
Richtlinien. 
Ein tatsächliches Medikations-assoziiertes Problem 
erfordert ein Abweichen von einer Guideline in 
Kombination mit einer physischen Manifestation in 
Zusammenhang mit einem Symptom oder einem von der 






Eine unerwünschte Patienten-Verletzung mit einem 
wissenschaftlich plausiblen kausalen Zusammenhang mit 
entweder a) einer Medikamententherapie und/oder b) 
einer unbehandelten Indikation für eine 
Medikamententherapie. 
Medikations-assoziierte Mortalität beinhaltet signifikante 
unerwünschte Arzneimittelwirkungen oder toxische 
Effekte, Therapieversagen, und Situationen mit einer 
unbehandelten Indikation.2 







Effectiveness Wirksamkeit / 
Effektivität 
Günstige Effekte eines Medikamentes unter nicht-idealen 
Bedingungen im täglichen klinischen Gebrauch.2 
Efficacy Wirksamkeit Günstige Effekte eines Medikamentes unter idealen 
Bedingungen, z.B. eine kontrollierte klinische Studie.2;6;8 
Efficiency Wirksamkeit / 
Effizienz 
Günstige Effekte eines Medikamentes beurteilt unter 
Berücksichtigung der benötigten Ressourcen.2 
Error Fehler Eine Handlung oder ein Unterlassen bei dem eine 
Abweichung vom Plan, ein falscher Plan oder kein Plan 
vorliegt. Ob daraus ein Schaden entsteht, ist für die 
Definition eines Fehlers irrelevant.2;6;8  
Ein richtiges Vorhaben wird nicht wie geplant 





Eine systematisch entwickelte Beschreibung von 
wünschenswerten Behandlungsentscheidungen unter 
spezifischen klinischen Umständen in einem typischen 
Patienten.  
Die Evidenz-basierte Leitlinie wird in der Regel durch 
einen formalen, konsultativen Prozess entwickelt und 
beinhaltet klinische Evidenz, Expertenmeinungen und 
professionelle Beurteilung. 
Eine Leitlinie kann auf Prävention, Diagnose oder 
Behandlung abzielen.  
Der Hauptzweck ist die Evidenz-basierte Behandlung der 
Patienten.2 
Leitlinien sind systematisch entwickelte Empfehlungen für 
Ärzte über die angemessene Vorgehensweise in 
Diagnostik und Therapie bei speziellen Erkrankungen zur 
Wahrung von Qualitätsstandards in der medizinischen 
Versorgung. Sie sind keine verbindlichen Rechtsnormen, 
sondern Orientierungshilfen im Sinne von „Handlungs- 
und Entscheidungskorridoren“, von denen im begründeten 
Einzelfall abgewichen werden kann oder muss.1 
Incidence Inzidenz Die Anzahl neuer Fälle in einer Population pro Zeiteinheit. 
Ein Mass für die Frequenz für das Auftreten eines 
Ereignisses in einer Population, z.B. einer neuen 
Erkrankung.  
Der Nenner ist die Risikopopulation, der Zähler ist Anzahl 
auftretender Fälle während einer spezifischen Zeiteinheit.2 
Incident Zwischenfall Ein Ereignis (Incident) im Rahmen einer Heilbehandlung, 
welches zu einer unbeabsichtigten und /oder unnötigen 
Schädigung einer Person oder zu einem Verlust hätte 
führen können oder geführt hat.1 
Incident reporting 
system 
Fehlermeldesystem Relevante Fehler, die von Ärzten und anderen 
Leistungsträgern im Gesundheitswesen beobachtet oder 
begangen werden, können über strukturierte 
Datenerfassungssysteme gemeldet werden. Solche 
Meldesysteme, einschließlich Umfragen unter 
Leistungsträgern und strukturierte Befragungen, stellen 
eine Möglichkeit dar, die Leistungsträger im 
Gesundheitswesen an Forschungs- und 
Qualitätsverbesserungsprojekten zu beteiligen.1 
Indicator Indikator Eine Beobachtung oder Messung, welche den 
zugrundeliegenden Zustand widerspiegelt.  
Ein als Indikator geeignetes Signal / Symptom ist stark 
korreliert mit dem eigentlichen Zustand / Ereignis, hoch 
signifikant und praktisch schlüssig.2 







Injury Schaden Ein Schaden liegt vor, wenn der negative Nutzen einer 
medizinischen Massnahme den positiven Nutzen 
übersteigt (Nettonutzenprinzip).3 
Eine schwerwiegender, gefährlicher oder 
beeinträchtigender klinischer Ausgang, der nicht 
korrigierbar ist oder signifikante zusätzliche Ressourcen 
zur Behandlung benötigt, wie z.B. eine Notfallbehandlung 
oder eine Hospitalisation.2 
Latent error 
Systematic error 
Systemfehler In einem Arbeitssystem latent vorhandener Fehler oder 
fehlerhafter Prozess, der bei Zusammentreffen mehrerer 
Ereignisse oder Versagens mehrerer „Schutzfunktionen“ 
auftritt; oft fokussiert auf eine Person oder einen 
Vorgang.1 
Medical error Medizinischer Fehler Ein „medizinischer Fehler“ (medical error) ist definiert als 
jede geplante Vorgehensweise, die nicht plangemäß 
ausgeführt wurde (d.h. Ausführungsfehler) oder das 
Anwenden einer Vorgehensweise, die zum Erreichen 
eines Ziels ungeeignet ist (Planungsfehler).1 
Medication error Medikationsfehler Im angelsächsischen Sprachraum wird ein 
„Medikationsfehler“ definiert als eine Medikamentengabe, 
die anders als in der Krankenakte vermerkt, verabreicht 
wurde; Medikationsfehler gelten als Systemfehler.  
Es werden verschiedene Kategorien unterschieden:  
- nicht zugelassenes Medikament  
- zusätzliche Dosis  
- Dosierungsfehler  
- Unterlassung einer Verordnung  
- falscher Verabreichungsweg  
  (z.B. oral statt intramuskulär)  
- ungeeignete Darreichungsform  
- falsche Verabreichungstechnik  
- falscher Verabreichungszeitpunkt.1 
Mistake Irrtum Im englischen „Mistake“; eine geplante Vorgehensweise, 
die nicht plangemäß vollendet wird, bzw. Anwendung 
einer Vorgehensweise, die zum Erreichen eines 
gegebenen Ziels ungeeignet ist. Anders als im Bereich der 
deutschen Rechtsprechung wird in Untersuchungen und 
Berichten aus englischsprachigen Ländern der Begriff des 
Fehlers „error“ nicht notwendiger Weise im engen Kontext 
mit Vernachlässigung der Sorgfaltspflicht und Schaden 
gebraucht. Einem Behandlungsfehler mit vermeidbarem 
Schaden entspricht am ehesten der Terminus 
„negligence“ (Vernachlässigung), was in der Regel 
gleichbedeutend ist mit „substandard care“. 
Konsequenzen dieser uneinheitlichen Begriffsdefinitionen 
sind u.a. unterschiedliche Angaben zur Häufigkeit von 
unerwünschten Ereignissen, Fehlern und Schäden in der 
medizinischen Versorgung.  
In den meisten Publikationen zunächst definiert als 
Problem in der Versorgung, handelt es sich meist nur 
einen „Ergebnisparameter“ mit dem die Untersucher 
definieren wollen, ob ein unerwünschtes Ereignis als 
vermeidbar angesehen werden kann/konnte.1 














Ein Fehler ohne Schaden, der zu einem Schaden hätte 
führen können.6 
Ereignisse, bei denen ein Schaden trotz eines Fehlers 
ausgeblieben ist. Ereignisse, bei denen durch Korrektur 
eines Fehlers ein Schaden verhindert werden konnte, 
zählen ebenfalls zu den Beinahe-Schäden.3;4 
Fehler, wobei das Abweichverhalten rechtzeitig erkannt 
wird und so ein tatsächlicher Fehler vermieden wird. Als 
Beinahe-Fehler gilt jedes Vorkommnis, das unerwünschte 
Folgen hätte haben können, es im konkreten Fall jedoch 
nicht hatte und abgesehen vom Ergebnis (Outcome) von 
einem „richtigen“ (tatsächlich eingetretenen) 





Die Wahrscheinlichkeit, dass ein negatives Resultat 






Ein Behandlungsfehler, wenn die ärztliche, pflegerische 
oder therapeutische Handlung gegen bewährte 
Handlungsregeln oder gesicherte medizinische 
Erkenntnisse verstösst.3;4 
Patient safety Patientensicherheit Patientensicherheit ist das Produkt aller Maßnahmen in 
Klinik und Praxis, die darauf ausgerichtet sind, Patienten 
vor vermeidbaren Schäden in Zusammenhang mit der 
Heilbehandlung zu bewahren.1 
Im englischen Sprachraum versteht man unter 
„Patientensicherheit“ das Vermeiden, die Verhütung und 
Verbesserung von unerwünschten Ergebnissen oder 
Schäden durch Gesundheitsversorgungsmaßnahmen. 
Solche Ereignisse umfassen “Fehler”, “Abweichungen” 
und “Unfälle.” Sicherheit entsteht durch 
Wechselwirkungen zwischen Systemkomponenten; sie 
ruht nicht in einer Person, einem Apparat oder einer 
Abteilung. Die Verbesserung der Sicherheit hängt ab von 
der Erkenntnis, wie Sicherheit aus dem Zusammenwirken 
der einzelnen Komponenten des Systems entsteht. 








Die Wahrscheinlichkeit, dass ein positives Resultat 
tatsächlich positiv ist.9 





Ereignisse, bei denen ein Schaden trotz eines 
Medikationsfehlers ausgeblieben ist, sind Beinahe-
Arzneimittelereignisse. Ereignisse, bei denen durch 
Korrektur des Fehlers ein Arzneimittelschaden verhindert 







Eine unerwünschte, aber vermeidbare Wirkung, 
zurückzuführen auf die Anwendung oder Verabreichung 
eines Medikaments.3;4 












Ein unerwünschtes Ereignis, das auf einen Fehler 
zurückzuführen ist. 
Ein vermeidbares unerwünschtes Ereignis hat eine 
Schädigung zur Folge, die das Ergebnis einer 
medizinischen Behandlung ist und vermeidbar gewesen 
wäre.3;4 
Vorkommnisse, die möglicherweise, aber nicht 
zwangsläufig zu einem konsekutiven Schaden für den 
Patienten führen. Als vermeidbar sind unerwünschte 
Ereignisse dann einzustufen, wenn sie durch Einhaltung 
der zum Zeitpunkt des Auftretens geltenden 
Sorgfaltsregeln zu verhindern gewesen wären.1 
Preventable death Vermeidbarer 
Todesfall 
Todesfälle, die auf eine unsachgemässe medizinische 
Behandlung zurückzuführen sind.3;4 
Risk Risiko Sowohl die Durchführung wie auch das Unterlassen von 
Interventionen beinhalten ein Risiko, das durch den 
Behandler selbst bei sorgfältigster Beachtung nicht 
auszuschließen ist.1 
Risk management Risikomanagement Risiko Management ist eine Prozessanalyse im 
Behandlungsumfeld mit dem Ziel, Risikosituationen mit 
möglichen mediko-legalen Konsequenzen aufzudecken, 
bzw. eine Managementmethode, die das Ziel hat, in einer 
systematischen Form Fehler und ihre Folgen  
- zu erkennen  
- zu analysieren und 
- zu vermeiden.1 
Root cause analysis Ursachen-Analyse In der Fehlerforschung geht man davon aus, dass 
Incidents wie auch Unfälle / Fehler gleiche Ursachen 
(Wurzeln = Roots) haben. Somit kann man durch die 
Evaluation von Incident Reporting sowie durch 
Unfallanalysen auf gemeinsame Ursachen für System-
Mängel stoßen.1 
Sensitivity Sensitivität Sensitivität bezeichnet das Verhältnis zwischen positiven 
Testergebnissen und den tatsächlich positiven 
Ereignissen. 
Im Rahmen eines medizinischen Tests bezieht sich die 
Sensitivität auf den Anteil Personen, welche ein positives 
Testresultat für eine Krankheit aufweisen in einem 
Kollektiv von Personen, die tatsächlich krank sind.  
Kein Test hat eine 100%ige Sensitivität, weil einige kranke 
Personen negative Testresultate aufweisen (=falsch 
negative Testresultate).9 
true positives / (true positives + false negatives) x 100% 
Specificity Spezifität Die Spezifität eines Tests beschreibt den Anteil an richtig 
negativen Resultaten, den der Test entdeckt, verglichen 
mit allen Patienten ohne die zu diagnostizierende 
Erkrankung.9 
true negatives / (true negatives + false positives) x 100% 
Standard Standard Standard in der Medizin repräsentiert den jeweiligen 
Stand naturwissenschaftlicher Erkenntnis und ärztlicher 
Erfahrung, der zur Erreichung des ärztlichen 
Behandlungszieles erforderlich ist und sich in der 
Erprobung bewährt hat, demnach ist der Standard eine 
normative Vorgabe qualitativer und/oder quantitativer Art 
bezüglich der Erfüllung vorausgesetzter oder festgelegter 
(Qualitäts-) Anforderungen.1 
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ABBREVIATIONS 
2-RN-check double-check by nursing  EPS extrapyramidal symptoms 
ACS acute coronary syndrome  ER extended release 
ADE adverse drug event  f female 
ADR adverse drug reaction  FDA The United States’ Food and Drug Administration 
AE adverse event  FIN Finland 
AI adverse incident  FTE full-time employee 
AIDS Acquired Immune Deficiency Syndrome  HCl hydrochloride 
AkdÄ German Physicians’ Association  hr hour 
AO adverse outcome  hrs hours 
aPTT activated partial thromboplastin time  ICSR individual case safety report 
ASHP American Society of Health System Pharmacy  ID identification 
AV arteriovenous  IHI Institute for Healthcare Improvement 
av atrio-ventricular  IM intramuscular 
C correct  INR international normalized ratio 
CBC complete blood count  IOM Institute of Medicine 
CERT Center for Education and Research on Therapeutics  IR incident report / incident reporting 
CH chart review  ISMP Institute for Safe Medication Practices 
CHE Switzerland  IU international units 
CI confidence interval  IV intravenous 
CIRS critical incident reporting system  IVAS intravenous additive services (pharmacy department) 
CJD Creutzfeldt-Jakob disease  κ Kappa value 
CL clearance  kg kilogram (bodyweight) 
CNS central nervous system  L liter 
CPOE computerized physician order entry  lab laboratory 
CT computerized tomography  LPN licensed practical nurse 
CUDA UCSF medical center inpatient pharmacy  m male 
CYP cytochrome P450 enzyme  MD medical doctor 
DDI drug-drug-interaction  ME medication error 
DRP drug-related problem  MedMarx Internet-based program to report, track, and share medication error data 
ECG electrocardiogram  med drug / medication 
eIR encouraged / solicited incident reporting  med rec medication reconciliation 
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MedWatch FDA’s safety information and AE reporting program  Pyxis Brand of an automated drug dispensing cabinet system 
mg milligram  QTP QT prolongation 
min minutes  QTc QT corrected for heart rate 
mL milliliter  RBC red blood cell count 
MRI magnetic resonance imaging  RN regular nurse 
msec millisecond/s  ROR reporting odds ratio 
N number (statistical)  SD standard deviation 
NA not applicable  sex. sexually 
NCCMERP The National Coordinating Council for Medication Error Reporting and Prevention  STEMI ST-segement myocardial infarction 
NLD The Netherlands  TDM therapeutic drug monitoring 
NR not reported  TdP torsades de pointes 
OB direct observation  TR trigger tool 
ok okay, e.g. tested  TTH time to hemostasis 
P&T pharmacy & therapeutics  U unclear 
PAB peripheral arterial bypass  UMC Uppsala Monitoring Center 
PCA patient controlled analgesia  US(A) United States of America 
PCP primary care provider  UCARE electronic clinic information system 
pharmCH review of prescription charts by a pharmacist  UCSF University of California San Francisco 
PharmD pharmaceutical doctor  UE unintended event 
physIR incident reporting by a physician  UFH unfractionated heparin 
pIR patient incident reporting  VAS visual analog scale 
Plts platelets  W wrong 
PO oral  WBC white blood cell count 
PPV positive predictive value  WHO World Health Organization 
premed premedication  WHO-ART The World Health Organization’s adverse reaction terminology 
PRN as needed (Latin: pro re nata)  wks weeks 
PSI patient safety incident  X not ordered 
PT prothrombin time  X/X number / total number 
PTT partial thromboplastin time  Y/N yes or no answer 
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INTRODUCTION 
The Institute of Medicine (IOM) report „To Err is Human“, published in 1999, alerted health care 
institutions worldwide to the necessity of a strategic approach to reduce medical errors.10 Although 
the report focused on the United States (US) health care system, it provided in-depth analysis of a 
wide range of universal patient safety concerns.11 
A major focus of the report was aimed at drug-related problems (DRPs), encompassing adverse 
drug reactions (ADRs) and medication errors (MEs).10 Medication errors represent the major 
fraction of DRPs.12 Although absolute numbers of their frequency and related cost is difficult to 
characterize, they pose a significant social and economic burden. Based on investigations by the 
Swiss Foundation for Medication Safety and on international scientific publications, it is estimated 
that up to 4% of all hospital admissions in Switzerland are due to DRPs, and that at least 7.5% of 
all Swiss inpatients experience an ADR and/or a ME.13;14 The additional costs associated with 
these errors has been estimated to be up to 100 million dollars per year for a university hospital in 
Switzerland.15  
 
Approximately a quarter of DRPs are preventable,16 thus health care institutions must develop a 
strategic approach to decrease DRPs and improve patient safety.11 Professional organizations, 
including the American Pharmacists Association stress the importance of interdisciplinary teams to 
comprehensively address medication safety.17 Based on their comprehensive education, 
pharmacists are  well-suited for an active role in the ME reduction.17 Clinical pharmacists provide 
added value by participating in multidisciplinary teams, and their interventions reduce preventable 
adverse drug events and prescribing errors, resulting in cost savings.18-22  
In addition to the previously described clinical pharmacy activities, a new role for hospital 
pharmacists, the medication safety officer, is emerging, primarily in the US. The medication safety 
officer is responsible for the management of all medication use safety and continuous quality 
improvement plans. Essential job functions include patient and medication safety, staff 
development / training and medication use improvement.23 Established organizations, including the 
American Society of Health-System Pharmacists (ASHP) and the Institute for Safe Medication 
Practices (ISMP) strongly recommend one full-time employee per hospital entirely dedicated to the 
reduction of DRPs and the improvement of medication safety.24;25  
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Medication safety issues are often identified via postmarketing pharmacosurveillance. In most 
instances, drugs have received approval based upon trials involving only certain patient 
populations. Pediatric or geriatric patients, women of childbearing age and patients with certain 
concomitant diseases are often excluded from clinical trials, although they are treated with these 
substances in daily practice nevertheless.26 Consequently, it is not surprising that some of these 
excluded groups are often those in whom unanticipated postmarketing adverse drug events are 
identified. 
Medication safety surveillance in the post-marketing phase is often limited to regulatory 
pharmacovigilance activities.27 Spontaneous reporting systems for ADRs have been the 
cornerstone of signal detection in pharmacovigilance for the last four decades. However, it is well 
known that some adverse effects of drugs are detected too late, only after many patients have 
been exposed. The need for earlier detection and a more proactive approach are strongly 
recommended in Europe and in North America.28 However, individual hospitals have an additional 
need for institution-specific assessments of DRPs.  
 
The aims of this thesis are to 1) Describe Swiss hospital pharmacists’ perceptions of their current 
and future role in medication safety and 2) Identify efficient tools to allow hospital pharmacists to 
proactively address medication safety. 
 
As a starting point, a survey was performed to evaluate current hospital pharmacist activities 
contributing to medication safety (Chapter 1). 
An internet-based tool was used to compose, distribute and analyze questionnaire-based surveys.  
 
Subsequently, commonly used or recommended methods were identified from the current literature 
for medication safety assessment and evaluated for potential application in the Swiss hospital 
pharmacy setting. 
 
Chapter 2 suggests structured approaches to a systematic literature review in order to assess the 
safety of active substances and drug products. The American Society of Health-System 
Pharmacists (ASHP) provides a number of recommendations to manage drug use in the inpatient 
setting. These include a multidisciplinary pharmacy & therapeutics committee, meeting regularly 
under a defined constitution, as well as the appropriate management of the drug formulary.29;30 An 
objective evaluation and selection process, using peer-reviewed publications is an important 
component for safe medication management.30-32 
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Once a product is chosen for formulary addition, regular medication use evaluations (MUEs) must 
be performed.33 Chapter 3 evaluates the most commonly recommended medication safety 
assessment methods in the literature for assessment of medication safety.34 
 
The Institute for Healthcare Improvement (IHI) specifically recommends the trigger tool or indicator 
technology in the identification of medication errors.35 Chapter 4 describes the development, 
piloting and use of a manual trigger tool process for unfractionated heparin. 
 
A method complementary to the trigger tool methodology is incident reporting.34 However, due to 
the widespread underreporting, this technique does not offer a comprehensive picture of a drug’s 
safety profile.2;36;36;37 
Alternatively, organizations systematically collecting critical incident reports like the US Food and 
Drug Administration (FDA) or the World Health Organization (WHO) can be accessed. The 
methodological approach to the evaluation of pharmacovigilance systems as well as the 
information obtained is discussed in chapters 5 and 6, addressing the controversy around the use 
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CHAPTER 1 
Medication safety activities in Swiss hospitals: 
A status report on the role of the hospital pharmacist 
This chapter has been published in an abbreviated format in: 




The role of hospital pharmacists in Switzerland has changed significantly over the past decade. 
Initially focused upon activities associated with the timely dispensing of drugs, the position has 
evolved into different specialties, including medication safety. 
Objective 
The aim was to investigate the role of the hospital pharmacists in medication safety improvement. 
Method 
An online survey (www.surveymonkey.com) containing 22 questions was sent to 41 Swiss 
pharmacy directors. The questions addressed 4 sections: demographic information, current 
medication safety, clinical pharmacy activities, and future medication safety-relevant activities. 
Results 
Twenty-six of 41 questionnaires were returned (response rate 62%).  
The hospitals (184 to 2000 beds) employed an average of 0.76 pharmacist full-time employees 
(0.33 - 1.94 FTEs) per 100 beds (European average: 1 FTE per 100 beds). In 23 of 26 hospitals 
(88%) a constant pharmacy & therapeutics committee was in place. Additional committees 
addressing medication safety were active in 17/25 hospitals (65%). Twenty-four of 26 hospitals 
(92%) maintained a critical incident reporting system. In 12/26 institutions (46%), the pharmacy 
was responsible for pharmacovigilance. Clinical pharmacy was established to some degree in 
25/26 hospitals (96%) Other medication safety activities were ongoing in 22/26 institutions (85%), 
including the implementation of eHealth tools (11/22 hospitals, 50%) and increasing the scope of 
clinical pharmacy services in 4/22 hospitals (18%).  
Conclusion 
Swiss hospital pharmacists are proactively supporting medication safety initiatives.  
However, staffing, which is lower in Swiss hospital pharmacies than the European average, must 
be increased to allow for adequate proactive medication safety activities. Future activities appear 
to be primarily focused on e-health technologies. In order to monitor the future trends, the survey 
should be repeated on an annual basis. 
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INTRODUCTION 
The role of hospital pharmacists in Switzerland has changed significantly over the past decade. 
First focusing on the timely dispensing of medication the hospital pharmacists has evolved into 
different specialties. From logistics, production, to analytics, clinical services and patient 
counselling, the hospital pharmacist has begun to navigate in an increasingly interdisciplinary field. 
There is strong consensus that hospital pharmacists can significantly contribute to medication 
safety from admission to discharge.18;19;21;22;38-44  
In the US, pharmacists are increasingly acknowledged as leaders in the field of medication 
safety.45 The Institute for Safe Medication Practices (ISMP), The American Society of Health-
System Pharmacists (ASHP), and other US organizations advancing medication safety, are 
promoting the role of the medication safety officer (or medication safety systems manager) through 
strategic initiatives and education.46-48  
The medication safety officer is intended to be a key member of the health care team, coordinating 
all activities related to patient safety and quality improvement in the medication use process.48 
ASHP offers guidelines for residencies in medication-use safety, enabling pharmacy graduates to 
transition from generalist practice to a specialized role as an organizational leader in the 
achievement of medication-use safety.47 As of 2010, the American Society of Medication Safety 
Officers (ASMSO) listed 500 members, representing nursing, pharmacy and medicine.49  
 
Although the prevalence of drug-related problems (DRPs) in Swiss hospitals is difficult to 
quantitate, it is estimated that 7.5% of medical inpatients experience at least one DRP during their 
hospital stay and that 0.4% of the events are associated with a medication error (ME).14;50 
Approximately 4% of patients are admitted to the hospital because of a DRP, leading to direct 
annual extra costs of 70–100 million Swiss francs.15;50;51  
 
Consequently, the proactive involvement of Swiss hospital pharmacist in medication safety is a 
logical next step both from a patient safety point of view and from an economical perspective. 
 
This chapter evaluates the current activities of Swiss hospital pharmacists in medication safety 
activities and proposes a questionnaire to assess the current state of the art. 
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METHODS 
An online survey with 22 questions was developed using the tool “SurveyMonkey” 
(www.surveymonkey.com).  
 
The concept of the survey was based on the ASHP survey of national hospital practice executed52-
54 and the publication by Longo et al.11. The questions were compiled in collaboration with the 
Swiss Patient Safety Foundation.  
The survey consisted of four major sections: 
1. Demographic information (hospital and hospital pharmacy / staffing) 
2. Drug and medication safety activities 
3. Clinical pharmacy activities 
4. Future prospects of medication safety activities 
An overview of the questions presented in this survey is available in appendix 1 at the end of this 
chapter. 
 
The Swiss Hospital Pharmacists’ Association GSASA provided a list of all Swiss hospital pharmacy 
directors.  
The survey was sent out to 41 directors of pharmacy, representing 41 hospitals in three language 
regions of Switzerland.  
Twenty-nine hospitals (71%) were located in the German speaking part, 10 (24%) in the French 
speaking part and 2 (5%) in the Italian speaking part. Therefore, the invitation letter was sent out in 
German, French and Italian. The survey itself was available in English and German in order to 
reduce the translation effort and to make the survey internationally approachable. 
 
A reminder to participate in the survey was sent out after three weeks. 
 
The results were transferred to an Excel file and analysed using descriptive statistics. 
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RESULTS 
After the second reminder, 26 of 41 surveys (63% response rate) were returned.  




The 26 participating hospitals maintained an average of 632 beds (184 – 2000 beds). 
The following hospital sizes were represented: 
 ≤ 200 beds:  2 hospitals 
 > 200 - ≤  400 beds: 7 hospitals 
 > 400 - ≤  600 beds: 7 hospitals 
 > 600 - ≤  800 beds: 4 hospitals 
 > 800 - ≤ 1000 beds: 4 hospitals 
  > 1500 beds:  2 hospitals 
 
Different types of hospitals were represented in the survey: 
University hospitals (3/26, 12%), cantonal hospitals (10/26, 38%), regional hospitals (5/26, 19%), 
private hospitals (3/26, 12%), hospital networks or groups of hospitals serviced by a central 
pharmacy (4/26, 15%), and one city hospital (1, 4%). 
The hospital pharmacies participating in the survey employ from 1 to 17 pharmacists, 
corresponding to 1 to 12 full-time equivalents (FTEs). This results in an average of 0.76 pharmacist 




In 25 of 26 hospital pharmacies (96%), 1 pharmacist is present in the hospital pharmacy during at 
least 8 hours every working day (excluding weekends and public holidays). A pharmacist is always 
available by telephone in all 26 hospitals during regular working hours. 
Fifteen of 26 hospital pharmacies (60%) offer a 24/7 emergency service. One pharmacy (8%) 
offers extended, albeit not around-the-clock services, 3/26 pharmacies (12%) have a pharmacist 
available on the phone and 6/26 pharmacies (23%) do not offer on-call services. One participant 
did not specify. Designated personnel other than pharmacy employees have access to the 
pharmacy in emergency situations in the absence of regular pharmacy personnel in 15/26 
hospitals (58%). 
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Drug supply 
While 2/26 hospital pharmacies (8%) offer unit dosing, 24/26 pharmacies (92%) supply drugs to 
satellite pharmacies on the wards, where nursing is responsible for the preparation and distribution 
of drugs to individual patients. 
In 3/26 hospitals (12%) pharmacy technicians are directly involved in drug distribution processes. 
Although automated dosing cabinets are used in Switzerland, none of the participating hospitals 
employed this technology. 
 
Participation in committees associated with medication safety 
A pharmacy & therapeutics (P&T) committee was in place in 23/26 hospitals (88%) at the time of 
the survey. In 2/26 institutions (8%), the pharmacy determined those medications which are 
available at the hospital; physicians were contacts for expertise as needed for decision making. 
One pharmacist did not answer this question. 
Of the 23 institutions with an established P&T committee, a pharmacist chaired the P&T committee 
in 20/23 (87%) and co-chaired it in 2/23 institutions (9%). In one case, the function was not 
specified. 
Seventeen of 26 institutions (65%) reported additional committees concerned with medication 
safety where pharmacists were involved: quality management and risk assessment committees 
(6/17 hospitals, 35%), critical incident reporting committee (5/17, 29%), medication safety 
committee (2/17, 12%), hygiene committee, antibiotics committee, pharmacovigilance committee, 
and pharmacy-nursing-exchange committee (1 hospital each, 6%). 
 
Critical incident reporting system (CIRS) 
Twenty-four of 26 hospitals (92%) maintain a CIRS of which 22/24 (92%) allow for anonymous 
reporting. Eighteen of 24 institutions (75%) offer electronic reporting. In 4/24 institutions (17%), the 
pharmacy is responsible for the CIRS, in 5/24 cases (21%), it is a physician’s responsibility, and in 
16/24 cases (67%) the centralized quality management handles the CIRS.  
In 12/26 institutions (46%) the pharmacy was responsible for post-marketing surveillance 
(pharmacovigilance) of the drugs used in the hospital. In the other institutions it was either the 
pharmacology department (2/26 hospitals, 8%), the P&T committee (2/26, 8%), or quality 
management (1/26, 4%). In 4/26 institutions (15%), there was no definite standard operating 
procedure on pharmacovigilance and 5/26 insitutions (19%) did not specify their policy. 
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Medication safety literature 
Different sources were used for medication safety issues. The 5 most used sources aside from in-
house CIRS analysis (60%) were information sent out by the regulatory drug agency (80%), 
scientific journals (76%), pharmavista information service (64%, www.pharmavista.ch), the FDA 
homepage (48%) and subscriptions to medication safety newsletters (36%). Five pharmacy 
directors were familiar with the ISMP homepage (www.ismp.org). 
 
Medication safety activities 
Different medication safety projects involving hospital pharmacists were ongoing at the time of the 
survey in 22/26 institutions (85%): eleven of 22 hospitals (50%) were implementing computerized 
physician order entry (CPOE) and/or the establishment of an electronic patient record, 4/22 
hospitals (18%) were increasing the scope of clinical pharmacy activities, 3/22 hospitals (14%) 
were promoting their CIRS and 1 hospital (5%) was in the process of creating a patient safety 
committee. Three of 22 projects (14%) were not specified. 
Clinical pharmacy services were established to some degree in 25/26 hospitals (96%, 1 
respondent skipped the question). All respondents (25/25, 100%) offered a drug information 
system by phone or email. Twenty-one of 25 institutions (84%) offered consulting for drugs 
administered through a feeding tube. Drug interaction checking was performed in 17/25 hospitals 
(68%) upon request. Rounding with physicians was established in 16/25 institutions (64%). Chart 
review was performed in 5/25 hospitals (20%). Therapeutic drug monitoring (TDM) was done in 
4/25 hospitals (16%). One hospital (4%) offered full medication reconciliation on admission and at 
discharge, while another hospital (4%) only offered this service on admission. No patient teaching 
is done in any of the 25 hospitals answering this question. 
The 4 services most often targeted by clinical pharmacy were medicine (68%), geriatric care 
(42%), surgery (31%) and intensive care (31%). 
 
Patient relevant data: access and availability 
The access of the pharmacy to patient-related information as well as the electronic availability of 
data is displayed in Table 1. Only one of 26 pharmacies reported no access to patient-related data 
4%). Two of 26 pharmacy directors (8%) stated that they have access to an individual patient’s 
information on a case per case basis. 
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Medication safety perspective 
Detailed information regarding the perception of the hospital pharmacy directors on the future 
development of medication safety is displayed in Table 2. In regard to the future development of 
medication safety related activities (24 respondents), the following projects were considered most 
important: the expansion of the IT-infrastructure including electronic prescribing, electronic patient 
record, automated dispensing, and clinical decision support (23/24 hospitals, 96%) and the 
expansion of clinical pharmacy services (19/24, 79%). 
 
Tools most possibly considered for use in medication safety activities among 24 respondents were 
direct observation of medication-related processes on the wards (23/24, 96%), analysis of the 
CIRS system (20/23, 83%), and chart review (16/24, 67%). Surveys (questioning health care 
professionals or patients using phone, email or paper-based questionnaires, 7/24, 29%), analysis 
of MedWatch-data (Swissmedic, WHO or FDA, 8/24, 33%), and trigger tool / indicator technology 
(9/24, 38%) were less popular. Of the respondents, 9/24 (38%) were not familiar with the trigger 
tool / indicator technology. 
 
When queried regarding the future role of the hospital pharmacist in medication safety 
improvement, pharmacy directors requested improved interdisciplinary collaboration particularly 
focusing on transition of care. Expanding the role of the hospital pharmacist to be a medication 
safety specialist was strongly recommended. 
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≤  400 9 0.68 4 (44%) 8 (89%) 9 (100%) 7 (78%) 8 (89%) 6 (67%) 5 (56%) 2 (22%) 3 (33%) 6 (67%) 6 (67%) 3 (33%) 
> 600 - ≤  800 11 0.75 6 (55%) 9 (82%) 9 (82%) 7 (64%) 10 (91%) 6 (55%) 6 (55%) 1 (9%) 5 (46%) 6 (55%) 4 (36%) 3 (27%) 
> 800 6 0.62 5 (83%) 6 (100%) 4 (67%) 3 (50%) 6 (100%) 6 (100%) 5 (83%) 1 (17%) 3 (50%) 6 (100%) 3 (50%) 4 (67%) 
Abbreviations: CIRS = critical incident reporting system, lab = laboratory, P&T = pharmacy & therapeutics, TDM = therapeutic drug monitoring 
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Table 2 Access to and availability of patient relevant data 
Information available electronically Information available to the pharmacy  
Type of data % of institutions Number of institutions 
N = 26 
% of institutions Number of institutions 
N = 26 
medication on admission 35% 9 42% 11
medication at discharge 
(prescription) 
46% 12 38% 10
lab data 81% 21 50% 13
prescriptions 35% 9 58% 15
nursing documentation  50% 13 50% 13
drug dispensing 12% 3 15% 4
physical examination report 
(e.g., radiology, CT, MRI) 
77% 20 38% 10
procedure report (e.g., 
surgery) 
58% 15 35% 9
discharge summary 69% 18 42% 11
incident reports / sentinel 
events 
42% 11 27% 7
Abbreviations: CT = computer tomography, lab = laboratory, MRI = magnetic resoncance imaging 
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Table 3 Importance of future medication safety activities 
RATING  
(24 respondents) 
[number of pharmacy directors] 
 
ACTIVITIES 
very important potentially 
important 
not important 
RATING – IMPORTANCE 
very important: 2 points 
potentially important: 1 point 
not important: 0 points 
expansion of the IT-infrastructure 
(electronic prescribing, electronic patient 
record, automated dispensing, clinical 
decision support) 
23 1 0 47 
expansion of clinical pharmacy 19 5 0 43 
medication safety education of other health 
care professionals (e.g., nurses, 
physicians) 
12 12 0 36 
increase the level of activity in the 
pharmacy & therapeutics committee 
14 7 3 35 
intensification of pharmacovigilance 12 9 3 33 
expand the hospital pharmacy team 10 12 2 32 
publication of a pharmacy newsletter 7 16 1 30 
centralized production /  
reconstitution of parenteral drugs 
8 14 2 30 
addition of content to the printed drug list / 
intranet page 
8 12 4 28 
foundation of a medication safety 
committee 
8 12 4 28 
patient education 4 14 6 22 
introduction of a unit dose system 1 12 11 14 
extend the pharmacy opening hours 0 12 12 12 
expand the emergency service of the 
hospital pharmacy 
1 10 13 12 
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DISCUSSION 
As reported in “To Err is Human”, DRPs are significant patient safety issues.7 Consequently, medication 
safety must be assessed regularly and strategies must be developed to address preventable DRPs.43;55  
As this survey demonstrated, pharmacy staffing in Switzerland is limited with an average of 0.76 pharmacist 
FTEs per 100 beds. In addition, an unknown number of primarily smaller hospitals have only consultancy 
services available through a public pharmacy and no in-house hospital pharmacist. Pharmacy technicians or 
nursing staff are responsible for the provision of pharmacy services. Supervision is provided by an external 
community pharmacist, irregularly attending on site. 
Similar problems are faced in other European countries: an average of 1 FTE per 100 beds is assigned to a 
pharmacist, only 0.3 FTEs per 100 beds exists in Germany.56 Bond et al. identified a direct relationship 
between the number of medication errors and staffing.57 Factors associated with decreased medication 
errors included drug information services, clinical research, adverse drug reaction management, medical 
rounds participation, drug admission histories, and increased clinical pharmacist staffing. The two most 
important variables toward reduction of medication errors were pharmacist-conducted drug histories and 
increased staffing levels of clinical pharmacists.57 
A comprehensive program intended to improve the status of health-system pharmacy practice is the “ASHP 
2015 Health-System Pharmacy Initiative”.58 
Hospital pharmacist should promote the introduction of e-health technologies59;60 and proactive medication 
safety assessment methods. 61 However, institutional commitment and leadership is critical toward the 




Increased clinical pharmacy activities with associated outcomes are crucial for medication error reduction.57 
Consequently, the following chapters focus on research tools for hospital pharmacists to allow for evidence-
based drug therapy. 
As per the American Society of Health-System Pharmacists, a sound formulary, managed by the pharmacy 
& therapeutics committee is a key cornerstone to evidence-based drug therapy.29;30  
In the next chapter, two examples of evidence-based reviews for formulary considerations are given. 
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 other sources (please itemize):     
8.  In which projects improving medication safety is the pharmacy involved? 
   

























 other departments:      






































therapeutics committee       
intensification of pharmacovigilance       








expansion of clinical pharmacy       
addition of content to the printed drug list / intranet 
page       
publication of a pharmacy newsletter       
patient education       






drugs       
medication safety education of other health care 
professionals (e.g., nurses, physicians)       
expand the hospital pharmacy team       
extend the pharmacy opening hours       
expand the emergency service of the hospital pharmacy       
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CHAPTER 2 
Evidence-based reviews for the comparative evaluation of drug products 
 
Example 1: 
Evidence-based review for the evaluation of a new opioid-analgesic (active substance. oxymorphone) 
considered for addition to the institution’s formulary. 
 
Example 2: 
Evidence-based review of three stand-alone topical thrombins in order to decide on a replacement of the 
current product on the institutions formulary. 
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CHAPTER 2, Example 1 
PHARMACY & THERAPEUTICS COMMITTEE 
DRUG EVALUATION – SUMMARY PAGE 
 
GENERIC NAME:   Oxymorphone 
PROPRIETARY NAME: Opana / Opana ER 
THERAPEUTIC CLASS: Analgesic, Opioid 
 
Salient Points:  
Oxymorphone (Opana®) is an opiate analgesic approved for the treatment of acute and chronic 
moderate-to-severe pain after surgery, available in a rapid and delayed onset form as well as in an 
intravenous form. The oral formulation is being requested for formulary addition as a result of our 
comprehensive formulary review. The request for Opana® addition was based on the need to have an 
oral opiate with fewer adverse effects, especially reducing the burden of nausea and vomiting in patients 
treated with opiate analgesic drugs. 
 
What is the efficacy of oxymorphone? 
 Oxymorphone has an efficacy profile similar to that of other commonly used opiates. 
 The quantity of existing comparative studies is very poor; there are only three published comparative 
studies in a hospital setting existent and one more in ambulatory care, treating chronic arthritis pain. 
 No studies comparing oxymorphone to fentanyl or methadone are available. 
 Existing studies are consistent, that the use of oral oxymorphone is as effective as various other 
comparator drugs (morphine, oxycodone, meperidine).  
 Although initially oxymorphone has a rapid onset of action (30 minutes), it appears less effective than 
morphine with repeat doses (chronic therapy). 
 In the three studies published to date, oxymorphone superiority with regard to efficacy was not 
observed. 
 
What is the comparative safety of oxymorphone with comparator drugs? 
 The adverse effects that have been observed with oxymorphone are similar to those seen with other mu 




 In one study, when administered IV via patient controlled analgesia, oxymorphone caused significantly 
more nausea and vomiting (28%), when compared with morphine (9.5%) but less sedation (0.81 +/- 0.47 
on a scale of 4) when compared with morphine (1.29 +/- 0.42 on a scale of 4)). These findings have not 
been confirmed in more recent studies. 
 An overall advantage regarding nausea and vomiting wasn’t observed. 
 There are no studies available treating the abuse potential of oxymorphone compared to other opioids. 
 
What are important aspects of oxymorphone regarding use in a hospital setting? 
 Oxymorphone has a very rapid onset of action; however, formulary agents methadone and oxycodone 
do as well. 
 Oxymorphone is not metabolized by the CYP 450 pathway; however, morphine provides a reasonable 
alternative. 
 The influence of food on the absorption of oxymorphone is significant and enhances the absorption 
about 38%. This could be a critical issue especially when used as rescue medication. 
 
Recommendations:  
Therefore, given the available oral opiate options on the formulary and the lack of supporting literature 
demonstrating any advantage of this drug, we recommend Opana® not be added at this time. 
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PHARMACY & THERAPEUTICS COMMITTEE 
DRUG EVALUATION  
 
GENERIC NAME: Oxymorphone hydrochloride 
BRAND NAME: OPANA® 
THERAPEUTIC CLASS: Analgesic, opioid 
Prepared by: Carla Meyer-Massetti, MSc 
 Candy Tsourounis, PharmD 
 UCSF Medication Outcomes Center 
 Department of Clinical Pharmacy 
 
Table 4: Products in Class62-67 
Generic Brand Manufacturer FDA Approval 
Oxymorphone hydrochloride Opana ENDO pharm 22/06/2006 
Oxymorphone hydrochloride Opana ER ENDO pharm 22/06/2006 
Methadone hydrochloride Dolophine RLI 08/13/1947 
Morphine sulphate MS contin Purdue Frederick 05/29/1987 
Oxycodone hydrochloride Oxycontin  Purdue Pharma LP 12/12/1995 
Fentanyl Duragesic ALZA 08/07/1990 
 
INDICATIONS: 




Treatment of moderate-to-severe acute pain following orthopedic and abdominal surgeries, 
where the use of an opioid is appropriate. 
Opana ER 
(oxymorphone HCl) 
Treatment of moderate-to-severe acute pain in patients requiring continuous opioid treatment 
for an extended period of time. 
The drug is not intended for: 
- an “as needed” analgesic 
- for pre-emptive analgesia 
- pain in the immediate post-operative period (12-24 hrs following surgery for patients not  
  previously taking the drug) 
- mild pain, that is not expected to persist for an extended period of time. 
Dolophine 
(methadone HCl) 
- For the treatment of moderate-to-severe pain not responsive to non-narcotic analgesics. 
- For detoxification treatment of opioid addiction (heroin or other morphine-like drugs). 
- For maintenance treatment of opioid addiction (heroin or other morphine-like drugs),  
  in conjunction with appropriate social and medical services.  
MS contin 
(morphine) 
Management of moderate-to-severe pain when a continuous opioid analgesic is needed. 
The drug is not intended for: 
- pain in the immediate postoperative period (12-24 hrs after surgery) for patients not  
  previously taking the drug (reason: safety not established). 
- mild pain, that is not expected to persist for an extended period of time. 
Oxycontin 
(oxycodone) 
Management of moderate-to-severe pain when a continuous opioid is needed for an extended 
period of time. 
The drug is not intended for: 
- an “as needed” analgesic 
- pain in the immediate postoperative period (12-24 hrs after surgery) for patients not  
  previously taking the drug (reason: safety not established). 
Duragesic 
(fentanyl) 
Management of persistent moderate-to-severe chronic pain. 
The drug is not intended for: 
- patients who are not opioid-tolerant 
- an “as needed” analgesic 
- management of acute pain for a short period of time 
- management of post-operative pain, including use after out-patient or day surgeries. 
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BACKGROUND: 
The World Health Organization (WHO) developed a step-ladder approach to the management of pain.  
The WHO suggests the use of non-opioid analgesics initially; if pain persists or increases, and the addition 
of “mild opioids” for mild-to-moderate pain. If pain persists or increases further to moderato-to-severe, the 
use of strong, morphine-like analgesic drugs is recommended.68 
After major surgery, the majority of patients experience moderate to severe pain. Opioid analgesics are 
considered a key component in the standard management of postoperative pain.69 Patients are typically 
switched from parenteral opioids to oral opioids during 24 to 48 hours after surgery.70 
Currently, the formulary includes several oral opioids as well as the transdermal patch: 
 methadone HCl (Dolophine®) 
 morphine HCl (MS contin®) 
 oxycodone HCl (Oxycontin®) 
 fentanyl (Duragesic®). 
The Department of Anesthesiology wishes to include another oral opioid to the formulary: oxymorphone.  
In June 2006, an oral immediate release as well as a prolonged release form of oxymorphone were 
approved by FDA for the treatment of acute moderate to severe pain: Opana® and Opana ER®.62;63 
The intention of this request is to treat patients with a more potent opioid that causes fewer adverse side 
effects like nausea, vomiting and sedation. 
Quantitatively, oxymorphone has tenfold less affinity to the κ receptor than the μ or σ receptor. The 
advantages of the σ affinity may be twofold: agonist actions at the σ receptor potentiate μ-mediated 
analgesic effects. They also may lessen the development of tolerance. The decreased affinity for the κ 
opioid receptor may explain the decreased sedation seen in previous studies compared to morphine. This, 
however, has not been confirmed by recent trials.71 
The aim of this review is to evaluate the clinical impact of the above mentioned pharmacokinetic data, 
assessing the following aspects: 
 analgesic efficacy of oxymorphone compared to the opioids available on the formulary, 
 incidence of adverse drug effects of oxymorphone compared to the opioids already available. 
 
CLINICAL PHARMACOLOGY:  
Oxymorphone hydrochloride is a semi-synthetic opioid analgesic. In addition to analgesia, other 
pharmacological effects of opioid agonists include anxiolysis, euphoria, feelings of relaxation, respiratory 
depression, constipation, miosis and cough suppression. The precise mechanism of the analgesic action is 
unknown. Specific central nervous system opioid receptors have been identified throughout the brain and 
spinal cord and play a role in the analgesic effects of this drug. The role that the opioid receptors play in the 
peripheral nervous system is unknown.62 
 
Table 6: Pharmacology of comparator drugs64-66 
Drug Clinical Pharmacology 
Dolophine 
(methadone HCl) 
synthetic mu-opioid agonist with multiple actions similar to those of morphine (see MS contin) 
possible antagonist at the N-methyl-D-aspartate (NMDA) receptor (the contribution of NMDA 





pure opioid agonist 
principal therapeutic action: analgesia 
other pharmacologic effects: the same as with Opana® 
no ceiling effect expected 
Duragesic 
(fentanyl) 
pure opioid agonist, affecting predominantly the mu receptor 
principal therapeutic action: analgesia 
other pharmaceutical effects: the same as with Opana® 
BLACK BOX WARNING: TRANSDERMAL USE IN OPIOID-NAÏVE PATIENTS 
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PHARMACOKINETICS: 
Like all pure opioid agonist analgesics, with increasing doses of oxymorphone there is increasing analgesia.62 
 
 













Dose (mg/day)  depending on pre-treatment and level of pain 
Bioavailability 10% 36 – 100% 40% 60-87%% 92% 
Absorption NA 
38% higher with fatty food 
30 – 60 min* 1.5 hrs biphasic: 
0.6 and 6.9hrs 
according to the 
dosage indicated 
Time to peak 
concentration 
30 min 3 hrs 
(1 – 12 hrs) 
1 – 7.5 hrs 3 – 4 hrs* 2.7 – 3.2 hrs 24-72 hrs 
Volume of 
distribution 
NA 1 – 8 L/kg 4L/kg 2.6L/kg 6L/kg 
Effect of food high influence 
dose prior or after eating 
NA NA, probably none with high fat food none 







10% - 12% 
(20% - 40%) 
85 - 90% 35%* 45% 79 - 87% 
Steady-state level after 3 days of multiple dosage after days of 
regular dosing 
after 1 day 24-36hrs several 72 hrs 
applications 
Half-life single dose:  
7.25 – 9.43 hrs 
multiple dose:  
NA 
single dose:  
9.35 – 11.30 hrs 
multiple dose:  
NA 
8 - 59 hrs 2-4 hrs 4.5 hrs 17 hrs 
(13 – 22 hrs) 
Renal Excretion unchanged: < 1% 
total: 33 – 38% 
mainly renal enterohepatic  mainly renal 80% 
CYP Substrate none 
CYP2C9 and CYP3A4 slightly increased 





none CYP2D6  




* Information not available in the packaging insert of the product. 
Source: Swiss federal approved drug information www.kompendium.ch, April 2008, updated 11.201072 
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Clinical Trials 
















To assess the 
analgesic 
effectiveness and 



















known at time of 
investigation] 
Population: N=86, 
no significant demographic and 
baseline pain differences present 
among groups 
 age 21 to 80 years 
 female 62% 




 adults age 18-80 years 
 history of chronic moderate-
to-severe cancer pain 
 requiring at least oxycodone  
20 mg or morphine 30 mg/day 
 stable analgesia (≤ 30% 
rescue medication within 3d) 
 pre-menopausal women not 




 interference with absorption 
of study drug  
 hypersensitivity to the drug 
Medications 
 oxymorphone ER 20mg 
[Opana ER] 
 morphine sulfate ER 
15, 30, 60, 100 mg 
[MS contin] 
 oxycodone HCl 
20, 40, 80 mg 
[Oxycontin] 
orally every 12 hrs 
 
use of other analgesics: 
none unless stable for  




 3 days of titration with 
morphine or oxycodone 
When stable analgesia: 
 period 1  
7 day treatment without 
dose adjustment 
 period 2 
crossover to 7 day 
treatment with 




study medication in the IR 




Exclusion criteria during 
the study 
patients unable to tolerate 
the assigned opioid were 
discontinued on this drug 
and treated with the 






 sleep quality 
 scheduled drugs 
 rescue medication 
 
Pain assessment 
 visual analog scale VAS 
0 mm=no pain 
10 mm excruciating pain 






 every 4 hrs from  
8 am to 8 pm 
 
Adverse effects 
visual analog scale 
   0 mm=no nausea 
10 mm=severe nausea 
   0 mm=no drowsiness 
10 mm=extreme drowsiness 
 
Patient satisfaction 
4 times VAS to assess least, 
worst and average pain during 
the previous 2 days 
 
Safety 
regular assessments of vital 
signs and adverse effects 
Period 1 





No significant differences in VAS for 




 no significant difference in pain relief 
among the three drugs 
 use of morphine rescue was twice as 




Treatment with oxymorphone after 
treatment with either morphine or 
oxycodone had no clinically meaningful 




linear dose relationships between 
oxymorphone and morphine as well as 
between oxymorphone and oxycodone 
were observed 
 Oxymorphone ER and IR 
are effective for acute, 
moderate-to-severe pain.  
 Opioid rotation from 
morphine to oxymorphone 
was easily manageable. 
 Equivalent analgesia was 
obtained. 
 A linear relationship 
between oxymorphone and 
the two comparator drugs 
was observed. 
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Clinical Trials 
Sinatra RS et al. A comparison of morphine, meperidine and oxymorphone as utilized in patient-controlled analgesia following cesarean 
































Duration = 24 
hours 
Population: N = 75 
 
demographic variety and 
intraoperative anesthetic 




 healthy females 
 no history of drug / alcohol 
abuse (ASA PS I or II) 
 elective cesarean delivery 
 under epidural anesthesia 
 
Exclusion Criteria 
 severe respiratory depression 
during treatment 
 
Drop out during study period 
none 
Treatment: 
3 drug solutions 
containing 1ml each 
prepared by the 
pharmacy: 
 1.5 mg  
morphine / ml 
 15 mg  
meperidine / ml 
 0.25 mg  
oxymorphone / ml 
 
Randomly assigned 




Four 1 ml 
increments, 5 min 
apart (total:  
6 mg morphine /  
60 mg meperidine / 
1 mg oxymorphone) 
 







(equivalent to  
1.8 mg morphine /  
18 mg meperidine / 
0.3 mg 
oxymorphone, max. 
every 8 min. 
Data collection points: 
 first request 
 completion of loading 
 1,2,4 hrs following PCA 
 then every 4 hrs 
    - at rest 
    - while moving 
 
Measures for: 
 pain intensity 
 satisfaction with drug 
10-cm visual analog scale 
0cm: no pain/very good 
10cm: worst pain/very bad 
mild: VAS 1-3 
moderate: VAS 4-6 
severe: VAS 7-10 
 
 total amount of drug 
 number of demands 
 number of PCA inject. 
 ratio injections/attempt 
 level of sedation 
0= alert 
1= drowsy, oriented 
2= drowsy, nonconversant 
3= very drowsy, disoriented 
 nausea & vomiting 
0= none 
1= occasional mild 







 covariance with Tukey 
and paired t test 
 Pearson r correlation 
 significance: P<0.5 
Pain scores after loading dose 
Difference was not statistically significant. 
 
Amount of drug used 
Total dose requirements not statistically different; 
BUT: morphine was self-administered more often 
during the first 4 hrs of treatment. 
 
Number of rescue medication requests by PCA 
most frequent in the morphine group 
 
Ratio injections to attempts I:A 
 morphine significantly less  
than meperidine (p<0.05) 




a) Scores not statistically different at rest; 
BUT:  
 morphine: highest score in the first 4 hrs 
 meperidine: as morphine, but score isn’t as high 
 oxymorphone: most rapid onset. 
superior analgesia with oxymorphone during hrs 
1 and 2, with morphine at hrs 12 and 24 (p< 0.05) 
b) Scores while moving: 
more severe pain following meperidine IV (p<0.005) 
 
Patient satisfaction 
 Highest incidence of sedation, restlessness and 
anxiety: morphine (p<0.05) 
 Highest incidence of nausea / vomiting: 
oxymorphone (28%, p<0.05) 
 Best overall satisfaction: meperidine vs. morphine 
(p<0.05) 





 All drugs offered 
excellent pain relief. 
 Significantly higher 
doses of morphine were 
administered during the 
first 4 hrs of treatment 
because of the delayed 
onset. 
 Meperidine offered the 
best I:A ratio followed by 
oxymorphone. 
 Meperidine was least 
effective in controlling 
pain during movement. 
 Oxymorphone spared 
excessive discomfort 
during early hours, but 
was not as effective as 
morphine at later 
intervals. 
 The incidence of nausea 
was significantly higher 
in the oxymorphone 
group. 
 Satisfaction with 
morphine was lowest 
because of analgesic 
delay, level of sedation, 
need for supplemental 
analgesic. 
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Clinical Trials 
Aqua K et al. Efficacy and tolerability of oxymorphone immediate release for acute postoperative pain after abdominal surgery: a randomized, 










Treatment Measures/definitions Results Outcomes 







release) in the 












maximal 48 hours 
Population: N=331 
similar demographic data 
 women 98.8% 
 hysterectomies 80.1% 
 mean age: 42.6 (9.3) yrs 
 
Inclusion Criteria 
 men, women aged ≥18 yrs 
 women: no pregnancy, sex. 
abstinent or contraception 
 abdominal surgery 
 requiring an incision ≥3 cm 
After surgery: 
 hospitalization for ≥36 hrs  
 oral opioid therapy for ≥48 hrs 
 capability of swallowing 
Within 30 hours of surgery 
 moderate to severe pain after 
stopping IV opioids  
[scale: 1=none, 2=mild, 
3=moderate, 4=severe] 
 pain intensity ≥ 50 mm 
[100mm visual analog scale; 
0= no pain, 100= worst pain] 
 
Exclusion Criteria 
 laparoscopic surgery 
 lactating women 
 anticonvulsants within 4 wks 
 MAO inhibitors within 2 wks 




median time to study 
discontinuation for all causes 
assessment of tolerability 
discontinuations due to treat-
emergent adverse events (AEs) 
Initial postoperative treatment 
short acting IM or IV opioid 
 
defined washout periods 
 
Four treatment groups 
 oxymorphone IR 10 mg 
 oxymorphone IR 20 mg 
 oxycodone IR 15 mg 
 placebo 
 
Two treatment schemes 
 single dose treatment 
1 single dose of drug 
 multiple dose treatment 
1 dose every 4 to 6 hrs 
upon request for 48 hrs 
 
Exclusion criteria during the 
study 
 single and multiple dose 
treatment 
need for additional 
analgesic within 4 hrs after 
study dose 
 single dose treatment 
need for additional 
analgesic 4 to 6 hrs after 
study dose: switch to 
multiple dose treatment 
 multiple dose treatment 
no need for additional 
analgesic at >6 hrs after 
previous dose 
Two efficacy assessments 
 single-dose evaluation  
6 hrs after the dose 
 multiple-dose evaluation  
48 hrs after the dose 
 
Measures taken: 
 in the hospital:  
measured by hospital staff 
 if discharged: 




 scale: 1=none, 2=mild, 
3=moderate, 4=severe 
 pain intensity ≥ 50 mm 
[100 mm visual analog 
scale; 0= no pain, 100= 
worst pain] 
 
Time data points: 
15, 30, 45, 60 minutes 
2, 3, 4, 5, 6 hrs after dose 
 
Efficacy endpoint 
median time to study 
discontinuation for all causes 
Assessment of tolerability 
discontinuations due to treat-
emergent adverse events  
 
Patient satisfaction at the end 





 Oxymorphone IR 20 mg was 
significantly more effective over the  
6 hrs-single-dose-evaluation (P<0.05). 
 Multiple dosing with active drugs has 
been significantly more effective than 
placebo (P<0.004 to P<0.005). 
 Average pain scores were significantly 




AEs did not differ significantly among 
active drug groups (P=NS): 
 oxymorphone IR 10 mg: 46.3% 
 oxymorphone IR 20 mg: 51.9% 
 oxycodone IR 15 mg:      54.2% 
 placebo:                         34.1% 
Higher doses of oxymorphone were less 
well tolerated than lower doses. 
 
Median time to study discontinuation  
P <0.006 
 oxymorphone IR 10 mg: 17.9 hrs 
 oxymorphone IR 20 mg: 20.3 hrs 
 oxycodone IR 15 mg:       24.1 hrs 
 placebo:                          4.8 hrs 
 
Overall patient satisfaction 
no significant difference in “good to 
excellent” among active drugs: 
 oxymorphone IR 10 mg: 62.0% 
 oxymorphone IR 20 mg: 67.5% 
 oxycodone IR 15 mg:      67.5% 
significant compared to placebo (P<0.017) 
 placebo:                         45.1% 
 Administration of 
multiple doses of 
oxymorphone and 
oxycodone provided 
significant relief of pain. 
 Oxymorphone IR 10 mg 
and oxycodone IR 15 mg 
single dose were not 
significantly better than 
placebo in single doses. 
 Oxymorphone IR 20 mg 
single dose was effective 
vs. placebo. 
 A rigid dosing schedule 
is not appropriate using 
opioids. 
 Discontinuation rates 
were similar among 
groups. 
 Higher doses of 
oxymorphone caused 
slightly higher rates of 
AEs (not significant). 
 Nausea, vomiting and 
pruritus were more 
frequent in the active 
treatment group, 
especially for 
oxymorphone IR 20 mg 
& oxycodone IR 15 mg. 
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CONTRAINDICATIONS / WARNINGS:  













Hypersensitivity yes yes yes yes yes yes 
Respiratory 
depression 
yes yes yes yes yes yes 
Bronchial asthma yes yes yes yes yes yes 
Paralytic ileus yes yes yes yes yes yes 
Hypercarbia not mentioned yes yes not mentioned yes yes 
Interaction with 
alcohol 
yes yes yes yes yes yes 
Head injury and 
increased 
intracranial pressure 
yes yes yes yes yes yes 
Hypotensive effect yes yes yes yes yes yes 
Anaphylaxis not mentioned not mentioned not mentioned yes not mentioned not mentioned 
Hepatic impairment yes yes yes no yes unclear 
Renal impairment yes yes unclear yes yes unclear 
 
PRECAUTIONS:  
















no no no only 100mg, 200mg tablets 





yes yes yes yes yes yes 
Interactions with 
agonist/antagonists 
yes yes yes yes yes NA 
Pre-existing heart 
disease 
yes yes yes yes yes yes 
Biliary tract disease yes yes yes yes yes yes 
Carcinogenicity no (rats) no (rats) unclear NA no (assays) no (assays) 
Pregnancy Category C Category C Category C Category C Category B Category C 
Lactation not recommended not recommended not recommended 
for analgesia 
not recommended not recommended not recommended 
Pediatric use not tested < 18 yrs not tested < 18 yrs not tested < 18 yrs not tested not tested < 18 yrs yes (>2 years) 
Geriatric use dose reduction dose reduction unclear unclear reduced clearance reduced clearance 
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ADVERSE EFFECTS: 
Table 11: Adverse reactions reported in at least 2% of patients treated with Opana62;63 




Nausea 19.0 11.5 
Pyrexia  14.2 8.1 
Somnolence 9.3 2.2 
Vomiting 9.0 7.0 
Pruritus 7.9 3.7 
Headache 6.8 4.4 
Dizziness (excl. Vertigo) 6.5 2.2 
Constipation 4.1 1.1 
Confusion 4.7 0.7 
 
The adverse effects listed in Table 11 have been found for all comparator drugs as well.64-67  
A thorough review of the published comparative studies didn’t show any advantage of oxymorphone over the comparator drugs.69-71;73;74  





Table 12: Possible interactions (list not complete) 62-67 












CNS depressants yes yes yes yes yes yes 
Mixed agonist / 
antagonists 
yes yes yes yes yes  
Anticholinergics yes yes yes yes yes NA 
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PRODUCT AVAILABILITY AND DOSING: 
As with any opiate, dosing should be adjusted for each patient individually, taking into account the patient’s prior analgesic treatment.62;63 
 
Table 13: FDA approved dosing of opioids62-67 
Trade Name Strength Usual Starting Dose 
 
Maximum dosage Special Instructions 
 OPANA tablets: 
5 mg 
10 mg 





10 to 20 mg by oral administration 
may repeat every four to six 
hours depending on the pain 
intensity 
initiation of therapy with doses 
higher than 20 mg is not 
recommended because of 
potential serious side effects 
 
1hour prior or two hours  
after eating 
OPANA ER tablets: 
5 mg  
7.5 mg  
10 mg  
15 mg  
 
20 mg  
30 mg  
40 mg 
opioid-naïve patients: 
5 mg every 12 hrs 
in 12-hour-intervals, dosage 
depending on the pain intensity
Titration by increments  
of 5-10 mg every 12 hrs  
every 3-7 days 
swallow whole 
 







2.5 to 10 mg every 8 to 12 hrs 
slow titration to effect conversion from parenteral to oral 
methadone or from other chronic 
opioids is highly variable and 
depends on baseline morphine as 
well as every individual 
MS Contin tablets:  
15 mg  
30 mg  




<60 mg morphine/day:  
15 mg twice daily 
in 12-hour-intervals,  












160 mg  
opioid-naïve patients: 
10 mg every 12 hrs 
in 12-hour-intervals,  
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ISMP SAFETY ALERTS (www.ismp.org): 
None.  
Tall man lettering, however, is recommended, e.g. OxyMORPHONE to minimize confusion with 
oxycodone or hydromorphone.75 
 
MONITORING: 
Respiratory rate, blood pressure, pulse, level of pain, sedation. 
UCSF has established processes and mechanisms for the appropriate monitoring of this 
medication. 
 
Table 14: COST COMPARISONS (April 28, 2008):  
Trade Name Cost Regimen Cost/day 
Opana  
  5 mg $1.94 5 mg PO Q 6 hours $7.76 
10 mg $3.52 10-20 mg PO Q 6 hours $14.00 - $28.00 
 
Opana ER  
  5 mg $1.28 5 mg PO Q 12 hours $2.56 
10 mg $2.70 10 mg PO Q 12 hours $5.40 
20 mg $4.35 20 mg PO Q 12 hours $8.70 
 
MS Contin  
30 mg $0.41 MS Contin 30 mg PO Q 24 hours $0.41 
60 mg $0.73 MS Contin 60 mg PO Q 24 hours $0.73 
 
Methadone  
10 mg $0.24 Methadone 20 mg PO Q 24 hours $0.48 
 
Oxycontin  
10 mg $1.22 Oxycontin 10 mg PO Q 24 hours $1.22 
20 mg $2.33 Oxycontin 20 mg PO Q 24 hours $2.33 
30 mg $3.50 Oxycontin 30 mg PO Q 24 hours $3.50 






CONCLUSION AND RECOMMENDATIONS: 
 Oxymorphone is an oral therapeutic option approved for the treatment of acute and chronic 
moderate-to-severe pain after surgery, available in a rapid and delayed onset form as well as in 
an IV form.62;63 
 Oxymorphone has a safety and efficacy profile similar to that of other commonly used pure 
opioids.76 
 Existing studies are consistent, that the use of oral oxymorphone is as effective and safe as 
comparator opiates.  
No superiority of oxymorphone regarding efficacy and safety has been observed.69-71;73;74;76;77  
 The quantity of existing comparative studies is very poor. No studies comparing oral or IV 
oxymorphone to oral or transdermal fentanyl or oral or IV methadone are available. The three 
comparative studies used in this review were conducted in different settings and used varying 
oral and IV formulations. 
 Although initially oxymorphone has a rapid onset of action, it appears less effective than 
morphine with repeat dosing (chronic therapy).70 
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 The adverse effects that have been observed with oxymorphone are similar to those seen with 
other mu-agonists currently available on the US market. An overall advantage regarding 
nausea and vomiting wasn’t observed.69-71;73;74;76;77  
 In one study, when administered IV via patient controlled analgesia, oxymorphone caused 
significantly more nausea and vomiting, but less sedation when compared with morphine.73 
This findings have not been confirmed in more recent studies.71 
 There are no studies available comparing the abuse potential of oxymorphone compared to 
other opiates. 
 More concerning is the significant influence of food on the absorption of oxymorphone, 
especially when used as rescue medication. 
 
Further comparative studies targeting potential advantages of oxymorphone over other 
opioids in the UCSF formulary have to be carried out before considering this opioid for 
addition to the UCSF formulary. 
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CHAPTER 2, Example 2 
A review of three stand-alone topical thrombins for surgical hemostasis 
This part of the PhD thesis has been published under the supervision of Christine M. Cheng, 





Topical thrombins are active hemostatic agents that can be used to minimize blood loss during 
surgery. Before 2007, the only topical thrombins available were derived from bovine plasma. 
Antibody formation to bovine thrombin and/or factor V, with subsequent risk of cross-reactivity with 
human factor V, and hemorrhagic complications associated with human factor-V deficiencies have 
been described in case reports of surgeries in which bovine thrombins were used. This risk is now 
included in the boxed warning section of the bovine thrombin prescribing information.  
In 2007 and 2008, 2 new topical thrombins from nonbovine sources received approval for use from 
the US Food and Drug Administration. The 3 active topical thrombins that are currently marketed 
are bovine plasma-derived thrombin, human plasma-derived thrombin, and human recombinant 
thrombin.  
Objective:  
The purpose of this review was to evaluate the literature on the efficacy and safety of topical 
thrombins and discuss the pharmacoeconomic considerations associated with their use.  
Methods:  
Pubmed, Embase, and International Pharmaceutical Abstracts were searched for relevant papers 
published in English through October 10, 2008, using the terms thrombin, human recombinant 
thrombin, bovine thrombin, plasma derived thrombin, and topical thrombin. Manufacturer-provided 
materials were also reviewed. Abstracts and unpublished data, as well as evaluations of sealants, 
adhesives, glues, and other hemostats that contain thrombin mixed with fibrinogen and other 
clotting factors, were excluded.  
Results:  
Four randomized, double-blind studies involving the active, stand-alone topical thrombins were 
found. The bovine thrombin involved in these studies was the predecessor to the currently 
marketed, highly purified bovine formulation. No studies comparing the human products, studies 
involving the highly purified bovine preparation, or placebo-controlled studies involving bovine 
thrombin were found. In a Phase III comparison of human recombinant thrombin and bovine 
thrombin, the percentages of patients who achieved hemostasis within 10 minutes of topical 
thrombin application were 95.4% and 95.1 %, respectively (95% CI, -3.7 to 5.0).  
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The incidence of hemostasis within 10 minutes was also similar in a Phase III comparison of 
human plasma-derived thrombin and bovine thrombin (both, 97.4% [95% CI, 0.96 to 1.05]).  
In the study that compared human recombinant and bovine thrombin, the incidence of antiproduct 
antibody formation was 21.5% (43/200) in the bovine thrombin group and 1.5% (3/198) in the 
human recombinant thrombin group (P < 0.001); patients with antibodies to bovine thrombin had 
numerically higher incidences of bleeding or thromboembolic events than did patients without 
these antibodies (19% vs. 13%; P value not reported).  
Human plasma-derived thrombin is available as a frozen sterile solution that must be thawed 
before application, whereas the human recombinant and bovine plasma-derived products are 
supplied as unrefrigerated sterile powders that must be reconstituted before use.  
The human thrombins are more costly than bovine thrombin on a per-vial basis. The average 
wholesale prices (US $, 2008) for 5000-IU vials of bovine thrombin and human recombinant 
thrombin were $87.85 and $103.20, respectively; the average wholesale price for a 4000- to 6000-
IU vial of human plasma-derived thrombin was $96.00. 
 
Conclusions:  
Topical thrombins vary in the ways in which they are manufactured and their safety profiles, 
storage requirements, and costs. Human recombinant thrombin and human plasma-derived 
thrombin have each been shown to have hemostatic efficacy comparable to that of bovine 
thrombin. Bovine thrombin carries the risk of formation of cross-reactive antibodies to bovine 
thrombin, factor V, and other impurities that may be present in these formulations.  
Immunogenicity data for the currently marketed, highly purified bovine thrombin relative to older 
formulations of bovine thrombin could not be found. Whether the potential safety advantage 
justifies the added cost of the human products remains to be established. 
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INTRODUCTION  
Topical thrombin is a hemostatic agent that is commonly used to facilitate hemostasis in a variety 
of surgical settings.79 Topical thrombin may be applied directly to the wound via topical spray, used 
in conjunction with absorbable gelatin or collagen sponges, or included as a component of wound 
dressings and fibrin and platelet sealants.79 It has been conservatively estimated that topical 
thrombin is used in >1 million surgical procedures and costs $250 million annually in the United 
States.80 
The first topical thrombin* to be approved by the US Food and Drug Administration (FDA) for use 
in the United States emerged in 1943. Two additional products were approved decades later (one 
in 1986** the other in 1995***).81 All of these products were derived from bovine plasma through 
different purification processes. Historically, bovine-derived thrombins have been associated with 
rare reports of hemostatic abnormalities, ranging from asymptomatic laboratory changes (e.g., 
prolonged prothrombin time [PT] and partial thromboplastin time [PTT]) to severe refractory 
bleeding and thrombosis.80
 
These events may be related to the development of antibodies to 
bovine factor V and other bovine protein contaminants present in the thrombin preparations. In 
some cases, these antibodies cross-reacted with homologous human factors, resulting in factor-V 
deficiency and impaired hemostasis.80;82;83 Manufacturers of bovine thrombins have responded to 
immunogenicity issues by preparing bovine products of increasing purity. The currently marketed 
formulation of bovine plasma-derived thrombin (Thrombin-JMI), approved for use in the United 
States in January 2008, represents the purest bovine thrombin yet, with bovine factor-Va levels 
below the limit of detection by semi quantitative Western blot analysis.82;84  
Recently, two topical thrombin products from nonbovine sources became available. Human 
plasma-derived thrombin was approved for use in the United States in August 2007+, and human 
recombinant thrombin was approved in January 2008§. The human thrombins are not associated 
with the risk of antibovine factor-V development or potential factor-V antibody formation.81  
The FDA-approved indication for each of the available topical thrombin products is identical. They 
are used as adjunctive hemostatic agents whenever oozing blood or minor bleeding from 
capillaries and small venules is accessible and not manageable by conventional methods (e.g., 
pressure, suture, ligature, cautery).84-86 They may be applied directly to the bleeding site or in 
conjunction with an absorbable gelatin sponge.84-86 
This review summarizes the published literature on the efficacy and tolerability of the 3 
commercially available stand-alone, single-ingredient, topical thrombin products available in the 
United States and discusses pharmacoeconomic considerations associated with these products.  
 
* Trademark: Thrombostat' (Parke-Davis, Morns Plains, New Jersey) 
** Trademark: Thrombogen' (Ethicon Inc., a Johnson & Johnson company, Somerville, New Jersey).  
*** Trademark: Thrombin-JMI (King Pharmaceuticals, Inc., Bristol, Tennessee).  
+ Trademark: Evithrom (Johnson & Johnson Wound Management, Somerville, New Jersey).  
§ Trademark: Recothrom (ZymoGenetics Inc., Seattle, Washington)
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METHODS  
Pubmed, Embase, and International Pharmaceutical Abstracts were searched for 
clinical trials and review articles on the use of active, stand-alone, topical thrombin 
products that were published in English through October 10, 2008. The search was 
conducted using the terms thrombin, human recombinant thrombin, bovine thrombin, 
plasma derived thrombin, and topical thrombin. References in the retrieved articles 
were also reviewed for additional relevant articles. The manufacturer's prescribing 
information and formulary dossiers for the 3 products were also obtained.84-86
 
Abstracts and unpublished information were excluded from analysis. Evaluations of 
sealants, adhesives, glues, and other hemostats that contain thrombin mixed with 
fibrinogen and other clotting factors were excluded from the review. 
 
RESULTS  
Product Description  
Topical thrombins vary in the ways in which they are manufactured and their safety profiles, 
storage requirements, and costs. Bovine thrombin is produced by extracting prothrombin from 
bovine plasma. After activation to thrombin, the product undergoes a chromatographic purification 
process that includes ion exchange and viral filtration.82;84 The added step of viral filtration reduces 
bovine factor-Va levels to <92 ng/mL, which is below the level of detection by semi quantitative 
Western blot analysis.82
 
The previous formulation of Thrombin-JMI, which underwent 
chromatographic purification, had a factor-Va concentration of <200 ng/mL.87 
Human thrombin is derived from human plasma from FDA-licensed plasmapheresis centers in the 
United States.85
 
Plasma is screened and tested for hepatitis B surface antigen; human 
immunodeficiency virus type-l and type-2 antibodies; hepatitis A, B, and C viruses; and parvovirus 
B19 according to FDA regulations. Prothrombin is extracted, activated, and then purified by 
solvent-detergent treatment and nanofiltration to inactivate and remove any viruses. The purified 
solution is then mixed with calcium chloride, sterile filtered, and frozen.85 
Human recombinant thrombin is produced via recombinant DNA technology from genetically 
modified Chinese hamster ovary cells that produce human thrombin precursors.86
 
Enzymes derived 
from snake venom are used to activate the precursors to human thrombin. The thrombin is then 
purified in a chromatographic process that includes solvent-detergent treatment and nanofiltration. 
Human recombinant thrombin is identical in amino-acid sequence to naturally occurring human 
thrombin. Other characteristics of these thrombin products are shown in Table 15.84-86 
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Sterile powder with 
diluent 
 
Pump spray kit 
(5, 10, 20 mL) 
Syringe spray kit 
(10, 20 mL) 
Epistaxis kit (5 mL) 
Vial 1 mL (ready-
to-use) 
Vial 5 mL 
Vial 10 mL 
Vial 20 mL 
1000 IU/mL Unopened vials at 2 to 25°C 
1 mL ready-to-use vial at 2-8°C 
 
Reconstituted solution at 2 to 8°C for up to 





















Frozen at 18°C for up to 2 years 
 
Refrigerated at 2 to 8°C for up to 30 days 
 
Thawed at room temperature for up to  










1000 IU/mL Unopened vials at 2 to 25°C 
 
Reconstituted solution at 
2 to 25°C for up to 24 hours 
 
Pharmacology  
Thrombin (activated factor II) is a serine protease that has multiple functions in the coagulation 
cascade. It converts fibrinogen into fibrin monomers, which cross-link to form a stable fibrin clot.80
 
Thrombin also activates clotting factors V, VIII, XI, and XIII and promotes platelet aggregation and 
adherence in wounds.81 Inhibition of thrombin activity by antithrombin III and protein C-mediated 
inhibition of factors V and VIII occur rapidly; hence, the thrombin effects are local and limited, and 
intravascular coagulation is avoided.80;81 Thrombin has also been shown to affect a multitude of 
other cell types, including fibroblasts, cardiomyocytes, keratinocytes, and monocytes, as part of the 
hemostatic and inflammatory response to vascular tissue injury. The multifunctional roles of 
thrombin are actively being explored and researched.80;88  
Pharmacokinetics  
No formal pharmacokinetic studies on topical thrombin products were identified in the literature 
search. Topically applied thrombin is expected to have only local effects.84-86 
Product-Specific Risks  
The prescribing information for topical bovine thrombin includes the following boxed warning:  
"The use of topical bovine thrombin preparations has occasionally been associated with 
abnormalities in hemostasis ranging from asymptomatic alterations in laboratory determinations, 
such as prolonged PT and PTT, to severe bleeding or thrombosis which rarely have been fatal.  
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These hemostatic effects appear to be related to the formation of antibodies against bovine 
thrombin and/or factor V, which in some cases may cross-react with human factor V, potentially 
resulting in factor V deficiency. Repeated clinical applications of topical bovine thrombin increase 
the likelihood that antibodies against thrombin and/or factor V may be formed. Consultation with an 
expert in coagulation disorders is recommended if a patient exhibits abnormal coagulation 
laboratory values, abnormal bleeding, or abnormal thrombosis following the use of topical 
thrombin. Any interventions should consider the immunologic basis of this condition. Patients with 
antibodies to bovine thrombin preparations should not be re-exposed to these products."84 
Antibodies to bovine factor V may cross-react with human factor V, leading to human factor-V 
deficiency that may be severe enough to cause excessive bleeding.80
 
Paradoxical cases of 
thrombosis have also been documented in patients who developed factor-V inhibitors following 
bovine thrombin treatment.89 Although many anecdotal reports of adverse reactions to topical 
bovine thrombins have been published, the true frequency of these events, in relation to the 
worldwide utilization of topical thrombins, is not known.80;89-91  
The association between antibody development and coagulopathies following bovine thrombin use 
has been established through case reports, rather than rigorous clinical trials. For example, the 
frequency of antibody development ranges from 10% to 95% in the published literature, and the 
cases are difficult to compare because of differences in the types of surgery, types of bovine 
antibodies being measured (thrombin, factor V, or other clotting factors), bovine thrombin 
preparations used, antibody detection techniques, and other patient factors.81;90-94 The rate of 
serious bleeding among patients with bovine thrombin-induced factor-V antibodies was 33 % 
according to a review of 58 cases, 6% of which were fatal.89
 
In addition, cases of coagulopathies 
that may be associated with topical bovine thrombins may be unrecognized and unreported.89  
Despite the FDA recommendation that patients with these antibodies not be re-exposed to topical 
bovine preparations, there is presently no FDA-approved laboratory test available to screen 
patients for the presence of antibodies to bovine thrombin.80
 
Attempting to identify patients 
previously exposed to bovine thrombin is often difficult to achieve by reviewing medical records 
because thrombin use may not be documented consistently in the patient's hospital chart.89  
Symptoms of factor V deficiency include prolonged PT and activated PTT, which may occur within 
7 to 14 days after bovine thrombin exposure and persists for an average of 2 months.87;89 
Excessive bleeding that is refractory to vitamin K and fresh frozen plasma is usually indicative of 
factor-V activity that is <30% of normal.87 
Treatment of antibody-induced factor-V deficiency is guided by symptom severity. Asymptomatic 
laboratory abnormalities require no specific treatment but should be monitored closely. 
Immunosuppression with corticosteroids and combination chemotherapy agents, high-dose 
intravenous immune globulins, plasmapheresis, and plasma and platelet transfusions have been 
effective in managing hemorrhagic complications.89;92;95
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Although human plasma-derived thrombin avoids the issue of cross-immunogenicity, it does carry 
the potential to transmit infections from infected plasma donors. Screening plasma donors for 
exposure to certain infectious agents, such as viruses and Creutzfeldt-Jakob disease (CJD), and 
testing for infectious agents reduces but does not eliminate the risk of transmitting disease, 
including unknown infectious agents. Patients should be aware of the risks and benefits of human 
plasma-derived thrombin use before undergoing treatment. To date, no cases of CJD or viral 
seroconversion have been reported.85 
Human recombinant thrombin is the only plasma-free thrombin product available. It minimizes the 
risks of immunogenic cross-reactivity and infection transmission from human plasma donors.81  
 
Therapeutic Efficacy  
Four randomized, double-blind studies on the efficacy and safety of active, stand-alone topical 
thrombins were identified in the literature search.96-99 One was a placebo-controlled study of 
human recombinant thrombin,97 2 studies compared the efficacy and safety of human recombinant 
thrombin and bovine thrombin,96;98 and 1 study compared the efficacy and safety of human plasma-
derived thrombin and bovine thrombin99.
 
All of these studies were conducted between April 2004 
and July 2006. Despite the use of topical bovine thrombins for decades before they were approved 
by the FDA, no published studies evaluating the efficacy of stand-alone topical bovine thrombin 
relative to placebo were identified in the literature search.  
In a Phase II, double-blind, placebo-controlled, efficacy and safety analysis of human recombinant 
thrombin conducted by Chapman et al.,97 130 adults undergoing arteriovenous (AV) graft formation 
for hemodialysis, major hepatic resection, peripheral arterial bypass (PAB) surgery, or spinal 
surgery were randomized to receive a single application of either human recombinant thrombin 
(1000 IU/mL) or placebo. Patients with hypersensitivity to thrombin or other coagulation factors 
were excluded. The treatments were added to either Gelfoam® (Pharmacia, Kalamazoo, Michigan) 
or Surgifoam® (Johnson & Johnson, Somerville, New Jersey) gelatin surgical sponges before 
application. Time to hemostasis (TTH) was measured for a maximum of 10 minutes, after which 
human recombinant thrombin could be used as rescue therapy if needed. Ten percent (9/93) of the 
bleeding sites in the thrombin-treated group and 20% (18/90) of those in the placebo group 
required rescue therapy. A hazard ratio of 1.3 was reported for the comparison of TTH for thrombin 
versus placebo, although the authors state that the study was not powered to detect significant 
differences between the 2 groups or designed to test any formal statistical hypotheses. In addition, 
the results were not stratified by surgery type or type of sponge used; thus, the wound site and 
severity of bleeding, as well as any differences in the intrinsic properties of the gelatin sponges, 
were not addressed.  
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Chapman et al.96 also conducted a Phase III non-inferiority evaluation, in which the efficacy and 
tolerability of human recombinant thrombin (1000 IU/mL) was compared with bovine thrombin 
(1000 IU/mL) in 401 adults undergoing hepatic resection, spinal surgery, PAB surgery, or AV graft 
formation. Patients with known sensitivity to bovine materials were excluded from the study. Both 
treatments were applied with an absorbable gelatin sponge (Gelfoam® for spinal surgeries, 
Surgifoam® for nonspinal surgeries). Overall, the TTH within 10 minutes after a single application 
of study drug was 95.1 % in the bovine thrombin group and 95.4% in the human recombinant 
thrombin group (95% CI, -3.7 to 5.0). Because this study did not include a placebo arm, no 
conclusions can be drawn about the efficacy of either human recombinant thrombin or bovine 
thrombin relative to placebo. 
In a separate subanalysis led by Weaver et al.98 data from 144 vascular surgery patients (PAB or 
AV graft formation) who had participated in the Phase III human recombinant thrombin 
comparative trial were further evaluated. This study found that, among the 88 patients who 
underwent PAB surgery, 55% (45/82) of the bleeding sites treated with human recombinant 
thrombin and 39% (32/83) of those treated with bovine thrombin achieved hemostasis within 3 
minutes (P = 0.046). The clinical significance of this finding is not known and has yet to be 
reproduced in other studies. 
Doria et al.99 conducted a randomized, double-blind study in which human plasma-derived 
thrombin (800-1200 IU/mL) was compared with bovine thrombin (1000 IU/mL) in 305 adults 
undergoing elective cardiovascular, spine, and general or posttraumatic surgery. Patients with 
known antibodies to bovine thrombin preparations were excluded from the study. Treatments were 
applied using a gelatin sponge (Surgifoam®), and hemostasis was assessed at 3, 6, and 10 
minutes after treatment. The treatments were considered equivalent if the 95% CIs for both 
treatments were between 0.8 and 1.25. When all surgical types were combined, 97.4% of the 
human plasma-derived thrombin recipients and 97.4% of the bovine thrombin recipients 
experienced hemostasis within 10 minutes (95% CI, 0.96 - 1.05). At 6 minutes, the success rate for 
human plasma-derived thrombin was 94.8% compared with 92.8% for bovine thrombin (95% CI, 
0.96 - 1.09); at 3 minutes, the success rates were 73.2% and 72.4%, respectively (95% CI, 0.88 - 
1.16). The proportion of patients achieving hemostasis was also equivalent at each time point 
when analyzed by surgery type. Again, this study lacked a placebo group, so no conclusions could 
be drawn about the absolute benefit of thrombin compared with conventional care. 
Based on the results of these studies, the efficacy of the human and bovine thrombin products 
seems to be comparable; however, several inherent limitations should be noted. Differences in 
surgical technique, hemostasis assessment, patient-specific bleeding risk, type and size of sponge 
used, thrombin application technique, and use of preoperative hemostatics may have influenced 
the TTH.  
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Perhaps even more important, the only study to include a placebo arm was not designed to detect 
differences in efficacy; thus, the absolute utility of topical thrombins compared with conventional 
techniques to minimize intraoperative bleeding remains unclear. Furthermore, published 
comparative studies between human plasma-derived thrombin and human recombinant thrombin 
could not be found, and it should be noted that the comparator bovine product used in these 
studies was an older version of Thrombin-JMI than the one currently being marketed; no 
comparative studies involving the current formulation were identified in the literature search. 
 
Adverse Effects  
In the Phase II, placebo-controlled study of human recombinant thrombin in 130 adults conducted 
by Chapman et al.,97 patients exposed to human recombinant thrombin (n = 88) experienced a 
numerically higher incidence of mild to moderate nausea (26% vs. 45%), constipation (12% vs. 
27%), insomnia (5% vs. 19%), and vomiting (2% vs. 13%) than did patients in the placebo group (n 
= 42). Whether these differences were statistically significant is not known because no formal 
statistical tests were performed in this study, and there may not have been enough participants to 
detect significant differences between the treatment groups.97 These results may have been 
confounded by the number of patients who received rescue therapy with human recombinant 
thrombin, who also may have had more extensive bleeding or more complicated surgeries. 
Changes in laboratory and coagulation parameters were similar for the groups (incidences not 
reported). Two patients (1 in the thrombin group and 1 in the placebo group) developed antibodies 
to the human recombinant product; however, these antibodies had no effect on extrinsic or 
endogenous thrombin activity and were not associated with any bleeding complications. It is 
unclear why the patient in the placebo group developed these antibodies.97  
In the Phase III study conducted by Chapman et al.96 
 
the incidences of adverse events and 
abnormal laboratory parameters were similar for patients treated with human recombinant thrombin 
and those treated with bovine thrombin. The most common adverse events included nonspecific 
incision-site complications (63% in both groups), nausea and vomiting (33% vs. 40% in the human 
recombinant thrombin and bovine thrombin groups, respectively), procedural pain (29% vs. 34%), 
nonspecific cardiac problems (20% vs. 18%), and infection (13% vs. 15%). The human 
recombinant thrombin group had a significantly lower incidence of positive antibodies than the 
bovine thrombin group (1.5% [3/198] vs. 21.5% [43/200], respectively; P < 0.001); 1.5% (3/200) of 
the patients in the human recombinant thrombin group and 5% (10/198) of those in the bovine 
thrombin group already had antibodies to the administered product at baseline. Among these 
patients, 80% (8/10) of the bovine thrombin recipients experienced at least a 1-unit increase in 
antibody titer after treatment, whereas none of the human recombinant thrombin recipients 
experienced such increases.  
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The TTH was not affected by the presence of baseline antiproduct antibodies in either treatment 
group, and the presence of anti-recombinant antibodies did not have a neutralizing effect on native 
human thrombin activity. In a 1-month post hoc analysis, patients with antibovine thrombin 
antibodies had numerically higher incidences of undefined bleeding and thromboembolic events 
(19% vs. 13%), hypersensitivity events (18% vs. 16%), and elevated levels of activated PTT (33 % 
vs. 14%) compared with patients without these antibodies. None of the patients with antibodies to 
human recombinant thrombin experienced these adverse outcomes.98 The incidences of prolonged 
PT and international normalized ratio (INR) abnormalities were similar in patients with and without 
bovine antibodies (data not reported). The incidences of specific antibodies against bovine and 
human factor V were not reported. The FDA review of this study noted that it was unclear whether 
chance alone could have accounted for the rate of bleeding adverse events among subjects with 
positive antibovine antibodies, because the study was not designed to evaluate differences in 
immunogenicity.100  
In a Phase III study comparing human plasma-derived thrombin and bovine thrombin in 305 
patients, conducted by Doria et al. the incidence of laboratory abnormalities was 95% in the human 
plasma-derived thrombin group and 98% in the bovine thrombin group; however, the incidences of 
specific hematologic abnormalities, including elevated INR and prolonged PT and PTT, were not 
reported.99 Of the 248 patients included in the antibody assessment, the rate of antibody 
development was 3% (4/122) in the human plasma-derived thrombin group and 13% (16/126) in 
the bovine thrombin group (P < 0.01). The incidence of antibovine factor V/Va antibody 
development was also significantly higher in patients treated with bovine thrombin (10% [12/126]) 
than in those treated with human plasma-derived thrombin (2% [2/122]; P = 0.01). The 2 patients 
who developed antibovine antibodies in the human plasma-derived thrombin group had been 
exposed to bovine thrombin before study enrollment. None of the patients in this study developed 
antihuman factor-V antibodies; viral serologies were not monitored. 
 
Contraindications  
All thrombin products are contraindicated for injection into the circulatory system because of the 
risk of thrombosis, and they should not be used to treat severe or brisk arterial bleeding. Bovine 
thrombin should not be administered to patients with hypersensitivity to any of its components or to 
materials of bovine origin.84
 
The use of human plasma-derived thrombin is contraindicated in 
patients with a history of severe systemic reactions or anaphylaxis to human blood products.85
 
Patients with known hypersensitivity to hamster proteins, snake proteins, or any component of 
human recombinant thrombin should not be treated with this agent due to the risk of allergic 
reaction.86 
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Drug Interactions  
There are no known drug interactions with the topical thrombins.84-86
 
 
Dosing and Administration  
All topical thrombin vials and spray kits are intended for single use only. The amount of thrombin 
required for a particular surgery depends on the size of the bleeding site and method of 
application.84-86
 
Specific dosing guidelines for the individual thrombins could not be found. Topical 
thrombins should be applied to the surface of bleeding tissue, either directly to the site or in 
conjunction with an absorbable gelatin sponge, according to the manufacturer's instructions.84-86 
The clinical studies involving human plasma-derived thrombin used volumes of up to 10 mL.85 
The amounts of topical thrombins used in the other studies were not reported. 
 
Pharmacoeconomic Considerations  
The average wholesale prices of the topical thrombins are listed in Table 16.86;101;102 
 
Table 16: Average wholesale price of topical thrombin preparations (US $, 2008)86;101;102 
Product Vial size Price Cost/IU 
Bovine topical thrombin 
(Thrombin JMI) 
5,000 IU vial 
20,000 IU vial 
20,000 IU vial with spray pump 









Human plasma derived 
topical thrombin 
(Evithrom) 
1,600-2,400 IU vial (2 mL) 
4,000-6,000 IU vial (5 mL) 




$0.028 - 0.042 
$0.016 - 0.024 
$0.016 - 0.023 
Recombinant topical 
thrombin (Recothrom) 
5,000 IU vial 
20,000 IU vial 
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Bovine topical thrombin costs less than the human products on a per-vial basis.101 
Whether the potential safety advantage of the human thrombins justifies their added expense is 
unknown and depends on a variety of factors.  
First, the incidence of factor-Va antibody formation with the currently marketed, highly purified 
formulation of bovine thrombin is unknown; whether this preparation is less immunogenic, 
particularly for patients previously exposed to bovine products of lesser purity, has yet to be 
determined.  
The minimum concentration of bovine factor V needed to induce an immunogenic reaction has not 
been established. Although no immunogenicity data are available for the current formulation of 
bovine thrombin, this formulation carries the same black-box warning as previous thrombins of 
lesser purity that were derived from bovine sources.  
Differences in storage requirements for the 3 products should also be considered when selecting a 
topical thrombin. Human plasma-derived thrombin is supplied as a frozen sterile solution that may 
be stored frozen for up to 2 years or refrigerated for up to 30 days.85 Once refrigerated, the solution 
should not be refrozen. The thawed solution can be stored at room temperature for up to 24 hours 
before use. Once thawed, the solution should not be refrigerated; any thawed solution that is 
unused within 24 hours must be discarded.  
In contrast, bovine thrombin and human recombinant thrombin are supplied as sterile powders that 
are stored at room temperature. After reconstitution, bovine thrombin can be refrigerated for up to 
24 hours or stored at room temperature for up to 8 hours before use. Reconstituted solutions of 
human recombinant thrombin can be stored at room temperature for up to 24 hours before use.84;86  
These differences in storage requirements may be important when considering strategies to 
minimize potential waste from unused thawed or reconstituted drug.  




Topical thrombins vary in the ways in which they are manufactured and their safety profiles, 
storage requirements, and costs. No immunogenicity data are available for the currently marketed 
bovine thrombin, and no head-to-head comparison studies have been conducted on the current 
formulation. The clinical significance of manufacturing changes that have progressively reduced 
the level of bovine factor-V contaminants in bovine thrombin preparations has yet to be 
determined. The safety of repeated applications of human plasma-derived thrombin or human 
recombinant thrombin is also unknown. In addition, the lack of rigorous placebo-controlled studies 
of the topical thrombins also raises the question of their advantages over conventional techniques 
to minimize blood loss.  
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The number of randomized, controlled studies assessing the efficacy of the stand-alone topical 
thrombins is surprisingly sparse, given that topical thrombins have been in use for >60 years.  
It should be noted, however, that we excluded evaluations of sealants, adhesives, and glues, 
which often incorporate a mixture of platelets, thrombin, fibrinogen, and other clotting factors. 
Nevertheless, the impact of topical thrombin use on patient or surgical outcomes has yet to be 
clearly established.80 Mechanisms to document and track patient exposure to thrombins are also 
needed to determine the potential risk of developing antibovine, antibody-mediated coagulopathies 




Three topical thrombins are currently marketed in the United States: bovine plasma-derived, 
human plasma-derived, and human recombinant thrombin. The bovine thrombin is a highly purified 
preparation, although it still carries a boxed warning that describes the risk of immunogenicity 
reactions associated with formation of potentially cross-reactive antibodies to bovine thrombin, 
factor V, and other impurities that may be present in the bovine preparation. More experience with 
these products is needed to determine whether any efficacy, safety, or economic differences exist 







Since  the IOM report “To Err is Human”, health-care institutions must proactively pursue 
medication safety, assessing institution-specific data and ensuring the quality of drug therapy.7 
The previous chapter provided examples of evidence-based literature reviews for the consideration 
of formulary additions. In the following chapters, methods for the assessment of institution-specific 
medication use safety are discussed. 
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Myers et al. recommend an interdisciplinary approach to medication safety: 
1. Establishing a common agreement that there is a problem. 
2. Establishing a common aim (a shared vision) to improve. 
3. Identifying requisite elements of safety. 
4. Redesigning medication use, if necessary. 
5. Establishing ongoing surveillance. 
6. Establishing ongoing dialogue on the subject 
(educational conference, opinion survey, collaborative activities).103;104 
 
While the following organizations provide guidance for medication safety activities in individual 
healthcare institutions, it is unknown, which method is the most efficient and effective. 
[last accessed: February 27, 2011] 
 Institute for Safe Mediation Practices ISMP 
www.ismp.org 
 Institute for Health Care Improvement IHI 
www.ihi.org  
(see also: “The 100’000 lives campaign”) 
 National Health Service United Kingdom NHS 
www.nhs.co.uk 
 The Joint Commission 
www.jointcommission.org  
 Agency for Healthcare Research and Quality 
www.ahrq.org 
 U.S. Veterans Affairs National Center for Patient Safety 
www.patientsafety.gov 
 The Leapfrog Group 
www.leapfroggroup.org 
 The National Quality Forum 
www.qualityforum.org  
 Dennis Quaid Foundation (e.g., “Chasing Zero”) 
dsc.discovery.com/videos/chasing-zero-part-1.html 
 The World Health Organization 
www.who.org 
(see also: www.high5s.org) 
 The American Society of Health-System Pharmacists 
www.ashp.org 
(see also: “The 2015 Health System Pharmacy Initiative” www.ashp.org/2015) 
 
In the light of limited resources as for example in Swiss hospital pharmacies with only 0.76 FTEs 
per 100 beds, the question of an optimal method for medication safety assessment shall be 
addressed in chapter 3. 
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CHAPTER 3 
Medication safety assessment methods:  
How can institutions efficiently address drug-related problems? 
This chapter has been published in The American Journal of Health System Pharmacy 2011, 




Health care institutions continuously assess the safety of medication use through active 
monitoring, identification of important drug-related problems (DRPs) and development of 
remediation strategies. Recommended methods from organizations, such as the Institute for Safe 
Medication Practice, include incident reporting (IR), direct observation (OB), chart review (CH) and 
trigger tool analysis (TR).  However, the optimal method for identifying DRPs is unknown. The aim 
of this manuscript is to review the accuracy, efficiency and efficacy of these 4 commonly 
recommended medication safety methodologies. 
 
Methods 
Pubmed, Embase and Scopus databases were systematically searched for any comparative study 
in which at least 2 of the 4 chosen methodologies (IR, OB, CH and TR) were compared to one 
another.  
Any study which compared 2 or more methodologies for quantitative accuracy, adequacy for the 
assessment of medication errors and adverse drug events, efficiency (effort and cost) and efficacy 
and also provided numerical data were included in the analysis. 
 
Results 
Twenty-eight studies were included in this review. 
OB identified the greatest number of DRP reports, while IR identified the least. However, IR 
generally showed a higher specificity compared to the other methods and most effectively captured 
severe DRPs. In contrast, the sensitivity of IR was lower when compared to TR. Finally, while TR 
was the least labor-intensive of the 4 methodologies, IR appears to be the least expensive, 
however, only when linked with concomitant automated reporting systems and targeted follow-up. 
 
Conclusion 
All four assessment techniques have different strengths and weaknesses. In addition, overlap 
between different methods in identifying DRPs is minimal. While TR appears to be the most 
effective and labor-efficient method, IR best identifies high severity DRPs. Consequently, the 
review of the use of combination methodologies, such as the TR with IR, is strongly recommended 
for optimal identification of DRPs. 
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INTRODUCTION 
The health-related and economic burden associated with drug-related problems (DRPs), including 
adverse drug event (ADEs), adverse drug reactions (ADRs) and medication errors (MEs), has 
resulted in requirements to ensure improvement of medication safety.2;7;105 In the state of 
California, Senate Bill 1875 (SB1875) requires health care institutions to implement a formal plan 
to reduce drug-related problems as a condition of licensure.106 
Certain medications commonly referred to as “high-risk” or “high-alert” medications carry a high 
risk of patient harm if they are misused.107 The 2008 Joint Commission National Patient Safety 
Goals require that health care institutions improve the safety of medication use, particularly for 
certain high risk drugs.108 
The Institute for Healthcare Improvement’s “5 Million Live Campaign” similarly focuses upon 
prevention of harm associated with high-alert medications.109 Finally the United States 
Pharmacopeia and the Institute for Safe Medication Practices (ISMP) have identified those high 
risk drugs requiring medication use evaluation.110 
Detection and quantification of DRPs is critical to the identification of underlying causes as well as 
the creation of remedial action plans.111;112 The Institute for Healthcare Improvement (IHI)35, the 
Institute for Safe Medication Practices (ISMP)113 and the Joint Commission108 recommend various 
methods for medication safety assessment. However, the optimal methodology(ies) for an efficient 
identification of DRPs in an individual institution has not been identified so far in the published 
literature. The aim of this review is to characterize and compare the accuracy, efficiency and 




Identification of common approaches to identifying drug-related problems 
A literature search was conducted to identify common approaches for identifying DRPs within 
health systems. The search included the timeframe from January 2000 - October 2009. This 
timeframe was chosen because of the fundamental changes in drug safety awareness since the 
publication of the Institute of Medicines’ (IOM) report “To err is human”7, as well as the growing 
deployment of information technology in healthcare institutions. 
Books addressing medication safety issues and indexed in the library database of the University of 
California system2;7;105;113-118 as well as recommendations, guidelines and position papers 
published by IHI35, ISMP119, and the Joint Commission108 were reviewed. 
While up to 12 methods used in the assessment of medication safety were identified, we 
specifically focused upon the 4 most commonly recommended methods (incident report review 
(IR), chart review (CH), direct observation (OB), and trigger tool (TR)), all of which are widely used 
at UCSF.  
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Definitions 
The term “drug-related problem” was adopted from the publication of van Mil et al. to encompass 
all medication-related events.120 The term includes adverse drug events (ADEs) consisting of 
adverse drug reactions (ADRs) and medication errors (MEs). It also includes processes (causes) 
and outcomes (effects) and is not limited to events causing harm.120 
IR is defined as voluntary reporting of incidents by health care personnel and/or patients and 
parents. Reporting can either be executed by paper form, email, fax, telephone or via an interactive 
computer-based mechanism.113 
OB refers to a wide range of direct, real-time observation techniques of all aspects of the 
medication use process.121;122  
CH encompasses concurrent or retrospective medical record review, including, but not limited to, 
medical records, discharge summaries, pharmacy databases and/or laboratory data.105;123  
TR consists of a targeted medical record review, either manually or automatically (computer alerts, 
coded medical records) executed.105;111  
 
Identification of studies comparing two or more methods of identifying drug-related 
problems 
An additional systematic review of the literature was conducted including any study that directly 
compared the selected methodologies (IR, CH, OB and TR) to detect DRPs. Two authors 
independently reviewed and categorized the studies.  
All 4 tools were assessed with respect to:  
1) quantification of DRPs (quantity of DRPs identified),  
2) accuracy (ability to identify medication errors and adverse drug events),  
3) efficiency (effort and cost) and efficacy (ability to identify DRPs). 
In addition, the various methodologies were compared with respect to: the severity and type of 
DRPs, the interprofessional differences in reporting, and the specific component of the medication 
use process in which the DRP was identified. 
 
Literature search: 
The evaluation was based on a systematic literature review of Pubmed, Embase and Scopus 
databases. In order to search for comparative studies, the free text terms (drug therapy OR drug-
related problem OR medication error OR medication errors OR medication safety OR adverse drug 
event OR adverse drug reaction OR adverse effect OR high risk drug OR high alert drug) AND 
(assessment OR evaluation OR review OR screening OR surveillance OR strategy) were 
combined with each of the following permutations on the different methods: 
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‘ 
Set 1: (incident OR voluntary) AND (chart review OR chart reviewed) 
Set 2: (incident OR voluntary) AND (direct observation OR observer) 
Set 3: (incident OR voluntary) AND (trigger OR indicator) 
Set 4: (chart review OR chart reviewed) AND (direct observation OR observer) 
Set 5:  (chart review OR chart reviewed) AND (trigger OR indicator) 
Set 6:  (direct observation OR observer) AND (trigger OR indicator). 
No time or language restrictions were applied.  
After screening of the abstracts, all potentially relevant full-text publications were evaluated. A 
“related articles” search was run against those articles that were considered relevant.  
References of the retrieved articles were also reviewed for additional relevant articles. 
 
Study categorization 
Studies were included if they reported original, comparative, numeric data on at least 2 of the 4 
methods. 
Studies were excluded  
 if the primary objective of the study did not include comparison of at least 2 of the four 
medication safety assessment methods, 
 if the respective methods were studied during different time periods (unless results were 
adjusted for this difference), or  
 if individual numeric results for the methods assessed were not reported. 
Two authors independently reviewed and categorized the studies according to (1) whether the 
study met criteria for inclusion and (2) the types of methods being compared. Disagreements were 
resolved via consensus. In some cases, the method described in an article differed from the 
method categorization determined for this review. As an example, if the method assessing DRPs 
was identified in the primary reference as CH, but was determined to be a targeted study using 
specific indicators to identify DRPs, it was included in this review as TR.  
No other adjustments or recategorizations were undertaken. 
 
Data extraction: 
The following categories were evaluated and entered into an Excel spread-sheet: reference 
(author, year of publication, origin of the study), setting, methods, original outcome measures, and 
quantitative results. Accuracy of the different methods was evaluated for positive predictive value 
PPV, sensitivity, specificity, number of false negatives, and/or number of false positives and 
interrater agreement; resource utilization was reflected in time effort, and/or cost). Additional data 
included severity and type of DRPs, identification of the health care provider reporting, and 
medication use processes associated with the specific DRP.  
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RESULTS 
Our literature review (see figure 1) identified 65 comparative studies involving at least 2 of the 4 
medication safety assessment methods. Twenty studies were excluded because comparative data 
was not provided regarding the medication safety assessment methods. Four studies were 
excluded because they were determined to have compared different approaches to the same 
method. Twelve studies did not report comparative data or did not distinguish the results for the 
individual methods. One study was excluded because different time frames were used for the 
individual methods to collect DRP data. The remaining 28 studies were included for review.  
These studies are displayed in Table 17. 
 




Excluded due to violation 
of basic inclusion criteria 
(e.g, duplicates, 





Fulltext retrieval for 
critical appraisal 
(n=65) 
Excluded after critical 
appraisal 
(n=37) 
- Different primary 
objective: (n=20) 
- Different aspects of 
the same method 
(n=4) 
- No comparative 
individual data (n=12) 
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Twenty-two of the included 28 publications compared 2 of the 4 methodologies. Six publications 
compared 3 methods. No publication compared all 4 methodologies. 
Twenty-nine percent of the studies evaluated IR, 24% CH, 24% TR and only 9% OB. 
 
Comparative data was inconsistently presented. As an example, the denominator used for 
reporting detected DRPs varied from total number of DRPs to total number of opportunities for a 
DRP. The rate of reported DRP also varied with respect to rate per number of beds, number of 
patients or number of patient days. 
 
Quantification of DRPs  
In review of the 4 methodologies, IR was consistently least likely to identify DRPs.  
Thirteen studies compared IR to CH.36;124-135 Chart review consistently yielded more event reports 
than IR. However, targeted encouragement of providers to report IRs yielded higher rates of 
IRs.125;132;135  
In contrast, OB yielded the greatest number of DRP reports in most comparative studies, up to 400 
times reported DRPs when compared with IR, TR or CH.5;124;126;136-138  
Five studies directly compared CH to TR. Two studies reported a higher rate of DRPs using TR, 
while 3 documented the opposite.127-129;139;140 The number of DRPs detected by TR compared to 
CH was directly related to the specificity of the applied triggers; the specificity of the triggers varied 
from 19.6% to 76%.128;129;139 
Overlap in the identification of DRPs with the respective methods was rarely observed. As an 
example, the reported agreement between IR and TR was found to be only 0.5% - 10%.127;141 
In the majority of the IR-based studies, IRs were rarely, if ever, documented in patient charts.130-132  
OB was the most likely method to identify DRPs detected by other methods; all DRPs identified by 
IR or CH were detected by OB as well.136 
 
Accuracy 
Sensitivity, specificity, and predictive values of the different DRP assessment methods varied 
widely. 
IR was generally more specific in identifying DRPS than the other methods.124;129;142  
The rate of false positive DRPs has been reported to be 0% for IR, 0.3% for CH and 3.5% for 
OB.124 In contrast, IR is consistently less sensitive when compared to TR.124;129;143;144 The one study 
in which IR was found to be more sensitive than TR, interestingly, only included patient-reported 
IRs.143  
The PPV ranged from 0 to 100% for trigger tool, depending upon the design of the rules or 
triggers.127;137;139;142-144  
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Resource utilization 
While several studies provided information regarding resource utilization, only 7 studies provided 
numerical data.124;127;133;138;140;144;145 These studies are displayed in Table 18. 
Three studies provided comparative data regarding labor resource needs.124;127;138 OB and CH 
were found to be more labor-intensive compared with either IR or TR.127;138 TR was found to be the 
most time-efficient method.127;144 However, this advantage for TR was observed only if the triggers 
had been previously validated and defined. Comparing TR to IR and OB, TR was documented to 
be the least labor-intensive method, followed by IR and OB, respectively.124 Despite study 
limitations, including limited description of the cost of planning, training and evaluation, an 
automated IR was the least expensive methodology.124;127;132-134;138;139  
While startup-costs were substantial, once fully established, TR was less expensive to perform 
when compared with CH.140;145 One study documented that CH was associated with a cost of 
$68.70/ADR as compared to $42.40/ADR using TR.140 When evaluating cost per drug dose, CH 
cost only $0.63 per dose compared to $4.82 for OB.124 
Only one study, comparing IR and TR, evaluated both the cost and potential savings associated 
with DRP detection, and documented annual cost savings of $56,000 due to the avoidance of 
detectable DRPs.144  
 
Additional findings 
Depending upon the severity of the DRPs, certain methods may be superior to others. In general, 
IR detected more severe events, while CH was more likely to reveal moderate DRPs.130  
The likelihood of reporting DRPs differed accordingly to health care practitioner, but no definite 




To our knowledge, this study is the first investigation which has systematically compared 
commonly used DRP detection methodologies. Our findings suggest wide variation in the ability of 
the different methods to identify DRPs; in addition, some methodologies are superior to others 
depending upon the severity of the DRP. Lastly, substantial differences exist with respect to the 
accuracy and required labor to implement and utilize. 
The publications reviewed in this paper varied considerably in terms of their purpose, setting, 
methods and definition of DRP. A wide variety of terms and definitions is used to describe 
medication safety.146 While the World Health Organization makes specific recommendations 
regarding the definition of terms like ADE and ADR147;148, no universally accepted definition for 
either term exists.146;149;150 
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The studies included in this review used a wide range of drug-related terms, including “adverse 
drug events”, “adverse drug reactions”, “medication errors”, “medication misadventures”, 
“medication administration errors”, as well as medication-related consequences, such as ”adverse 
events“, “unintended events”, and “intraoperative events”. Consequently, we used the term “drug-
related problem” to encompass all definitions used in the studies.  
Considerable inter-institution differences may exist depending upon the given methodology. As an 
example, IR systems can be either anonymous or non-anonymous reporting, which may impact 
upon the willingness of health care practitioners to report. Similarly, TR or IR can be manual or 
automated reporting; an automated system is likely to be more time-efficient, increasing the 
likelihood that health care practitioners will participate. 
While we acknowledge that the above-stated variability can influence the comparability of the 
medication safety assessment studies, several definite trends are still indentifiable. 
IR was the most frequently studied methodology, which is consistent with the fact that it’s known to 
be commonly used in health care systems for the detection and assessment of medication error 
and adverse drug events.37 In addition, the collection of data through a voluntary IR system with a 
standardized form is considered relatively easy and generally at low cost. Of note, this method is 
recommended by the Institute of Medicine.7;151  
While IR is recommended by many organizations, these systems are associated with substantial 
under-detection bias.7;111;152-155 Our findings that IR was consistently inferior to other methods in 
reporting DRPs underscore this point. Reasons for underreporting include perceived lack of time 
and fear of consequences.2;111;124;152 Only active institutionally encouraged reporting results in 
increased reporting of DRPs.131;135;143 Patient-reported IRs, which potentially reveal DRPs not 
documented in the medical record, were rarely represented in the studies. However, these IRs may 
represent another viable approach in identifying DRPs.143  
In comparison with IR, OB consistently identified the greatest number of DRPs. While it may 
capture the most DRPs, OB is more resource-intensive compared to IR and CH.124 Considering its 
labor-intensiveness, OB must be performed over a relatively short period of time, which 
unfortunately results in only a brief snapshot of the medication use routine.156 Consequently OB is 
not suitable for long-time tracking of DRPs. 
In comparison with other systems, TR can examine the frequency and types of DRPs and also 
evaluate medication safety longitudinally over time.105;111;142;153;157;158 According to three studies 
included in our review, once implemented, TR required the least resources.127;140;144 A targeted 
process using specific triggers is more time-efficient, much less labor intensive than conventional 
CH and reproducible.114;151;156;159-163 It is estimated that an assessment of 24 clearly defined triggers 
necessitates about 20 minutes of work time per chart.111;157 The trigger tool is therefore suitable for 
a time-restricted approach.154 
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Although the IOM report on patient safety favors a computerized, validated set of triggers or alerts 
to detect DRPs114, the use of a paper form without sophisticated computerized technology may 
make TR financially more feasible.111;153 The IHI similarly champions the TR methodology.157 
Lastly, the Agency for Healthcare Research and Quality’s “Critical Analysis of Patient Safety 
Practices” ranked computerized DRP detection with TR as “high strength of evidence” for its 
impact and effectiveness.37 
The usefulness of a TR is particularly dependent upon its sensitivity and specificity. If validated 
appropriately, TR is as sensitive as CH and more sensitive than IR in identifying DRPs. The 
specificity of the method can be further enhanced if more stringent rules are applied.128;155  
The achievement of a high positive predictive value (PPV) is obviously an important outcome and 
reduces the necessity of labor-intensive follow-up.154;158;162;164;165 Depending on the validity of the 
triggers, PPV can range from 0 to 100%. The higher the PPV, the better the balance between 
review effort and DRP detection and follow-up.166 
 
As demonstrated in this review, each method substantially differs in its detection of DRPs, and 
overlap between different methods is minimal. To reinforce this point, the reported agreement 
between IR and TR ranged from only 0.5 - 10%.127;141 
While TR does not yield the greatest quantity of DRPs, it represents a time-efficient, practice-
oriented method to assess medication safety.123;130;142;143  
DRPs reported through IR may be more clinically significant than that reported via TR, which is 
reflected in the high PPV and low false positives associated with IR.124 Its superior ability to detect 
events of high severity with a reliable specificity is particularly valuable toward the identification of 
sentinel events.37;151;162 Non-punitive, confidential, simple and timely voluntary incident reporting 
can provide valuable background information for subsequent in-depth evaluations such as root 
cause analysis or trigger tool methodology.2;105;157  
The relative strengths of IR and TR suggest that some combination of these two methodologies be 
used to optimally detect DRPs.37;114;128;136;151;152;158;159;167 
It is important to note that retrospective DRP reporting is associated with relatively lower rates 
when compared with a prospective system.13 However, both IR and TR allow a real-time 
identification of DRPs, which may reveal errors before they reach the patient, for example during 
the prescribing and administration stage.168 Only one study included in this report assessed the 
methods specific to one or more component of medication use: in this study, OB identified 49.5% 
incorrect administration techniques, and CH detected 57.2% wrong dose errors, respectively.138 
The introduction of new computer-assisted technologies in the medication use process may help to 
solve some of these problems. Poon at al. found that barcoding significantly reduced order 
transcription and drug administration errors.59  
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Other technologies such as computerized physician order entry and automated allergy and 
interaction checks may also decrease DRPs.60;169;170 While new technologies can improve 
medication safety, they do not totally eliminate medication errors, and they can be associated with 
unintended consequences for error.171 As an example, introduction of computer-generated alerts 
may result in order entry “fatigue” allowing for administration of potentially toxic drugs and doses. 
Therefore, institutionalized, proactive medication safety assessment remains an important tool in 
quality improvement processes. In addition, the significant amount of structured and therefore easy 
accessible data gained by using IT tools can provide new means for the medication safety 
assessment. 
 
The studies included in this review varied widely in their purpose, setting, methods and 
nomenclature. In general, high quality comparative medication safety assessment studies are 
lacking, and standardization in medication safety assessment and language is insufficient.  
The most commonly used methodologies differ in their accuracy, scope of identified DRPs, and 
cost associated with implementation. Therefore, accuracy, effectiveness and cost should be 
considered to meet institution-specific requirements. 
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Table 17: Overview of medication safety assessment studies with the primary aim of gathering comparative data  
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miological team 






To compare the 
rate of ADRs (DDIs) 
as predicted by a 
computerized 
pharmacological 
database to the 
actual rate 
determined by 
direct observation in 
a sample of 
geriatric patients. 
ADR: (WHO) 
A response to a drug 
which is noxious and 
unintended, and 
which occurs at 
doses normally used 
in man for the 
prophylaxis, 
diagnosis, or therapy 




ADR rate:  
60.7% of patients 




TR: 64 (41.8% of 
patients) 
DDI: 










No data provided 
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baseline ME and 
ADE rates and 
characterize MEs 
and ADEs in 
pediatric patients in 
the prescribing and 
ordering process. 
Secondary 
objective: to affirm 
the effectiveness of 




compared with that 
of voluntary incident 
reporting. 
ADE: 
An injury, large or 
small, caused by the 
use (including non-
use) of a drug. This 
may be as harmless 
as a drug rash or as 




IR: 1.7/1000 days 
OB: 2.67/1000 days 
TR: 22.3/1000 days 
PPV: 






probability of ADEs: 
TR>IR 
Most common error type: 
overdose (63%; 95% CI, 
58–68%), underdose (14%; 
95% CI, 10–18%), and 
















list of automatic 
laboratory 
signals and 
alerts of ADRs, 
including patient 
data and dates 
of events. 
1. CH  
2. TR 
To investigate the 
effectiveness of a 
computer 
monitoring system 
to detect ADRs and 
to compare it to 
chart reviews. 
ADR: (WHO) 
a response to a drug 
which is noxious and 
unintended, and 
which occurs at 
doses normally used 
in man for the 
prophylaxis, 
diagnosis, or therapy 








CH only: 3 
TR only: 39 
not alerted by TR: 9 
PPV:  






61.5% by physician 






2 study cites 















To describe a 
process of ADE and 
ME identification 
and compare 
review of ADEs and 
MEs by the two 
methods of review. 
ADE: 
Harm associated with 
a drug. 
ME: 
An error in the 
medication use 






I: 5824; B: 2492 
total alerts: 11602 
CH ADEs: 
I: 242; B: 535 
CH MEs: 
I: 104; B: 562 
ADE PPV TR: 
I:10.2% 
B: 9.6% 
(p – 0,36) 
ME PPV TR: 
I: 4.4% 
B: 10% 
(p < 0:001) 
No data provided 
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patient case not 
review 
1 large NHS 
hospital 






2. Case not review 





To evaluate the 
relative 
performance of a 
routine incident 
reporting system in 
identifying patient 
safety incidents 





event caused by the 
health care that 
either did or could 

















10.9% (CI 95%, 






TR: 84-90% (CI 
95%) 















1. IR  
2. TR 
To identify the most 
deleterious drug 







to reduce harm. 
ADE: 
An injury resulting 
from the use of a 
drug, involving errors 
of omission where 
the initial drug order 
never reached the 
patient 





IR: 93 (849 reports) 
ADE identification: 
TR: 78 (1573 alerts) 










κ IR : ≥ 0.88 
By type: 
IR identified more systems 
failures (e.g., drug 
administration errors) while 
TR detected events caused 
by high-risk medications. 





















To compare AEs 
reported in post-
discharge patient 






Unintended harm to 
the patient by an act 
of commission or 
omission rather than 
by the underlying 
disease or condition 

















κ IR: 0.85-0.97 
κ CH: 0.61-0.96 
κ IR/CH: 0.20 
IR=CH: 79% 
By provider:  
Patients report many 
events that are not 
documented in the medical 
record. 
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compare its results 






ADR rate:  




















48%; detected by TR only 
By provider: 
ADRs not recognized by a 






















2. TR  




as a method for 
identifying adverse 
events on a medical 
service and to 
compare the 
physician reporting 




An injury that 
prolongs the hospital 
stay or leads to 
disability at the time 


















Preventable ADEs:  
physIR>TR 
The house staff did report 
statistically more 
preventable AEs (62.5% 
















2. TR  
To compare the 
rates and nature of 
ADEs at an 
academic medical 
center and a 
community hospital 




were compared with 
voluntary reporting. 
ADE: 
List of 69 rules. 














κ >0.88 for 
causality and 
severity 
No data provided 
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30 long term 
care nursing 
facilities 










To compare two 
methods of 
detecting MEs in 
long term care 
facilities. 
MEs: 
MEs are doses not 
administered in 
accordance with the 





wrong dose, wrong 

















OB: 49.5% incorrect 
administration technique 























To analyze the 
automated queries 
reporting in order to 
evaluate the role of 
man and machine 
in anesthesia AE 
reporting. 
AE: 
No data provided 
AE identification: 
IR only:  28.9% 
TR only: 28.9% 
No data 
provided 




















The feasibility of 
tracking the 
accuracy of hospital 
ADE self-reporting 
by comparing ADEs 
recorded in an 
occurrence 
reporting tool with 




An adverse event 
that occurs following 
the administration of 
a drug in the hospital, 
whether or not the 
patient was an 




of the hospital and 
including events 
following drugs given 











have only low 
specificity 
By severity: 
IR: higher proportion of 
moderate to severe ADEs 
By type: 
preventable ADEs: 
0.8% of discharges 
Mainly dose-related toxicity 
(47%), followed by allergic 
reactions (36%). 
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2. IR using TR 
3. TR 
To develop a new 
method to improve 
the detection and 
characterization of 
ADEs in hospital 
patients. 
ADE: (WHO) 
An ADE is one that is 
‘‘noxious and 
unintended and 
occurs at doses used 
in man for 
prophylaxis, 






















ADE adverse drug event DRP drug-related problem ME medication error 
ADR adverse drug reaction IHI Institute for Healthcare Improvement OB observation 
AE adverse event IR incident reporting PPV positive predictive value 
AI adverse incident eIR encouraged / solicited incident reporting PSI patient safety incident 
AO adverse outcome pIR patient incident reporting R.N. registered nurse 
CH chart review physIR physician incident reporting TR trigger tool 
pharmCH review of prescription charts by a pharmacist Κ Kappa value UE unintended event 
DDI drug-drug-interaction L.P.N licensed practical nurse WHO World Health Organization 
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Table 18: Studies providing numeric data on effort and cost of the evaluated medication safety assessment methods 




Type of DRP 
investigated 
Methods 






36 hospitals & skilled 
nursing facilities 
No data provided 
No data provided 
No data provided 
MEs IR vs. CH vs. 
OB 
IR: 10.3-18.57 min. 
CH: 1.21-2.61 min. 
OB: 13. –15.97 min. 
CH: $ 0.63/dose 






1 tertiary care hospital 
No data provided 
9 months 
Patient days: 21964 
ADEs IR vs. CH vs. 
TR 
TR: 11 hrs/week 
CH: 55 hrs/week 
TR<CH 
1 full-time equivalent needed 






1 district hospital 
Medical / surgical 
No data provided 
Patients: 288 
AEs IR vs. CH 0.5-0.9% of total annual working 
hours 






2 study sites 
Indianapolis (I):  
22 ambulatory clinics 
Boston (B): 
11 ambulatory clinics 
4 months  
No data provided 
ADEs & MEs CH vs. TR No data provided Cost/ADE incl. follow-up 
CH: $ 68.70 











Treatment days: 1718 
ADRs IR vs. TR Time: CH>TR Potential savings / ward and year 









ADEs IR vs. TR  IR: data not provided 
CH: 532 hours 
IR: $ 15,323 






30 long term care 
nursing facilities 
No data provided 
No data provided 
No data provided 
MEs OB vs. CH Mean time per chart or patient: 
OB: 9.18 min. 
CH: 11.56 min. 




ADE adverse drug event DRP drug-related problem ME medication error 
ADR adverse drug reaction IHI Institute for Healthcare Improvement OB observation 
AE adverse event IR incident reporting PPV positive predictive value 
AI adverse incident eIR encouraged / solicited incident reporting PSI patient safety incident 
AO adverse outcome pIR patient incident reporting R.N. registered nurse 
CH chart review physIR physician incident reporting TR trigger tool 
pharmCH review of prescription charts by a pharmacist Κ Kappa value UE unintended event 
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CONCLUSION 
All four assessment techniques have different strengths and weaknesses. In addition, 
overlap between different methods in identifying DRPs is minimal. While TR appears to be 
the most effective and labor-efficient method, IR best identifies high severity DRPs. 
Consequently, the review of the use of combination methodologies, such as the TR with IR, 
is strongly recommended for the future. Prospective, controlled trials comparing these 




In the light of these findings, the following chapters are dedicated to the discussion of a 
practice-oriented approach to the techniques of trigger tool and incident report review. 
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CHAPTER 4 
Medication use evaluation via manual trigger tool methodology in the inpatient setting 
ABSTRACT 
Background 
Regulatory agencies require health care institutions to regularly assess the safety of 
medication use through active monitoring.  
Intravenous (IV) heparin for anticoagulation therapy is one of the drugs considered high-risk 
by The Institute for Safe Medication Practices. The indicator or trigger tool technology is 
considered an efficient and effective tool for medication safety assessment. 
The aim of this study was to develop and pilot a manual trigger tool for the assessment of 
processes involving IV heparin use. 
Method 
A systematic literature review (Pubmed, Embase, Scopus) was undertaken in order to 
identify recommended medication safety indicators. Indicators addressing the defined 
process outcomes of IV heparin therapy (adequate prescribing, dispensing, administration, 
monitoring, and dose adjustments) were integrated into a manual trigger tool form and 
critically assessed by the thrombosis and hemostasis committee. Subsequently, the manual 
trigger tool was piloted with 20 randomly selected inpatients and repeated one year later. 
Results 
The literature search identified 79 indicators. Nineteen were used for the manual trigger tool 
form. The triggers successfully addressed the following therapeutic quality endpoints: use of 
the order form, therapy initiation, monitoring, time to therapeutic goal, and adequacy of dose 
adjustments. Completion of the trigger tool form necessitated 20 minutes per patient. 
Discussion 
The inclusion of only 20 randomly selected patients in a once-yearly assessment allowed the 
identification of critical aspects of IV heparin therapy involving different steps of the 
medication use process. However, the trigger tool was less valuable for the detection of 
problems with transcribing / documenting, dispensing by pharmacy and patient education.  
Conclusion 
A manual trigger tool form, developed based on expert consensus, was an efficient tool for 
the assessment of IV heparin use and the supervision of improvement projects. For a 
comprehensive monitoring of medication safety, indicators should address all aspects of the 
medication use process.  
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BACKGROUND 
Drug related problems (DRPs) represent a major threat to patient safety in health care 
institutions.176 DRPs cause approximately 5-7% of all hospital admissions and 7.5 – 20% of 
all inpatients experience DRPs, signficantly prolonging hospital stay.13;177-179 Importantly, 47% 
to 76% of all DRPs are preventable.180-183  
Only limited data on DRPs in Swiss institutions is available: 
Among 6383 medical inpatients analyzed in two Swiss primary care teaching hospitals, 481 
(7.5%) experienced at least one DRP during their hospital stay; 0.4% (95% CI; 0.2 - 0.7%) of 
the events were associated with a medication error.14;50 Approximately 4% of the patients 
were admitted to the hospital because of a DRP.50  
In 1999, Lepori et al. estimated that the cost associated with drug-related hospital 
admissions due to inappropriate or unnecessary drug treatment was 12’000–16’000, with 
direct annual extra costs of 70–100 million Swiss francs.15 This finding has been confirmed in 
the international literature as well.51 
Regulatory agencies require health care institutions to regularly assess the safety of 
medication use through active monitoring, identifying the most common DRPs and 
developing the necessary strategies to manage high-risk drugs.108;118 Procedures associated 
with their use should be assessed routinely and the results should be incorporated into 
prevention strategies. 
Unfractionated heparin (UFH), a drug commonly used in prophylaxis and treatment of 
thrombotic disorders184, is one of the agents highlighted as a high-risk drug by the Institute 
for Safe Medication Practices (ISMP).110 
UFH is approved by the Food and Drug Administration (FDA) for use in thrombotic disorders. 
In addition, UFH has demonstrated efficacy in acute coronary syndrome, STEMI, and 
unstable angina.184 An overview of approved indications and common off-label use is 
detailed in Table 19: 
Table 19: UFH indications 184 
FDA approved indications Unapproved indications 
1. Anticoagulation 
2. Atrial fibrillation 
3. Pulmonary embolism 




3. unstable angina 
In order to improve medication safety through targeted, institution-individual projects, 
hospitals need to measure meaningful baseline and post-improvement data.  
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In order to quantify DRPs efficiently, different methods have been discussed in the actual 
literature. While chart review might provide the best insight into individual cases, this 
methodology is very expensive in terms of cost and personnel required. The indicator 
technology (also referred to as trigger tool) is considered more efficient yet highly effective.34 
The aim of this indicator project was to develop and pilot a reliable indicator-based 
spreadsheet (trigger tool form) for the targeted, efficient manual collection of baseline data 
on the quality of heparin therapy processes in the inpatient environment and for the 





Development of the trigger tool spreadsheet 
A systematic literature review, using Pubmed, Embase and Scopus databases was 
undertaken in order to identify recommended medication safety indicators. 
The following search strategy was applied: 
Indicator [TITLE] AND drug safety [ANY]: 223 
Indicator [TITLE] AND medication safety [ANY]:     3 
Trigger [TITLE] AND drug safety [ANY]:   10 
Trigger [TITLE] AND medication safety [ANY]:   75 
No time or language restrictions were applied. References in the retrieved articles were also 
reviewed for additional relevant articles. After screening of the abstracts, all relevant full-text 
articles were retrieved.  
The process-related indicators for the evaluation of the drug therapy quality were derived 
from the literature, consensus-based among clinical pharmacists; one of the clinical 
pharmacists a specialist in anticoagulation therapy management, and three of them 
specialists in the field of medication outcomes research. In addition to the indicators 
suggested in the literature, additional indicators suggested by the experts were also 
considered for inclusion. 
Indicators derived from the literature review and suited to address the defined outcomes 
were integrated into a spreadsheet, called manual UFH trigger tool. In addition, a data 
collection sheet was developed for the analysis of the pilot phase and follow-up study 12 
months later. 
Subsequently, the spreadsheet was referred to the interdisciplinary thrombosis & hemostasis 
committee for approval.
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Piloting of the UFH trigger tool 
Twenty patients treated with UFH were randomly selected for inclusion into the pilot. The 
pharmacy system WORX allowed for automated screening for patients treated with UFH. 
The preliminary selection of patients was performed according to the following selection 
criteria: 
Inclusion criteria 
 The patient was treated with UFH during a specific time period, chosen for the pilot. 
 The patient was treated with UFH during at least 3 days.  
 The patient was already discharged or past the 3 initial days of the initiation of the 
UFH therapy. 
Exclusion criteria 
 Pregnant at the time of the pilot or an obstetrics / gynecology inpatient (reason for 
exclusion: utilization of different guidelines). 
 Pediatric inpatient, e.g., younger than 18 years (different guidelines). 
 UFH was already initiated at an outside hospital prior to the patients’ admission. 
 Intensive care unit when heparin therapy was started (different opportunities and 
rules for supervision and therapy management). 
Overall, 2 patients had to be excluded due to not complying with the initial inclusion criteria 
and were replaced. 
The necessary patient-information was manually obtained through the electronic hospital 
pharmacy information system, the electronic inpatient record, the automated nursing 
medication administration record, and the laboratory database. The data were collected 
retrospectively and for a maximum of 3 days of observation from heparin initiation. 
The results were independently analyzed by two pharmacists, compiled in a comprehensive 
report and handed over to the thrombosis & hemostasis committee, the medication safety 
committee as well as to the pharmacy & therapeutics committee. 
After 12 months and an adjustment of the UFH order set, the medication use evaluation was 
repeated. 
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RESULTS 
Development of the trigger tool spreadsheet 
Based on a thorough literature review, a total of 333 indicators were identified addressing 
medication safety issues. Seventy-nine of these 333 medication safety indicators involved 
anticoagulation. Details on the literature research are displayed in figure 2. 
 
Figure 2: Overview of inclusion and exclusion of articles 
 
 
Based on a consensus with the experts of the thrombosis & hemostasis committee, the 
following indicators were introduced into the manual UFH trigger tool: 
 Collection of basic patient data (age, weight, allergy information)8 
 Correct prescription: use of the appropriate form (correct indication, correct form)185;185 
 Correct prescription: calculation of the initial dose (weight-based)185;185 
 Existence of baseline labs150;186 
 Application of the appropriate product187 
 Appropriate administration technique188;189 
 Adequate calculation of the pump administration rate (application of the prescribed 
dose)188;189 
 Timeliness of follow-up labs150;190-192 
 Presence of low platelet count150;190;191 
 Presence of thrombocytopenia150;190;191 
 Presence of elevated aPTT150;186;190;191;193;194 
 Presence of a sub-therapeutic aPTT150;186;190;191;193;194 
 Presence of HIT166;195 
Identified articles 
(n=311) 
References retrieved from 










(n=57, no original 
indicators) 
Included articles 
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 Timeliness of drug administrationnew 
 Timeliness of adjustment to lab valuesnew 
 Inappropriate use of intramuscular drugs162;196 
 Application of the antidote protamine35;194 
 Transfer to a higher level of care due to DRPs35;194 
 Pharmacy intervention necessarynew 
 
The following endpoints were considered the most important indicators for appropriate UFH 
therapy and management processes by the experts involved in the indicator development 
project: 
 Appropriate bolus dosing based on patient weight 
 Appropriate timing of lab follow-up (aPTT, INR, PT levels) 
 Frequency of appropriate dose adjustment based on the institution’s protocol 
 Correct initial continuous infusion calculations 
The manual UFH trigger tool spreadsheet is displayed in figure 3. 
 
Piloting of the UFH trigger tool 
A table, focusing on process-related indicators, was developed in order to display the results 
collected in the trigger tool spreadsheet in a clearly laid out manner (Table 20). 
Table 20: UFH trigger tool data collection sheet 
DEMOGRAPHICS INITIATION MONITORING 
THERAPY  
STOP / INTERRUPTION 
             
 
 
The use of the trigger tool annually for 2 years allowed for the detection of the following: 
 The use of the order form vs. no use of the order form 
 The use of the correct order form (if different order sets for different indications are 
available) 
 The appropriate initiation of the UFH therapy (weight-based or aPTT-based bolus 
calculation and calculation of the infusion rate) 
 The appropriate monitoring of the UFH therapy (time of labs drawn, interval of labs 
drawn, amount of labs drawn 
 The time to therapeutic range 
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The details of two trigger tool analysis addressing process-relevant aspects of UFH therapy 
performed in 2008 and 2009 are displayed in Table 21. 
Table 21: Comparative findings from 2008 and 2009 
Endpoints Parameters 2008 2009 
Order form NOT used 1/19 (6%) 0/20 (0%) Order form use 
WRONG order form used 2/19 (11%) 3/20 (15%) 
    
Bolus dosing calculation NOT according to form 2/8 (25%) 2/5 (40%) 
    
Initial infusion calculation NOT according to form 8/20 (40%) 7/20 (35%) 
    
aPTT NOT drawn prior to initiation 0/20 (0%) 1/20 (5%) 
inadequate # of lab draws 13/20 (65%) 4/20 (20%) 
excess # of lab draws --- 8/20 (40%) 
at least one missing or delayed lab draw 18/20 (90%) 17/20 (85%) 
NOT correctly timed lab draws  
(i.e. not within 6-8 hrs of dose initiation /adjustment) 
36/82 (44%) 50/128 (39%) 
Monitoring 
NOT therapeutic in 24 hours --- 5/20 (25%) 
    
Dose adjustments Inappropriate dose adjustments in response to aPTT 36/82 (44%) 49/128 (38%) 
 
 
Additional findings allowed drawing conclusions on the following aspects of UFH therapy: 
 Off-label use of UFH 
 Execution of the double-check by nursing 
 Consistency of patient information (e.g., weight) in different hospital systems 
containing individual patient information 
 The necessity of clarifying physician’s orders by pharmacy 
 The use of antidotes. 
 
The completion of the manual UFH trigger tool form necessitated 20 minutes per patient on 
average, executed by a pharmacist with clinical experience. 
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DISCUSSION 
The Institute for Safe Medication Practices considers heparin to be one of the “high alert 
medications”.110 Intravenous heparin has a narrow therapeutic window, where 
supratherapeutic doses can lead to severe bleeding complications and subtherapeutic doses 
to inadequate anticoagulation. It is therefore important to ensure adequate prescribing by 
using the correct order form, correct dispensing and administration technique, timely 
monitoring, adequate response time to lab results and appropriate dosage titration.  
The trigger tool technology is considered an efficient and effective approach to proactive 
medication safety assessment.34 For this pilot and the subsequent follow-up medication use 
evaluation, a one-page trigger tool form was devised, containing 19 indicators addressing 
quality and safety aspects of heparin therapy. 
The current literature offers a variety of suggested indicators. However, many of them are not 
validated and might not account for institution-specific structures and processes, which 
should also be considered. 
 
Although we did include only 20 randomly selected patients in a once-yearly assessment, we 
were able to identify critical aspects of UFH therapy involving different steps of the 
medication use process. Problems involving drug prescribing, dispensing by nursing, 
administration, monitoring and dose adjustment were discovered. As per Bates et al. the 
process-steps of prescribing and administration are most often affected by errors in 
medication use, with 39% and 38%, respectively.123 However, the trigger tool seemed less 
suited for the detection of problems in the field of transcribing / documenting and dispensing 
by pharmacy. Because those process steps are affected by errors in 12% and 11% of the 
cases, more emphasis on those aspects might be sensible for future medication use 
evaluations.123  
The evaluation of one patient treated with UFH required approximately 20 minutes and 
allowed for the identification of areas for improvement. 
A prerequisite for the execution of a comprehensive and efficient trigger tool study is the 
access to all relevant patient information. The information might be fragmented, necessitating 
access to a variety of databases. Consequently, an electronic database containing all patient 
information in one place might accelerate the data collection process.186;197
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For future investigations, additional questions should be considered, specifically addressing 
the following stages of the medication use process: dispensing by pharmacy, and 
documentation. As recommended in a previous study, it might also be beneficial to 
investigate inpatient incident reports as an additional source for medication safety 
information.34;133  
Focusing on transfer of care situations might also increase drug safety: if a drug therapy is 
continued in the outpatient setting after discharge, individual patient education should be an 
aspect on the trigger tool form.52 The intensity of clinical pharmacy services might be a 
marker for quality of medication therapy.57 
 
Although indicators have proved to be an efficient tool for medication use evaluation with 
limited resources, investigators need to be aware, that the trigger tool approach has certain 
inherent limitations: the small sample size in order to limit resources as well as the fact that 






A manual trigger tool form, developed based on expert consensus, was an efficient tool for 
the assessment of IV heparin use and a promising instrument for the supervision of 
improvement projects. For a comprehensive monitoring of medication safety, indicators 
should address all aspects of the medication use process. Additional sources for information 






In addition to the manual UFH trigger tool, a variety of manual trigger tool forms, addressing 
different drugs and medication use processes, were developed, piloted and evaluated. They 
are displayed in Appendix 1 to chapter 4. 
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APPENDIX 1 TO CHAPTER 4: Examples of trigger tool forms 
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Adult inpatient oral anticoagulant therapy: template for data collection 
 
Hospital / Institution Version 02 / 12/05/2010 Author / Investigator 
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Adult inpatient oral anticoagulant therapy: template for data overview and analysis 
 
Month:   Year:   
 Marcoumar  Warfarin 













































































































































































































































































































































































































































































































































































                                  
                                  
 
Hospital / Institution Version 02 / 12/05/2010 Author / Investigator 
 
 Carla Meyer-Massetti PhD Thesis, March 2011  98 
Adult inpatient fentanyl therapy: template for data collection 
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Adult inpatient fentanyl therapy: template for data collection continued 
Scroll-down options: 





















female weight-based pain service experienced correctly yes yes yes yes 1 yes yes 
male pain-based primary care na!ive incorrect no no no no 2 no no 
other other both unknown not used 
at all 
unclear unclear unclear unclear … 10 sometimes unclear 
 unknown unclear  other      unclear  
 
Adult inpatient fentanyl therapy: template for data overview and analysis 
DEMOGRAPHICS INITIATION MONITORING DISCHARGE 















































































































































































































































































































































































































































































                                     
 
Hospital / Institution Version 02 / 01/28/2011 Author / Investigator 
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Oncology adult: Bone-marrow-transplant / Hematology / Oncology Process Trigger Tool 2009 
Inpatient Service Admission 
Prescribing Logistics Administration Monitoring 
Discharge 
       
Patient  
coordinator 
 patient packet on time 
  face sheet 
  actual weight info 
  actual height info 
  allergy info 
     follow-up  
Nursing  bed assignment  
    on time 
  pharmacy clarification 
    (chemo start time) 
 chemo on time 
 delivery 2-RN-check 
 premeds 
 IV access check 
 2-RN-check 
 guardrails used 
 IV access check 
 pump check 
 PRN drugs 
 teaching 
Medicine  prescription  
    (face sheet) 
 if chemo order form 
     completed by physician,
     state reason:…………. 
………………………….. 
 dose accepted 
 dose rejected 
 if chemo order form 
     scanned by physician, 
     state reason:…………. 
………………………….. 
  PRN prescription  final report 
 PCP info 































 orientation on time  med rec performed 
  allergies 
  interactions 
 lab screening done 
 chemo order form 
  template available 
 dose adjustment 
    reason:……………… 
 incompatibilities 
 order faxed 
 order scan on time 
 drug info  supervision: 
  incompatibilities 
  ADRs 
  med errors 
  meds given 
  PRN drugs 
 UCARE report 
 d/c med list 
 teaching 
 info materials 
 drug list 




   order received on 
time 
 order form complete 
 if clarification, reason: 
………………………………. 
 
  PRN meds on 
time 
 
Laboratory  complete admission 
lab 
    labs on time  
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Depending on the number of voluntary reports submitted and the quantity of patients 
available for trigger tool evaluation, additional means for medication safety assessment, 
complementing institution-specific data, might be necessary to obtain a comprehensive 
impression of a drug’s safety profile. 
Various institutions all over the world are systematically collecting and analyzing voluntary 
reports on adverse drug reactions, compiling large numbers of reports. 
 
In the United States, the National Coordinating Council for Medication Error Reporting and 
Prevention NCCMERP (www.nccmerp.org), the US pharmacopeia (www.medmarx.com) and 
the FDA (www.fda.gov) are involved in the reporting, discussion and communication about 
safe medication use, medication errors and error-prone processes. As the NCCMERP states: 
“There is no acceptable incidence rate for medication error!”. 
The content of the FDA MedWatch system, the central US database for adverse drug events, 
is accessible to healthcare providers under the “Freedom of Information Act” 
(http://www.fda.gov/RegulatoryInformation/foi/default.htm). 
 
The WHO’s adverse drug event database, maintained by the Uppsala Monitoring Center 
UMC, is accessible to national pharmacovigilance centers or external inquirers for a charge. 
 
In the following chapters, examples are provided using adverse event report data from the 
FDA database and the WHO adverse reaction report database. 
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CHAPTER 5 
The FDA extended warning for intravenous haloperidol and torsades de pointes:  
How should institutions respond?  
This chapter has been published in The American Journal of Hospital Pharmacy 2010, 




In September 2007 the Food and Drug Administration (FDA) strengthened label warnings for 
intravenous (IV) haloperidol regarding QT prolongation (QTP) and torsades de pointes (TdP) 
in response to adverse event reports. Considering the widespread use of IV haloperidol in 
the management of acute delirium, the specific FDA recommendation of continuous ECG 
monitoring in this setting has been associated with some controversy. We reviewed the 




Cases of intravenous haloperidol-related QTP/TdP were identified by searching Pubmed, 
Embase, and Scopus databases (01/1823 – 04/2009) and all FDA MedWatch reports of 
haloperidol-associated adverse events (11/1997-4/2008). 
 
Results 
Seventy cases of IV haloperidol-associated QTP and/or TdP were identified. There were 54 
reports of TdP; 42 of these events were reportedly preceded by QTP. When post-event QTc 
data were reported, QTc was prolonged >450msec in 96% of cases. Three patients 
experienced sudden cardiac arrest. Sixty-eight patients (97%) had additional risk factors for 
TdP/prolonged QT, most commonly receipt of concomitant proarrhythmic agents. Patients 
experiencing TdP received a cumulative dose of 5mg to 645mg, patients with QTP alone 
received a cumulative dose of 2mg to 1540mg. 
 
Conclusions 
While administration of IV haloperidol can be associated with QTP/TdP, this complication 
most often took place in the setting of concomitant risk factors. Importantly, the available 
data suggest that a total cumulative dose of IV haloperidol of <2mg can safely be 
administered without ongoing electrocardiographic monitoring in patients without concomitant 
risk factors. 
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BACKGROUND 
Haloperidol is FDA-approved in the United States for the management of acute and chronic 
psychotic disorders and widely used in the management of delirium-associated agitation in 
hospitalized patients.198 Delirium in the hospital is an acute confusional state that frequently 
arises from multiple complex factors and may affect up to 30% of hospitalized patients.199 
Although the first step in the management of delirium involves identification and treatment of 
underlying causes and offering supportive behavioral care, medications may be needed to 
control severe agitation.199 Low dose intravenous (IV) haloperidol (i.e., 0.25-0.5mg every 4 
hours) is a commonly used medication in this setting as recommended by expert-groups 
including the Cochrane Collaboration and the American Psychiatric Association.199;200  
Although injectable haloperidol, a butyrophenone-derived antipsychotic agent 
pharmacologically related to the piperazine phenothiazines201, is approved for IV use in many 
countries (see Table 22), parenteral use is approved only for intramuscular (IM) 
administration in the United States. Thus, IV administration of the drug in the U.S. is 
considered an off-label use.202 
Haloperidol is often preferred over other antipsychotics as a result of its effectiveness, low 
rate of anticholinergic side effects, familiarity with dosing and usage, and minimal respiratory 
or sedative properties.203 Use of the IV route in patients with acute delirium has several 
advantages over the IM or oral route204, including rapid onset, immediate bioavailability, and 
ease and safety of administration. 
Prior to September 2007, the package insert for haloperidol alerted health care professionals 
to the risk of cardiovascular side effects. Based on case reports of potentially fatal cardiac 
events, the FDA revised the label, warning that the QT prolongation (QTP) and risk of 
torsades de pointes (TdP) were increased with IV administration of haloperidol or 
administration of the drug at greater than recommended doses. Unfortunately, neither the 
“typical” dosing range nor the minimum dose associated with these cardiac side effects were 
specified in this recommendation.202 
It is well-established that haloperidol may prolong the QT interval by blocking the repolarizing 
potassium IKr current.205 Although drugs that block the IKr channel can produce arrhythmia in 
healthy individuals, additional risk factors, such as underlying heart conditions, electrolyte 
imbalances (i.e. hypokalemia and hypomagnesemia), concomitant proarrhythmic drug use, 
and mechanical ventilation may increase this risk.206 Prolongation of the QT interval has been 
associated with subsequent malignant cardiac arrhythmias including ventricular fibrillation 
and TdP.207 Prolongation of the QT interval is considered the strongest risk factor for TdP, 
particularly with a baseline QTc >450msec.206 
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Based on the increased risk for QTP and TdP and the case reports of cardiac events, the 
FDA advisory recommended continuous electrocardiogram (ECG) monitoring in patients 
receiving IV haloperidol.202 However, such monitoring may be impractical and costly in 
hospitalized patients who require low doses of IV haloperidol to manage acute delirium and 
who are not in telemetry or intensive care units. 
The aim of this review was to evaluate the case reports leading to the recent FDA warning 
for IV haloperidol, specifically focusing on the presence of risk factors for arrhythmias. Based 
upon the evidence, an additional aim was to provide an institutional response to this warning 
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Table 22: Package information of officially approved haloperidol IV products 
Country Canada208 France209 Germany210 Great Britain211 Italy212 Switzerland72 




of psychomotor agitation, 
excitement,  




short term treatment of 
agitation and 
aggressiveness during 
an acute or chronic 
psychotic episode, 
vomiting along with 
antimitotic post-
radiotherapy treatment 
acute and chronic 
schizophrenia, 
psycho-motorical 







violent or dangerous 
impulsive behavior 
resistant forms of 
psycho-motorical 
excitement, 





high doses restrictions: 
syndrome of psycho-
motorical excitement, 








IV dosing in 
adults 
1 - 2mg every 2 - 4 hours 5 - 10mg/day, 
daily max.: 30(-100)mg 
2 - 10mg initially, 
PRN every 4 to 8 
hours, 
daily max. 18mg 
5 - 10mg initially, 
PRN every hour,  
daily max. 60mg 
5mg 
PRN every 30 minutes 
IV dosing in 
geriatric care 
0.25 to 0.5mg single dose of 0.5 - 
1.5mg, daily max. 5mg 
half adult dose adjust to appropriate 
dose 
0.5mg, than PRN 








congenital long QT 
syndrome 
The use is limited to 
adult patients and the 
drug can be 
administered IM or IV. 
The IV route is 
restricted to the 



























cases of arrhythmia or 
torsades de pointes in 
the family history, 
untreated potassium 
imbalance, 









QT prolongation in the 
family history 
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Monitoring 
recommendations 
electrolytes ECG monitoring, 
electrolytes 








regular reevaluation in 
long-term use 
apply the lowest 
effective dose 
application per mouth 
is the route of choice 
decrease dose if  
QTc >500msec 
switch to PO as soon 
as possible 
Abbreviations: PRN=medication as needed 
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METHOD 
Two search pathways were used to evaluate reports of haloperidol-associated TdP and / or 
QT prolongation: 
 
1) Literature review 
We searched for published literature in humans indexed in Pubmed (1966-April 2009), 
Embase (1972-April 2009), and Scopus (1823-April 2009) using the search terms haloperidol 
or Haldol combined with intravenous or infusion and at least one of the following terms: QT 
prolongation, TdP, torsades de pointes, torsades with a specific focus on case reports. 
References from the retrieved articles were also reviewed to search for additional case 
reports.  
In addition to cases reported in English journals, several of our reports originated from 
Japan213 (translation provided by the FDA), Spain214 and Germany215 (translated by the 
primary author). 
 
2) Search of the FDA database 
We reviewed all adverse drug events reported through MedWatch or those submitted by the 
manufacturer from November 1997-April 2008 through the Freedom of Information Act 
(FOIA) request. The FDA provided a full-text summary of 5944 reports involving oral, 
intramuscular and IV use of haloperidol. The FDA data were transferred to a Microsoft 
Access® database and screened for the key terms torsade, QT, prolongation, wave. Incident 
report number, date of report, age, gender, origin of report, medication name, role of drug as 
categorized by the FDA (suspect, concomitant, primary suspect, secondary suspect), route, 
dose, units, duration, symptoms and FDA outcome category (death, life-threatening, 
hospitalization initial or prolonged, disability, congenital anomaly, required intervention to 
prevent permanent damage, other) were recorded. Only those reports in which IV haloperidol 
was considered by the reporter to be the primary causative agent for the adverse event were 
reviewed. Available information included diagnosis, laboratory parameters, QTc 
measurement, cardiac symptoms, outcomes and a description of recovery. No peer review 
was applied to the MedWatch reports and the data reported in this publication reflect the 
original information from the FDA MedWatch database.  
Baseline QTc was either the value defined as such in the original report or the lowest QTc 
reported.  
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Haloperidol doses administered were defined as cumulative dose at event, encompassing all 
doses administered during the hospital stay until the occurrence of the adverse cardiac 
event. 
The drugs listed in the case reports were assessed for proarrhythmic potential using two 
references: the individual package insert and the website of the Arizona Center for Education 
and Research on Therapeutics.216 
The drugs were only considered proarrhythmic when the 2 resources were in agreement. 
 
Duplicates and/or previously published cases, as well as reports involving adverse cardiac 
effects not associated with QTP or TdP, were identified and excluded. 
In their advisory, the FDA does not state the exact origin of the reports, their specific search 
strategy to identify haloperidol-associated adverse events, or the role IV haloperidol played in 
the individual events included in the extended warning. Consequently, the number of events 





A total of 70 reported cases of IV haloperidol associated TdP and/or QTP were identified. Of 
these 70, 41 were identified through the Pubmed/Embase/Scopus review, while an additional 
29 cases were identified through the FDA database search. 
Of the 29 cases in the FDA database, 21 were reported by health care professionals and 8 
by manufacturers. 
Thirty-five publications described cases originating from the US. Three cases took place in 
Japan and 1 case each in Canada, Germany and Spain. Several cases in the MedWatch 
database were reported outside the US: one case each originated from Austria, Canada, 
France, Japan, Spain, Switzerland and the UK. A summary of the published case reports is 
displayed in Table 23 and the FDA cases are summarized in Table 24. 
Of the 70 cases, 54 cases of TdP were reported. The remaining 16/70 cases involved cases 
of QTP, 9 of which did not progress to TdP and 7 of which the progression to TdP was 
unclear. Of note, 42/54 of the cases of TdP were reported as preceded by documented QTP. 
Presence of QTP was unknown in the other 12 original reports. Three out of 70 patients 
experienced sudden cardiac arrest, one of which was fatal. One arrest was preceded by TdP 
and 2 by QTP.  
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The patient age ranged from 18-86 years. Of note, 17 patients experiencing TdP and/or QTP 
were < 40 years old, and 2 of those patients were < 30 years old. 
Haloperidol-associated QTP and/or TdP were observed in 27 female and 42 male patients; 
the gender was not stated in one report. Of the 54 patients experiencing TdP (with or without 
report of previous QTP), 22 were female and 31 were male (1 gender unknown).  
Sixty-eight of 70 patients were determined to have associated risk factors217 for QTP/TdP 
(see Table 25). The circumstances of the remaining 2 patients were not described in 
sufficient detail to identify associated risk factors. 
Overall, 32 patients had underlying heart conditions. Electrolyte imbalances, including 
hypokalemia, hypomagnesemia, and hypocalcaemia, were present in 17 patients. At least 39 
patients were receiving potentially proarrhythmic agents (1-8 proarrhythmic drugs per 
patient) in addition to IV haloperidol. At least 23 patients were receiving additional drugs with 
a potential for other cardiac adverse events than QTP and TdP. 
A wide range of other disease states previously reported to be associated with QTP217 were 
identified in these patients: asthma (5 patients), diabetes (5 patients), obesity (3 patients), 
impaired renal and/or liver function (3 patients each), HIV (2 patients); COPD, pancreatitis 
and hypothyroidism (1 patient each). Twenty two patients had a history of substance abuse 
(alcohol and/or drugs), and 4 patients were smokers. 
The administered doses of IV haloperidol varied widely. Considering that information 
regarding the maximal daily dose was missing in 22 reports and ambiguous in another 20 
cases, the results have been presented using cumulative IV haloperidol doses. Patients 
experiencing TdP without preceding QTP received a cumulative dose (= total dose at event) 
ranging from 5mg to 645mg. Patients with both confirmed QTP and TdP were administered a 
cumulative dose of 2mg to 1700mg. Patients who experienced QTP without TdP received a 
cumulative dose of 2mg to 1540mg of IV haloperidol. 
Sudden cardiac arrest following administration of IV haloperidol was observed in cumulative 
doses ranging from 6mg to 35mg. The cardiac arrest leading to a fatal outcome was 
preceded by an administration of at least 6mg of IV haloperidol. Overall, 14 out of 70 patients 
received cumulative doses of ≤10mg IV haloperidol. 
The time from administration to documentation of QTP and/or TdP ranged from immediately 
post administration to 8 hours after administration of the last dose of IV haloperidol. 
Baseline QTc was known in 44 patients. Baseline QTc was >450msec in 18 of these 44 
patients. 
The change from baseline QTc varied widely from 20msec to 286msec; 36 patients 
demonstrated a prolongation of >50msec.  
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In those patients with reported haloperidol associated QTP, 25 patients demonstrated a QTc 
>600msec and 38 patients >520msec.206 Of the cases with known specific QTc values, the 
QTc was prolonged >450msec in 48 out of 50 cases. The lowest reported QTc leading to 
TdP was 413msec.  
Twenty patients were reported as having a “normalization of QTc” (as defined by the original 
reports) within several hours to 8 days; minimal QTP was reported as persisting in 2 patients. 
The specifics of the other patients were unknown, although 25 patients were categorized as 
“recovered”, 13 were stated as having an uneventful remainder of hospitalization, and 5 
patients were discharged to a rehabilitation facility or a nursing home. 
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TdP ECG normalization 
Outcome 
1 218 1991 56 m no yes 1200 ≥1540 NR yes 584 
(400) 
184 NR NR 
uneventful 





286 yes QTc normalization (440 msec) 
NR 
3 219 1993 39 f yes yes NR 580 max. QTc 




230 yes QTc normalization after 6 d 
uneventful 





120 yes QTc normalization after 8 d 
uneventful 





150 yes QTc normalization after 8 d 
uneventful 
6 219 1993 74 f yes yes NR 10 NR no 430 
(410) 
20 yes QTc unchanged after 8 d 
uneventful 
7 220 1993 39 m yes yes NR > 490 NR yes 457 
(348) 
109 yes QTc normalization within 2 to 3 d, 
no further TdP 
NR 
8 220 1993 61 m yes yes 115 ≥211 NR yes 500 
(390) 
110 NR QTc normalization within 2 d 
death 
9 220 1993 48 m yes yes 825 ≥825 NR yes 538 
(441) 
97 NR QTc normalization in 3 d 
rehabilitation 






















































TdP ECG normalization 
Outcome 





NR yes NR 
uneventful, extubation after 5 d 
discharge after 10 d 





NR yes no recurrence of arrhythmia 
patient death (multi-organ failure) 
12 222 1995 65 m yes NR 230 ≥410 worsening 





104 yes QTc normalization (406 msec) 
no cardiac problems at discharge 





225 yes QTc normalization (<400 msec), 
recurrence with oral haloperidol 
rehabilitation 






220 yes QTc normalization within several d 
(412 msec) 
rehabilitation 
15 223 1994 59 m NR yes 865 ≥1013 NR yes 640 
(480) 
160 NR QTc normalization in 24 hrs 
survived 
16 224 1995 76 f yes no NR 44.5 
plus 1 PO 
15 min yes 670 
(409) 
261 yes ECG normalized the next morning, 
no further events 
17 224 1995 49 m yes no NR 1150 
plus 20 IM 
45 min yes 648 
(380) 
268 yes QTc normalization in 24 hrs 
anoxic brain insult / rehabilitation 






















































TdP ECG normalization 
Outcome 
18 224 1995 65 f yes no 600 965 30 min yes 628 
(403) 
225 yes QTc normalization in 2 d, 
3 more episodes of TdP in 3 hrs, 
no recurrence with further 
haloperidol, 
NR 
19 225 1995 42 m yes no 28 28 20 min yes 610 
(533) 
77 yes QTc normalization in 5 d 
uneventful, ECG normal 
20 225 1995 39 m yes no 45 45 5 min yes 654 
(NR) 
NR yes QTc normalization after 24 hrs 
uneventful 
21 213 1997 56 f no no 10 10 shortly after NR NR 
(NR) 
NR yes TdP resolved after 8 hrs 
NR 
22 213 1997 82 f NR no 10 10 shortly after yes 680 
(NR) 
NR yes QTc normalization on d 6 after 
admission ( 470 msec) 
NR 
23 213 1997 35 m NR no NR 90 after 20mg yes 520 
(NR) 
NR yes TdP disappeared 12 hrs later 
NR 









































































1998 71 f NR NR 55 120 min paced paced paced yes 
28 207;2
26 















1998 47 m NR 
yes# 




overall survival 100%, 
significantly prolonged hospital 
stay 
32 227 1999 41 f yes yes 320 915 55 min yes 610 
(426) 
184 yes QTc normalization after  5 d 
uneventful 
33 227 1999 31 m yes yes 480 1700 40 min yes 599 
(491) 
108 yes QTc normalized in 4 d 
NR 
34 228 2000 64 f yes yes 175 175 NR no 413 
(418) 
(-5) yes QTc remained unchanged 
uneventful 
35 205 2000 75 m no NR >2 >2 NR yes 615 
(435) 
180 no QTc normalization in 48 hrs 
uneventful 






















































TdP ECG normalization 
Outcome 
36 205 2000 68 m yes yes >2 >2 NR yes 650 
(407) 
243 no QTc normalization after 4 d 
uneventful after extubation 
37 205 2000 77 m NR NR (4) 2 NR yes 550 
(393) 
157 no QTc normalization in 24 to 36 hrs 
NR 
38 214 2004 34 m yes NR ≥24.5 ≥24.5 20 min yes 560
(420) 
140 yes QTc normalization (440msec) 
ECG normal 
39 229 2004 58 f yes NR 340 1010 NR yes 533 
(460) 
73 yes QTc normalization 7 d later 
discharge after 27days 






no QTc normalization (445 msec) 
NR 
41 231 2009 74 m yes no 2 2 shortly after yes NR 
(579) 
NR yes pre-existing heart block and 
fibrillation resolved 
nursing home / rehabilitation 
Abbreviations: d=day/s; f=female; hrs=hours; m=male; min=minutes; msec=milliseconds; NR=not reported 
# Five of 8 patients in this case series received concomitant proarrhythmic drugs. The individual patients were unspecified. 
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1 3122988-1 1998 61 m no 48 48 yes NR NR yes intervention 
NR 
2 3157827-6 1998 44 f no 160 160 yes 550 
(440) 
110 yes intervention 
uneventful 
3 3178715-5 1999 60 m NR 415 645 yes NR NR yes life-threatening 
QTc normalization in 1 day,  
no recurrence 
4 3271261-X 1999 56 m NR NR ≥20 yes NR NR yes life-threatening 
QTc normalization  
5 3271080-4 1999 35 m yes ≥7 ≥7 NR NR NR yes NR 
event abated after dose 
stopped / reduced, 
hospitalization prolonged 
6 3325391-4 1999 55 f yes 75 ≥75 NR NR NR yes life-threatening 
event abated after dose 
stopped / reduced 
7 3381921-8 1999 52 m no 320 634 yes 458 
(430) 
28 yes death 
NA 
8 3483869-7 2000 18 m no >200 >310 yes NR NR yes intervention 
no recurrence after 
haloperidol reinstitution 
9 3516342-8 2000 NR NR NR NR NR NR NR NR yes NR 
NR 
10 3516320-9 2000 34 m yes ≥5 ≥5 yes NR NR no life-threatening 
event abated after dose 
stopped  
11 3552263-2 2000 46 f yes NR 97.5 yes NR NR yes life-threatening 
event abated after dose 
stopped / reduced 
12 3574705-9 2000 78 m yes NR 160 yes 603 
(453) 
50 yes intervention 
event abated after dose 
stopped / reduced 










































13 3703871-7 2001 27 m NR 530 530 yes NR NR yes death 
NA 
14 3724567-1 2001 31 m yes ≥6 ≥6 yes 496 
(449) 
47 no life-threatening 
ECG returned to baseline 
15 3851984-1 2002 72 f NR 18 18 NR NR NR yes hospitalization 
NR 
16 3942407-2 2002 51 m yes 14 14 yes 461 
(444) 
17 yes life-threatening 
no recurrence 
17 4066580-3 2003 > 
60 
f NR 50 50 yes >600 
(480) 
>120 no hospitalization 
QTc normalization, 
patient recovered 






19 4150700-6 2003 NR m NR 5 5 NR NR NR yes NR 
event abated after dose 
stopped / reduced 







21 4714692-0 2005 NR m NR NR NR yes NR NR yes hospitalization 
event abated after dose 
stopped / reduced 
22 4881813-9 2006 NR m NR NR 40 NR NR NR yes hospitalization 
event abated after dose 
stopped / reduced 
23 4892225-6 2006 NR f yes ≥10 >10 yes 493 
(300) 
193 no hospitalization, 
QTc normalization (403 
msec) 
24 4911873-8 2006 69 m yes ≥6 ≥6 NR NR NR yes cardiac arrest, death 
NA 
25 5366448-6 2007 53 m yes NR 35 yes NR NR NR cardiac arrest, 
life-threatening 
patient recovered 










































26 5563440-3 2007 58 m possible ≥5 ≥5 yes NR NR yes life-threatening 
event abated after dose 
stopped / reduced 
27 5642929-2 2008 42 m yes 165 165 yes 640 
(350) 
290 yes death 
NA 
28 5697758-0 2008 38 m yes NR 620 NR NR NR yes hospitalization 
patient recovered 
29 5254840-X 2008 19 f possible 15 25 yes 461 NR NR cardiac arrest, 
hospitalization 
patient recovered 
Abbreviations: d=day/s; f=female; m=mal; msec=milliseconds, NA=not applicable, NR=not reported 
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Table 25: Presence of risk factors associated with QTP and/or TdP in the published case reports and the FDA MedWatch database 
Patients Risk factor 
Number % 
Any risk factor 68/70 97 
Unknown  2/70 3 
Specific risk factors: 
Electrolyte imbalance 27/68 40 
Underlying cardiac disease 32/68 47 
Concomitant proarrhythmic agents 39/68 57 
Other drugs influencing cardiac function 23/68 34 
Baseline QTc > 450 msec 
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DISCUSSION 
The current review was performed in response to the FDA warning recommending the use of 
continuous ECG monitoring associated with the administration of intravenous haloperidol.202 
This warning has resulted in substantial dilemmas for health care organizations, additional 
resource allocation, and increased scrutiny from regulatory agencies. The results of our 
review reveal that intravenous haloperidol-associated QTP and TdP almost uniformly take 
place in patients with concomitant risk factors and with cumulative doses ≥2mg. In light of 
these findings, it is possible that hospitals may be able to administer intravenous haloperidol 
in patients without risk factors without continuous ECG monitoring. In reviewing these 
published reports, it is important to note that the FDA identified 28 published cases of 
haloperidol-associated QTP and TdP, while our review yielded a total of 41 published case 
reports. 
The FDA database included 73 cases of haloperidol-associated TdP in their database.  
However, these cases included both oral as well as IV administration; using our 
methodology, we identified 29 additional case reports associated with intravenous 
haloperidol from this database. Consequently, our review included 41 published case reports 
and 29 FDA database cases, resulting in the total of 70 patients. 
Our review revealed a number of practical findings. First, our summary demonstrated that 
neither QTP nor TdP has been documented with a cumulative dose of IV haloperidol of  
<2mg. The majority of patients (80%) received cumulative IV doses ≥10mg. The lowest dose 
associated with sudden cardiac arrest was 6mg and this took place in a 69 year old male 
patient. Second, the majority (97%) of our patients had additional risk factors for QTP and/or 
TdP. Pre-existing heart disease220;224;228;232, electrolyte imbalance220;227;232;233, concomitant 
proarrhythmic drugs220;224;227;232-234 and mechanical ventilation220;229 were identified as the 
most commonly observed risk factors (Table 25). Lastly, in those cases in which the data 
were reported, baseline QTc was >450msec in 41% of the patients, and 96% had a QTc at 
the time of the event >450msec. Therefore, we conclude that patients 1) receiving low 
cumulative doses (<2mg) with 2) no risk factors for prolonged QTc or TdP, and 3) with a 
normal QTc on baseline ECG can safely be given IV haloperidol in the hospital setting.  
This dosage range is consistent with the labeling for IV haloperidol dosing in Canada208 and 
Germany210 (see Table 1), where single doses of 0.25mg-1.5mg are recommended for the 
treatment of delirium or acute agitation in the geriatric population.208;210 
In a recent Cochrane review, low-dose IV haloperidol (<3mg per day) was concluded to be 
as safe and effective as atypical antipsychotics in the treatment of acute delirium with respect 
to extrapyramidal adverse effects.199  
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The American Psychiatric Association recommends an initial IV dose of “1-2mg every 2-4 
hours as needed (0.25-0.50mg every 4 hours as needed for elderly patients),” with titration to 
higher doses for patients who continue to be agitated for the treatment of patients with 
delirium (issued 1999, updated 2004).200 
While several expert-groups and investigators currently consider IV haloperidol as an 
important therapeutic option for treating acute delirium and agitation in the dose range 
presented above, less consensus exists regarding monitoring requirements.199;200;235;236  
The American Psychiatric Association recommends IV haloperidol only after a baseline ECG 
is obtained. These guidelines have not been updated since the release of the FDA extended 
warning.200 In their recent review, Morandi et al. support the dosage recommendation of the 
1999 American Psychiatric Association’s practice guidelines for treatment of delirium200, i.e. 
administration of IV haloperidol in single doses of 0.5 to 2mg in elderly patients, however, 
only after a baseline ECG is obtained.237 While the package insert of IV haloperidol in 
France209 recommends a baseline ECG, Germany210, Italy212, and Switzerland’s72 package 
information states the need for regular ECG monitoring. Guidelines for the treatment of 
delirium in the intensive care unit published by the American College of Critical Care 
Medicine and the Society of Critical Care Medicine in collaboration with the American Society 
of Health-System Pharmacists consider IV haloperidol as the preferred agent for the 
treatment of delirium in critically ill patients. (Grade of recommendation = C). These expert 
groups recommend that patients should be monitored for electrocardiographic changes (QT 
interval prolongation and arrhythmias) when receiving haloperidol (Grade of recommendation 
= B).238  
Nevertheless, continuous ECG monitoring (i.e. telemetry) is expensive, labor-intensive and 
potentially overutilized.239;240 Requiring clinicians to place all patients receiving intravenous 
haloperidol on telemetry is impractical and potentially costly. Mandating telemetry could also 
lead to unintended harm, i.e. use of a less effective or less safe drug to avoid compliance 
with the telemetry mandate. 
Based on our findings and the current recommendations in the literature, inpatient providers 
should be thoughtful and deliberate in the use of haloperidol to treat acute delirium with 
agitation. Patients requiring pharmacologic management of their delirium should be screened 
for risk factors for QTP and TdP (see Table 22) and a baseline ECG should be obtained prior 
to haloperidol administration. If significant risk factors exist or the baseline ECG reveals a 
prolonged QTc, then the patient should receive continuous ECG monitoring. Similarly, if 
cumulative doses of ≥2mg are needed, the patient should be placed on telemetry. 
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There are some limitations to our study design. Our findings are based upon previously 
published case reports or data submitted to the FDA MedWatch. While the content of the 
FDA’s MedWatch database is accessible to the public via the Freedom of Information Act 
(FOIA), the events are neither categorized nor peer-reviewed upon entry into the database. 
Consequently, information may be incomplete or inaccurate. In addition, the denominator 
representing the overall use of IV haloperidol is unknown, thus a rate of event cannot be 
assigned and the true scope of the problem cannot be determined. Despite these limitations, 
this summary represents the most comprehensive review of the literature to date, expanding 
on the analysis performed by the FDA. Of note, in our review of the FDA database, we noted 
several cases of haloperidol-associated QTP or TdP associated with other routes of 
administration. Thus, it is unknown whether this complication is any greater with IV versus 




Although the proarrhythmic potential of haloperidol and other antipsychotics has been well 
established in the literature, IV haloperidol has been considered relatively safe with respect 
to this complication from the time of its approval in 1967.202;218;220;227;228;232-234;241 In reviewing 
all reported cases of cardiac complications associated with IV haloperidol, as well as the 
current literature, an association with QTP and TdP is likely. However, the case reports 
reveal that QTP and TdP generally occur in the setting of concomitant risk factors, and no 
cases have been reported utilizing a cumulative IV dose of <2mg. It may therefore be safe to 
administer a cumulative dose of IV haloperidol of <2mg without ECG monitoring in patients 
without risk factors for QTP. However, ECG monitoring should take place with IV haloperidol 
doses ≥2mg and/or in those patients with additional risk factors of developing QTP and/or 
TdP. 
Based on the findings of this review complemented by the guidelines of various expert-
groups and the official labeling information of different countries, the pharmacy & 
therapeutics committee of the UCSF Medical Center revised the IV haloperidol policy: 
Administration of a total dose of <2mg IV haloperidol without concurrent telemetry is allowed 
in a non-critical care setting in patients without risk factors for QTP and TdP. 
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CHAPTER 6 
The case of IV haloperidol – Does the WHO pharmacovigilance database offer 
evaluable comparative safety data?  
This chapter has been submitted for publication to The International Journal of Clinical 




In September 2007, the United States Food and Drug Administration (FDA) strengthened 
label warnings for intravenous (IV) haloperidol. Based on adverse event reports, continuous 
telemetry was recommended due to an increased risk of QT prolongation (QTP) and 
torsades de pointes (TdP).  
Considering that IV haloperidol is commonly used as a first line treatment for acute delirium, 
the extended warning has caused widespread uncertainty among health care professionals 
and further exacerbated by the threatened withdrawal of IV haloperidol from the market in 
Europe. 
The aim of this study is to critically evaluate the WHO adverse drug reaction (ADR) reports of 
QTP, TdP and/or cardiac events involving IV haloperidol specifically compared to other 




All WHO reports (1972- January 2010) of cardiac ADRs associated with haloperidol, 
quetiapine and olanzapine were evaluated, including dose, route of administration and 




The absolute number of ADR reports regarding QTP, TdP and/or cardiac arrest were as 
follows: haloperidol (365 cases), olanzapine (489 cases) and quetiapine (520 cases). 
However, reporting rates of haloperidol did not increase over the last two decades, and 32% 
of the haloperidol cases involved PO, 16.4% IM and 22.7% IV administration.  
The difference of the RORs of haloperidol and quetiapine were not statistically significant. 
Olanzapine was associated with a slightly lower ROR when compared with quetiapine and 
haloperidol. 
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Conclusion 
While regulatory agencies recommend caution regarding the use of intravenous haloperidol, 
review of the WHO ADR database does not reveal that the intravenous route is any more 
likely to be associated with QTP, TdP and/or cardiac arrest than oral or intramuscular.  
Furthermore, our results do not demonstrate any additional risk associated with haloperidol 
when compared with alternative agents. Since pharmacovigilance data does not routinely 
include a denominator regarding frequency of use, it should only be used for trending.  
Nonetheless, regulatory agencies are currently advising against the use of IV haloperidol 
based on pharmacovigilance data.  
Transparency regarding the decision-making process of regulatory agencies would be highly 
desirable from a clinician’s point of view. In addition, improved pharmacovigilance 
approaches are needed to more accurately recommend changes in policy regarding the safe, 
effective use of medicines. 
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BACKGROUND 
In September 2007, in response to adverse event reports, the United States Food and Drug 
Administration (FDA) strengthened label warnings for intravenous (IV) haloperidol. The label 
change included a warning that the risk of QT prolongation (QTP) and torsades de pointes 
(TdP) might be increased with IV administration or administration of more than 
recommended doses. Unfortunately, specific dosing recommendations and information 
regarding potential alternatives were not included in the warning.202 
Although the American Psychiatric Association and the Society of Critical Care Medicine 
recommend haloperidol, a first-generation-antipsychotic as first-line agent for the treatment 
of delirium200;238, IV haloperidol has always been off-label in the United States198. The IV 
route was approved in several other countries including Switzerland72, Canada208, France209, 
Germany210, Great Britain211, and Italy212 until June 2010, when the current controversy 
resulted in removal of this route from the labeling. While the package insert for IV haloperidol 
prior to September 2007 alerted healthcare professionals to the risk of cardiovascular side 
effects, recommendations regarding monitoring were inconclusive.61 However, in May 2010, 
the Pharmacy and Therapeutics committee of the German Physicians’ Association (AkdÄ) 
followed the FDA recommendation and sent out a drug safety letter regarding the use of IV 
haloperidol. According to the revised manufacturer information, continuous 
electrocardiogram (ECG) monitoring was strongly recommended when administering IV 
haloperidol.242  
While the IV administration is not necessarily the route of choice, it is considered an 
alternative particularly with acute agitation. Oral or intramuscular administration offers 
additional challenges for patients with acute delirium, particularly in the general ward setting 
in which continuous ECG monitoring is not feasible.  
In a recent systematic review of published case reports on IV haloperidol and the FDA 
pharmacovigilance database, a dose of less than 2mg of IV haloperidol was considered safe 
for patients with no pre-existing risk factors for cardiac side effects.61 However, it is possible 
that this dose might be too low for highly agitated patients. Consequently, physicians are 
considering therapeutic alternatives to IV haloperidol.  
It is unknown whether the intravenous route of haloperidol is indeed unsafe and whether the 
route of administration influences the safety profile of haloperidol.  Furthermore, it is not 
known whether other agents used for the treatment of acute agitation and delirium, i.e. 
quetiapine and olanzapine, are also associated with electrocardiac changes.  
The aim of this study was to use the WHO ADR database to 1) assess the relative cardiac 
safety of the respective routes of administration for haloperidol and 2) compare the safety of 
haloperidol to the atypical antipsychotics quetiapine and olanzapine.  
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METHOD 
Analysis of the WHO adverse drug reaction database 
In 1968 the WHO established the “Program for International Drug Monitoring” with the aim of 
monitoring, assessing and collecting information from the pharmacovigilance centers of 
member countries. Since 1978 the Uppsala Monitoring Centre (UMC) has been responsible 
for the program.243 The UMC collects cases of suspected adverse drug reactions 
spontaneously reported by health care professionals, hospitals, lawyers and manufacturers 
of member countries. Currently, the WHO ADR database contains more than 4 million 
individual case safety reports (ICSRs). Cases reported in the published literature are not 
included in the database.243 
 
An official search was performed in the WHO ADR database for the drugs haloperidol, 
quetiapine and olanzapine combined with cardiac adverse drug reactions described with the 
WHO-ART terms “QT prolonged” (high level term), “torsade de pointes” (preferred term) and 
/ or “cardiac arrest” (excluding: “cardiac arrest neonatal” / preferred term). Reports from 1972 
until January 4, 2010 were included, no country restrictions were applied.  
 
The data was obtained in an Excel-sheet showing single case reports in multiple rows. The 
data was converted by a professional programmer to organize each case report in a single 
row for optimal searching for trends. 
 
The reporting odds ratio (ROR) of haloperidol is defined as the ratio of the exposure odds 
among reported cases of haloperidol-associated cardiac adverse reactions to the exposure 
odds of all the other reported ADRs of haloperidol-induced cardiac ADRs. The ROR of 
haloperidol in comparison with the ROR of cardiac ADRs of olanzapine and quetiapine was 
calculated as previously described.244;245  
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RESULTS 
Analysis of the WHO adverse drug reaction database 
Overall data 
During the period from 1972 until January 4, 2010 the UMC received 1374 ICSRs on QTP, 
TdP and/or cardiac arrest associated with the administration of haloperidol (365 cases), 
olanzapine (489 cases) or quetiapine (520 cases). The reported cases included 529 males 
and 605 females; in 240 cases the gender was not provided by the reporter.  
The first reports of cardiac ADRs associated with haloperidol, olanzapine and quetiapine 
dated back to 1972, 1996 and 1995, respectively. The detailed data on the ICSRs overall is 
displayed in table 26. 
The reporting numbers of the study drugs per year are displayed in table 27. Reporting rates 
of haloperidol did not increase over the last two decades.  
The average age of patients with cardiac events associated with the administration of 
haloperidol was 49 years (S.D. ± 16.2 years), with olanzapine 47 years (S.D. ± 14.5 years) 
and with quetiapine 45 years (S.D. ± 13.3 years). In 149 case reports (10.8% of the total) the 
age of the patient was not specified. 
Only limited data regarding route of administration and dose was available in the ICRS. The 
information is displayed in tables 28 – 30. Of the 365 haloperidol reports, 120 cases involved 
PO administration (32.9%), and 60 IM administration (16.4%), 83 IV administration (22.7%). 
In 90 cases (24.7%), the route of administration was unknown, in 2 cases (0.5%) “parenteral” 
was indicated. Daily doses of haloperidol ranged from 0.6 mg to 675 mg, with an average 
daily dose of 49 mg (SD +/-113 mg, median 15 mg).  
Overall nine patients with a reported cardiac ADR (all in relation with QTP and/or TDP) 
received haloperidol doses <2mg/day. The lowest dose associated with a fatal event was 
1mg. (see table 31)  
Of the 489 olanzapine reports, only in 75 cases (15.3%) was the route of administration, 
dose and frequency of administration available to allow for calculation of the daily dose. Daily 
doses administered ranged from 1.25 mg to 700 mg, with an average daily dose of 25 mg. 
(SD +/-72 mg, median 10 mg). 
The quetiapine reports contained 89/520 (17.1%) detailed case descriptions. Daily 
administered doses ranged from 25 mg to 4500 mg, with an average daily dose of 623 mg 
(SD +/-760 mg, median 400 mg). One case, a non-fatal suicide attempt with 30,000 mg of 
quetiapine, was excluded from the calculation. 
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Table 26: Details of case reports in the WHO ADR database 
 Total reports 
N = 1374 
Haloperidol 
N = 365 
Olanzapine 
N = 489 
Quetiapine 
N = 520 
Age (mean +/- SD) 47 +/- 14.5 49 +/- 16.2 47 +/- 14.5 45 +/- 13 
Age unknown (%) 149 (10.8%) 40 (11%) 47 (9.6%) 62 (11.9%) 
N ≥ 65 years (%) 212 (15.4%) 78 (21.4%) 78 (17.6%) 56 (12.2%) 
Sex male (%) 529 (46.6%) 200 (58.5%) 182 (47.2%) 147 (36.2%) 
Sex female (%) 605 (53.4%) 142 (41.5%) 204 (52.8%) 259 (63.8%) 
Sex unknown 240 23 103 114 
Number of reports with 
available route, daily dose  
 100 75 89 
PO (%)  120 (32.9%) 70 (93%) 89 (100%) 
IV (%)  83 (22.7%) NA NA 
IM (%)  60 (16.4%) 5 (7%) NA 
Parenteral unspecified  2 (0.5%) NA NA 
Unknown  90 (24.7%) 0 (0%) NA 
Outcome fatal 739 155 (42.5% of haloperidol) 276 (54.6% of olanzapine) 308 (59.2% of quetiapine) 
 male 262 89 93 80 
 female 279 53 96 130 
 unknown 198 13 87 98 
NA = not applicable (no formulation approved) 
 
Table 27: Number of ADR reports per year and drug 
Haloperidol Olanzapine Quetiapine  
Timeframe overall PO IV IM overall PO IM PO 
1972 - 1979 13 (6.5%) 8 (12.3%) 1 (1.5%) 4 (11.1%) NA NA NA NA 
1980 - 1989 33 (16.5%) 16 (24.6%) 3 (4.6%) 7 (19.4%) NA NA NA NA 
1990 - 1999 78 (39%) 19 (29.2%) 32 (49.2%) 17 (47.2%) 62 (31.6%) 29 (25.9%) 0 (0%) 10 (7.4%) 
2000 - 2009 76 (38%) 22 (33.8) 29 (44.6%) 8 (22.2%) 134 (68.4%) 83 (74.1%) 5 (100%) 126 (92.6%) 
NA = not applicable (no formulation approved) 
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A total of 743 cases with fatal outcome were reported (54.1%), 4 of these were excluded 
because they were explicitly reported to be unrelated to cardiac etiology, resulting in a total 
of 739 cases. In 155 patients the cardiac event was associated with haloperidol (89 males, 
53 females, 13 unspecified), doses ranging from 1mg to 530mg; in 276 patients with 
olanzapine (93 males, 96 females, 87 unspecified), doses ranging from 5mg to 80mg; and in 
308 patients with quetiapine (80 males, 130 females, 98 unspecified), doses ranging from 25 
to 4500mg. Details on the doses administered are displayed in table 32. 
Of the 78 elderly patients whose cardiac events were associated with the administration of 
haloperidol, 45 died (57.7%). Of the 78 elderly patients whose cardiac events were 
associated with the administration of olanzapine 53 (67.9%) died, whereas of the 56 elderly 
patients whose cardiac events where associated with quetiapine 41 (73.2%) died. 
 
Reporting odds ratio 
The ROR for the risk of cardiac ADRs associated with the use of any one of the study drugs 
(haloperidol, olanzapine, quetiapine) compared with cardiac ADRs associated with all other 
drugs in the WHO database was 3.15 (CI 95%, 2.98 - 3.33). The ROR for haloperidol was 
3.66 (CI 95%, 3.30 – 4.07), for olanzapine 2.67 (CI 95%, 2.44 – 2.92) and for quetiapine 3.39 
(CI 95%, 3.11 – 3.70) compared to cardiac ADRs following therapy with other drugs. The 
difference of the ROR between haloperidol and quetiapine was statistically not significant 
(p>0.05, overlapping confidence intervals). Olanzapine was associated with a slightly lower 
ROR when compared with quetiapine and haloperidol. 
 
 
Table 28: Distribution of administered doses of haloperidol associated with adverse cardiac 
reactions (QTP and/or TdP and/or cardiac arrest), stratified by route of 
administration 
Number of reported cases Haloperidol 
daily dose PO [n=47] IV [n=23] IM [n=30] 
< 2 mg* 4 1 1
2 mg - ≤ 3 mg 11 4 4
> 3 mg - ≤ 5 mg 6 0 5
> 5 mg - ≤ 10 mg 5 3 6
> 10 mg - ≤ 20 mg 8 2 5
> 20 mg - ≤ 50 mg 7 2 4
> 50 mg - ≤ 100 mg 5 4 5
> 100 mg 1 7 0
* route unknown: 3 
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Table 29: Distribution of administered doses of olanzapine associated with adverse cardiac 
reactions, stratified by route of administration 
Number of case reports Olanzapine 
daily dose PO [n = 70] IV [n = 5] 
≤ 3 mg 4 0
> 3 mg ≤ 5 mg 13 0
> 5 mg ≤ 10 mg 23 2
> 10 mg ≤ 20 mg 18 2
> 20 mg ≤ 50 mg 9 1
> 50 mg ≤ 300 mg 2 0




Table 30: Distribution of administered doses of quetiapine associated with adverse cardiac 






≤ 100 mg 25
> 100 mg ≤ 200 mg 11
> 200 mg ≤ 300 mg 8
> 300 mg ≤ 400 mg 8
> 400 mg ≤ 500 mg 5
> 500 mg ≤ 600 mg 11
> 600 mg ≤ 700 mg 2
> 700 mg ≤ 800 mg 3
> 800 mg ≤ 900 mg 2
> 900 mg ≤ 1000 mg 3
> 1000 mg ≤ 1200 mg 2
> 1200 mg ≤ 1400 mg 3
> 1400 mg ≤ 1600 mg 1
> 1600 mg ≤ 1800 mg 1
> 1800 mg ≤ 2000 mg 1
> 2000 mg ≤ 5000 mg 2
> 5000 mg ≤ 30,000mg  1
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Table 31: Daily doses of Haloperidol, Olanzapine and Quetiapine, overall and with fatal outcome after QTP and/or TdP and/or cardiac arrest 
Haloperidol Olanzapine Quetiapine  
Overall cases 
[mg] 








Cases with fatal 
outcome [mg] 
Daily dose total PO IV IM total PO IV IM total PO IM total PO IM PO PO 
Lowest 0.6 1 1 1 1 1 1 1 1.25 1.25 10 5 5 10 25 50 
Highest 675 500 675 85 530 500 530 85 700 700 20 80 30 20 4500 4500 
Mean 49 31 102 26 39 35 81 27 25 25 14 17 13 17 623 928 
SD 113 24 179 27 96 101 177 29 72 84 5.5 14 8 6 760 1156 
Median 15 12 20 15 10 8 5 15 10 10 10 10 10 20 400 600 
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1 1985 USA 72 Female 1 mg daily PO Cardiac 
arrest 
NR Died NR Other None reported NR CV Disease 
2 1986 USA 73 Male 1 mg daily IV Cardiac 
arrest 
Death Died NR Other None reported NR NR 
3 1986 USA 37 Male 1 mg daily IM Cardiac 
arrest 




4 NR USA 12 Male 1 mg daily PO Cardiac 
arrest 
Death Died NR Other None reported NR NR 
5 1999 FIN 75 Female 1 mg daily PO  QTP,  
TdP 
NR Died Probable Hospital Furosemide 160 mg 
PO,  




metoprolol 95 mg 
PO 
NR NR 
6 2004 NLD 84 Female 1.5 mg daily NR TdP Other Unknown NR NR None reported NR NR 







Recovered Possible NR Amantadine,  







8 2009 CHE 82 Female 1 mg daily PO QTP Other NR NR Physician Acetylsalicylic acid 
100 mg PO, 
metoprolol 12.5 mg 
PO, 
Calcium gluconate 
500 mg PO, 




9 NR USA 18 Female 1 mg NR NR Cardiac 
arrest 









AV = atrio-ventricular, CHE = Switzerland, FIN = Finland, CV = cardio vascular, HCl = hydrochloride, IM = intramuscular, IV = intravenous, NLD = The 
Netherlands, NR = not reported, PO = oral, QTP = QT prolongation, TdP = Torsades de pointes, USA = United States of America 
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DISCUSSION 
In 2007, the FDA strengthened label warnings for IV haloperidol in response to reports on 
cardiac adverse events. The release of this warning was based on post-marketing 
pharmacovigilance data.202 
The request of continuous ECG monitoring, often impractical on non-intensive care units, 
raised the question among health care professionals if different routes of administration or 
the use of atypical antipsychotics might be an alternative to IV haloperidol, specifically in 
treating acute conditions like delirium.202 
The WHO ADR database is based on spontaneous, voluntary reporting and does not allow a 
definite quantitative comparison of events due to underreporting influencing the nominator as 
well as due to the missing denominator of overall use, overall use per route of administration, 
gender and age. However, it is clear that cardiac adverse events involve a wide variety of 
doses, different routes of haloperidol administration and other antipsychotics quetiapine and 
olanzapine.  
One limitation with the calculated ROR is that it is not corrected for year of registration and 
highly dependant on the number and types of cases reported. Furthermore, it is difficult to 
clearly link cause and effect between the agent and the adverse event. Thus, the ROR 
simply reflects the comparative reporting behavior regarding different drugs and is quite 
limited in its ability to reflect actual incident rates.246 Nevertheless, the difference of the ROR 
between haloperidol and quetiapine was not statistically significant in our analysis, 
suggesting no increase in reporting for haloperidol compared to atypical antipsychotics. If 
one bases conclusions upon spontaneous reporting systems, there is no evidence that 
haloperidol is more dangerous than other antipsychotics. This notion is further supported by 
the fact that haloperidol has been marketed much longer than olanzapine and quetiapine, 
and that there was no increase in reporting for haloperidol over the last two decades.  
 
Haloperidol has never been evaluated in a prospective, controlled trial to evaluate the true 
incidence of cardiac adverse events associated with the route of administration. Ozeki et al. 
calculated the relative risk of QTP associated with the administration of various drugs for the 
treatment of schizophrenia. The administration of 2mg of IV haloperidol resulted in a 
calculated relative risk of 1.29 compared to 0.99 for 2mg of PO haloperidol. The authors 
conclude that IV haloperidol is significantly more likely to be associated with QTP compared 
with the oral route.247 
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Atypical antipsychotics are associated with substantially less EPS when compared with 
conventional antipsychotics such as haloperidol. Consequently, these agents are commonly 
used in the management of psychiatric disorders.248 With this increase in the use of second 
generation antipsychotics, concerns about efficacy and safety in vulnerable patients (e.g. 
geriatric patients with dementia) have been raised.249  
Accordingly, in 2005 the FDA issued a Public Health Advisory warning against the use of 
atypical antipsychotics in elderly patients with dementia because of the associated increased 
risk of death.202 
Only 2 studies directly compare haloperidol with olanzapine, while only 1 study compares 
haloperidol with quetiapine in the treatment of delirium.250-252 
Skrobik et al. performed a single-blind, randomized study comparing the efficacy and safety 
of PO haloperidol and PO olanzapine in 73 critically ill patients with delirium. Fourty-two 
percent of the patients treated with olanzapine and 35% of the patients treated with PO 
haloperidol required rescue therapy with IV haloperidol. None of the 73 patients experienced 
a QTP or other cardiac events.250 
Sipahimalani et al. conducted a retrospective, nonrandomized study comparing haloperidol 
and olanzapine in 22 patients with delirium. Significant symptom improvement was observed 
in 5 patients treated with olanzapine and in 6 patients treated with haloperidol. The only side 
effects reported were EPS and over-sedation in the haloperidol group.251 
Schwartz et al. performed a retrospective chart review comparing haloperidol and quetiapine 
for the treatment of 22 patients with delirium. Satisfactory clinical responses with overall 
improvements in delirium symptomatic were observed in 10 patients in each group. No 
cardiac side effects were reported.252 
While these 3 comparative studies are not adequately powered to detect differences in rare 
ADRs, they are the only controlled trials that exist.250;251 
 
Czekalla et al. summarized the results of 4 controlled randomized clinical trials conducted 
with 2700 patients and concluded olanzapine is associated with the lowest risk of QTP when 
compared with other atypical antipsychotics.253 Another prospective clinical study 
documented olanzapine-induced QTP, however this prolongation was not statistically 
significant.254 In another study QTc prolongation was not observed even after olanzapine 
overdose.255 In contrast, in a study performed at the Beer-Sheva Mental Health Center in 
Israel, a mean prolonged QTc interval of 504.6 ± 7.0msec was observed in 17 patients with 
no known underlying cardiac diseases, but regularly taking olanzapine.256 
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Like all other atypical antipsychotics olanzapine shows an advantage over haloperidol 
because of the low risk of EPS.257 However, the relatively long onset of action of the PO form 
(from 5 to 8 hours) greatly diminishes its value in emergency cases of delirium.72 
The finding of Schwartz et al. that quetiapine is a safe and efficacious therapeutic alternative 
to haloperidol in the treatment of delirium might be worth further investigation252, especially 
due to its very low propensity to cause EPS.249 An interesting characteristic of quetiapine is 
the relatively short half life (7 hours), which allows for rapid elimination in the case of serious 
ADRs.258 
While some experts state that atypical antipsychotics might have a more favorable cardiac 
safety profile, this benefit has not been clearly established. The Arizona Center for Research 
and Therapeutics (Arizona CERT) still categorizes haloperidol as a “drug with risk”, while 
quetiapine is only classified as “drug with possible risk”. Olanzapine is not included on any 
risk list.259 
Prescribers should recognize QTP is more likely when treating patients with baseline risk 
factors.61 These factors include female sex (71.4%), drug interactions and polypharmacy 
(44.7%), cardiac disorders (43.1%), overdose (27.0%), electrolyte imbalances (17.0%), 
congenital Long QT Syndromes (17.1%).260 Notably 70 patients with antipsychotic-induced 
TdP were included in this review, and most presented with 2 or more risk factors.260  
 
While some authors suggest an increased risk of cardiac events with intravenous haloperidol 
administration, review of the WHO ADR database does not support this conclusion. From a 
practical point of view, intravenous administration offers distinct advantages in the inpatient 
setting. In the absence of controlled trials, oral administration with drops or fast-melt tablets 
represent a potential option.61 While obviously more painful compared with intravenous, 




While pharmacovigilance data is substantially limited due to underreporting and the missing 
denominator pertaining to use, regulatory agencies are using this information to produce 
medication warnings. Specifically, these data have been used in advising against the use of 
IV haloperidol in the treatment of acute delirium. The WHO database reveals a greater 
number of cardiac ADR reports for PO haloperidol when compared with the IV route. Also of 
note, the number of overall cardiac ADRs involving QTP and/or TdP was greater for 
quetiapine and olanzapine when compared to haloperidol.  
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Transparency regarding the decision-making process of regulatory agencies would be highly 
desirable from a clinician’s point of view. Improved pharmacovigilance approaches are 
needed to more accurately recommend changes in policy regarding the safe, effective use of 






(i) The data on which this work is based were obtained from the WHO Collaborating 
Centre for International Drug Monitoring, Uppsala, Sweden. 
(ii) The information contained in this work is not homogeneous at least with respect to 
origin or likelihood that the pharmaceutical product caused the adverse reaction. 
(iii) The information contained in this work does not represent the opinion of the World 
Health Organization. 
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SUMMARY AND PERSPECTIVES 
Ten years after the publication of “To Err is Human”, patient safety is a significant concern for 
regulatory agencies and hospitals. Despite this report, patient safety is still lacking and 
additional efforts are needed to improve health care quality.7;262 Medication-related harm is 
among the top reasons for decreased patient safety.263 Most importantly, more than 60% of 
the adverse events are considered preventable.262 
Although adverse drug event reduction is clearly an interdisciplinary approach, the current 
literature shows that clinical pharmacy services, involving drug information services, clinical 
research, proactive adverse drug reaction management, medical rounds participation, drug 
protocol and therapy management, and drug counseling, can improve medication safety 
significantly (see also Figure 4).42;57;57 
 
Figure 4: Clinical pharmacist’ activities improving medication safety 
 
 
A survey among Swiss hospital pharmacy directors has shown clearly, that the improvement 
of medication safety through the implementation of clinical pharmacy services is a priority. 
 Carla Meyer-Massetti PhD Thesis, March 2011  139
Patient-specific medication during transition of care is important to improve individual drug 
therapy outcomes21;22;38;41;43;264, however, a more systematic approach should be considered 
in order to address system failures regarding medication use45. 
While the role of the clinical pharmacist as a medication safety officer is emerging quickly in 
the United States48;49, clinical pharmacy in Switzerland is still very much focused upon 
patient-specific counseling on drug use.265;266 With Swiss physicians increasingly dispensing 
drugs and the discipline of pharmacology also in the hands of physicians, comprehensive 
medication safety assessment potentially creates important professional opportunities for 
hospital pharmacists in Switzerland. 
However, our survey showed that pharmacy staff resources, which are lower in Swiss 
hospitals than the European average, likely inhibit proactive efforts.267 Consequently, 
targeted, effective and low-cost tools are required to address individual institutions’ 
medication safety issues. 
A carefully managed drug formulary is a cornerstone for safe medication use.33 The 
American Society of Health-System Pharmacists recommends oversight by the pharmacy & 
therapeutics committee.29;33 
Once drug products are approved for addition to an institution’s formulary, regular medication 
use evaluations (MUEs) are warranted.31-33;58 A systematic review of the current literature 
showed, that the trigger tool technology is the most efficient approach compared to incident 
report analysis, chart review and direct observation.34 Establishing electronic means of data 
collection, management and exchange such as electronic prescribing, barcoding, automated 
dispensing and an electronic patient record not only improves medication safety59;171;268-270, 
but also allows for more efficient collection and analysis of medication use related data195;197.  
Considering that different approaches to medication safety assessment reveal different types 
of medication errors, a combination of techniques is recommended. Specifically, the  
combination of trigger tool and incident report analysis is considered complimentary.34  
Although spontaneous reporting does not provide an adequate denominator to allow for the 
calculation of true incidence rates, pharmacovigilance-derived data can reveal high severity 
medication use problems.34  
As our survey showed, the use of incident reporting systems is common in Swiss 
hospitals.267 Utilization of such systems already in place might be a time saving approach to 
systematic medication use evaluation. In addition, active promotion of incident reporting is 
associated with increased reporting, allowing for a more comprehensive view of an 
institution’s medication use. 
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 Sir Liam Donaldson, chair of the WHO’s World Alliance for Patient Safety stated:  
 
“The belief that one day it may be possible for the bad experience 
suffered by a patient (in one part of the world) to be a source of 
transmitted learning that benefits future patients (in many countries) is a 
powerful element of the vision behind the WHO World Alliance for 
Patient safety.” 
 
Hospital pharmacists in Switzerland can fulfill this belief by playing an important role in 
improving drug safety through a systematic, interdisciplinary approach at medication use 
evaluation.  
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